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QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
Perspectives on Malignant Biliary Obstruction: 
Does the Surgeon Have a Role in Management?
Concepts of intervention for malignant 
biliary obstruction have altered substan­
tially since the first reports of successful 
percutaneous drainage in 19781 and 
endoscopic drainage in 1979.2 Manage­
ment previously had been entirely opera­
tive with most treatment decisions being 
made by surgeons, who carried out pal­
liative bypass in the majority of cases. 
However, current imaging techniques for 
obstructive jaundice often involve radi­
ologists and gastroenterologists before the 
surgeon is consulted. In fact, the imag­
ing requests may be followed directly by 
an interventional procedure that is con­
sidered definitive treatment by the 
operator.
This may be appropriate if all biliary 
strictures were considered to be incura­
ble malignant lesions. However, most 
authorities accept that certain ampullary 
and bile-duct carcinomas are curable. 
Whether the same is considered true for
pancreatic carcinoma is debatable. None 
the less, not all lesions obstructing the bile 
duct will prove to be of pancreatic origin, 
so consideration of surgical cure should 
not be withheld from patients when even 
slight hope of resectability exists.
The combination of cholangiography 
and sophisticated abdominal scanning 
techniques should allow biliary disease to 
be categorized, so that the surgeon, radi­
ologist and gastroenterologist together 
could select the appropriate therapeutic 
technique. Advanced metastatic obstruc­
tion of the bile duct or primary 
hepatobiliary-pancreatic carcinoma with 
proven unresectable spread should be 
considered for nonoperative palliation. 
But a distal bile-duct stricture without any 
definition of the mass by scanning 
demands that resectability be verified by 
operation. Even hilar bile-duct lesions 
without a large mass effect or intrahepatic 
spread may be resectable, although not
always curable.3 I propose that, before 
any intervention, the mode of treatment 
should be decided upon jointly by staff 
from all disciplines involved, using the 
experience and expertise of all available 
specialists.
Discussion of the management of 
unresectable disease frequently compares 
the results of various forms of palliative 
intervention with those of operative 
bypass. Often the surgical statistics 
quoted are outdated and describe small 
numbers of cases; universally, the results 
from the surgical series selected are 
inferior to those of the palliative tech­
nique under consideration. Sarr and 
Cameron4 reported the results of surgi­
cal palliation for pancreatic carcinoma 
collected between 1965 and 1982. Over 
10 000 patients were treated by biliary- 
enteric bypass, with a mean survival of 
5.5 months. Patients who did not undergo 
bypass survived 3.4 m onths after
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laparotomy alone — a result similar to 
those from many reports of nonoperative 
biliary drainage.4 This historical baseline 
must be considered whenever results of 
intervention are debated.
The results of prospective randomized 
trials may be valuable to compare the 
quality and duration of palliation for 
unresectable disease. Such analysis offers 
an improvement over retrospective anal­
ysis of interventional palliation describ­
ing success in terms of radiologic illustra­
tions or biochemical changes. Any trial 
must indicate success or failure in terms 
of restoration of normality, the severity 
and frequency of disabling morbidity, 
recurrence of presenting problems and 
length of survival. For comparative 
results to be meaningful, they must be 
categorized. Cholangiography and scan­
ning will be valuable in this respect. 
However, pathologic features of the 
tumour may not be obtainable in all 
cases, and the biologic behavioural differ­
ences between bile-duct carcinoma and 
pancreatic carcinoma are enough to affect 
the evaluation of data from any sample 
size.
Nonoperative biliary drainage is 
associated with a lower morbidity and 
mortality than surgery in most reports 
from experienced units. This is particu­
larly true for the procedure alone, con­
sidering the complexities associated with 
operation and anesthesia in patients with 
decompensated liver function and sup­
pressed immune response. However, the 
30-day death rate may be equal to or 
greater than that for operation when 
short-term complications of percutaneous 
and endoscopic stenting are included in 
the analysis.5
As Olak and associates report in 
this issue (pages 243 to 246, sepsis is 
extremely important whenever palliative 
bypass is not wholly internal. External 
cannulas are considered important for 
changing stents in the presence of infec­
tion. Indeed, the results justify the need. 
Similar requirements exist for endoscopic 
stenting due to infection and occlusion of 
the prosthesis. Surgically placed U tubes 
suffer a similar fate and require frequent 
changes. Surgically placed endopros­
theses, free of external conduits, are 
rarely complicated by infection or occlu­
sion.6,7 This may also correlate with the 
increased luminal diameter of the stent 
sustaining improved bile flow.
No area has so long been the sacred 
ground of general surgery as has the 
biliary tract. Surgical competence in this 
region is rarely questioned of qualified 
specialists. Our results are so uniformly 
outstanding that we almost never audit 
our work and rarely publish the results 
of other-than-unusual cases or collected 
series from referral centres. However, be 
aware of intrusion from non-surgeons, 
who are capable of treating our diseases. 
They have little more than scopes, nee­
dles and catheters. They understand 
imaging as well or better than we do. 
They communicate with patients and 
referring colleagues as well or better than 
we do. Indeed, they may be as aggressive 
as we think we are! And they do audit 
their results and publish even small ser­
ies of cases, creating awareness of the 
frontiers that have been opened in our 
field by non-surgeons.
We cannot all become endoscopists 
capable of interventional techniques, nor 
radiologists skilled in percutaneous ther­
apy; however, we can evaluate our role 
in current-day management of disorders 
of the biliary tract, determine our place 
on the team that will be involved in inves­
tigation and treatment, upgrade our sur­
gical skills and techniques, take part or 
direct audits of the therapies applied, and 
report results in print or presentation. The 
alternative does not bode well for general 
surgery.
Roger G. Keith , md, frcs, frcsc, facs
Member,
Editorial Board.
Associate professor of surgery,
University of Toronto,
Ste. 407,
55 Queen St. E,
Toronto, Ont.
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Modern Management of the 
Unruptured Tubal Pregnancy
Between 1970 and 1980 there was a 
threefold increase in the occurrence of 
ectopic pregnancy.1 In 1883 Lawson Tait 
performed the first salpingectomy for this 
condition. After excision of the affected 
oviduct, the standard gynecologic prac­
tice for ectopic pregnancy, patients can 
be expected to conceive in 50% of cases, 
have a live birth in 34% and a repeat 
ectopic pregnancy in 16% of cases.2 This 
traditional form of surgical management, 
while undoubtedly life-saving, does little 
to enhance the future fertility of women
wishing to preserve their reproductive 
potential. During the past decade alter­
native, more conservative, methods of 
management have been explored with 
considerable success. Since little other 
than partial salpingectomy can be offered 
to the woman who has suffered catas­
trophic rupture of a tubal pregnancy, 
earlier diagnosis before rupture is the 
keystone of a more conservative 
approach.
The combination of acute clinical 
awareness of the condition, measurement
of the circulating levels of the beta subu­
nit of human chorionic gonadotropin3 
and ultrasonographic assessment of the 
pelvic organs in most cases will allow 
early diagnosis to be made. The woman 
with a short period of amenorrhea, pel­
vic pain and vaginal spotting, in whom 
an elevated level of beta human chorio­
nic gonadotropin is detected may indeed 
suffer from this condition. By the 25th 
day after conception a gestational sac can 
be detected by ultrasonography within the 
uterine cavity. If no such sac is detected,
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the patient should be considered to have 
an ectopic pregnancy until proven other­
wise. The next logical investigation is 
laparoscopy. Of 165 patients examined 
laparoscopically by Samuelsson and 
Sjovall4 and believed to have an ectopic 
pregnancy 164 did so and of 312 thought 
not to have ectopic pregnancy the diagno­
sis was correct in all but 6. Laparoscopy 
provides the opportunity to make a con­
crete diagnosis, to assess the status of the 
contralateral oviduct and, in many cases, 
to perform definitive conservative sur­
gery. The use of laparoscopic electrosur- 
gical methods will allow performance of 
linear salpingostomy or minimal segmen­
tal resection of the gestational sac.5
For the surgeon unfamiliar with 
laparoscopic surgical techniques, a sim­
ple alternative is to combine laparoscopy 
with mini-laparotomy. Such a procedure 
is feasible only in the slim patient in 
whom the uterus and affected oviduct are 
freely mobile. When a uterine cannula is 
placed in the cervix it is possible to 
manipulate the uterine fundus immedi­
ately beneath the anterior abdominal 
wall. A 1- to 2-cm suprapubic incision is 
all that is required to deliver the tube to 
the exterior where a conservative surgi­
cal approach can be undertaken.6
If formal laparotomy is undertaken the 
pregnancy can be milked from the tube 
if it is in the ampullary portion. The 
results have been less than satisfactory, 
with a repeat incidence of ectopic preg­
nancy of 21.4%.7 The optimal approach 
would appear to be linear salpingostomy. 
Women whose incisions were permitted 
to heal by secondary intention have been 
shown by DeCherney and colleagues8 to 
do better than those in whom primary 
closure was undertaken. Langer and 
colleagues9 studied 54 patients in whom 
linear salpingostomy was performed 44 
times and milking 13 times. Of 49 patients 
who wished to become pregnant, 71% 
experienced a live birth and there was an 
ectopic pregnancy rate of only 12%. 
Perhaps more impressive than the intrau­
terine pregnancy rate of 90% in patients 
with a healthy contralateral tube was the 
intrauterine pregnancy rate of 62.5% in 
patients in whom the contralateral tube 
was absent or damaged.
U ndoubtedly these conservative 
approaches are more effective when 
microsurgical techniques are used. Such 
a statement may intimidate the practising 
surgeon who has not had special training 
in microsurgery, but there is nothing mys­
tical about these procedures, relying as 
they do on the principles of magnifica­
tion, pinpoint electrocautery and delicacy 
in tissue handling. Magnification for the 
conservative management of the tubal 
pregnancy is provided very adequately by 
opthalmologists’ loupes which give a 
magnification of 4 x or 6 x . Any solid- 
state electrocautery machine can be used
in conjunction with a pinpoint electrocau­
tery needle. Irrigation can be provided by 
a 20-ml syringe and an Angiocath. When 
salpingostomy is performed, a few fine, 
preferably 8-0, sutures at the angles of the 
incision will usually be all that is needed 
to secure hemostasis. Perhaps in the 
future ectopic pregnancy diagnosed early 
will no longer be treated surgically. A 
recent report10 demonstrated that when 
six patients with unruptured ectopic preg­
nancies were treated with methotrexate 
and folic acid, all responded to one course 
of treatment and none required surgery. 
Hysterosalpingography performed 3 
months after treatment revealed patent 
tubes and normal uterine anatomy. While 
such reports are preliminary and do not 
provide information about subsequent 
pregnancy and ectopic pregnancy rates, 
they do hold promise for noninvasive 
management.
Although in-vitro fertilization techni­
ques may provide future hope for women 
who suffer from ectopic pregnancy, 
attempts at primary conservation add 
little to the operating time, do not involve 
expensive high-technology methods and 
appear to have a gratifying success rate 
with respect to live births. It should now 
be incumbent upon any surgeon involved 
with the gynecologic care of women to 
consider early diagnosis and conservation 
of the affected fallopian tube.
P a t r ic k  J. T a y l o r , m d , fr c s c , f r c o g
Director, Endocrine/Infertility Clinic, 
University of Calgary,
Health Sciences Centre,
3330 Hospital Drive NW,
Calgary, Alta.
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CORRESPONDENCE
Contributions to the Correspondence section are welcomed. 
They should be typewritten and double spaced.
Campylobacter jejuni Associated 
With a Perirectal Abscess
To the editors.—Campylobacter jejuni is 
a slender, curved, S-shaped or spiral, 
motile, microaerophilic, gram-negative 
bacillus, positive for sodium hippurate 
hydrolysis.1 Acute enteritis is the com­
monest clinical manifestation of infection 
due to this bacterium,2 which may cause 
a variety of other intestinal disorders— 
toxic megacolon and colitis,3 massive 
gastrointestinal hemorrhage,4 chole­
cystitis5 and pancreatitis.6
We report a case of C. jejuni isolated 
directly from a perirectal abscess, which 
we believe is the first such report.
Three weeks before being seen in the clinic, 
a 64-year-old woman experienced an episode 
of diarrhea (5 to 10 movements daily), 
associated with abdominal pain. The attack 
resolved spontaneously within a week. There 
was no fever, nausea, vomiting or hematoche- 
zia. There had been no recent exotic travel or 
consumption of unpasteurized dairy products 
or inadequately cooked meat.
Two weeks later, a gradually increasing pain­
ful mass developed in the right perianal area, 
unassociated with fever or chills. A right 
perirectal abscess was found and drained 
through an incision placed in the squamous 
epithelium of the right buttock after appropri­
ate disinfection. Pus was sent to the microbi­
ology laboratory. However, owing to a cleri­
cal error the specimen was labelled as “ rectal 
swab”  rather than “ perirectal abscess” , and 
was handled as a stool sample rather than an 
abscess. As such, cultures for anaerobes were 
not done. Campylobacter jejuni and Citrobac- 
ter freundii were isolated from the specimen.
Most perirectal abscesses are thought 
to arise in the 6 to 10 anal glands that 
empty into the anal canal at the dentate 
margin. The infection begins in the plane 
between the internal (visceral) and the 
external (somatic) sphincters. From there 
the infection progresses caudally to form 
the common low variety of perianal 
abscess that accounts for about 80% of anorectal suppuration.
The bacteriologic findings in perirectal 
abscess have been well described; they
usually represent mixed infections involv­
ing anaerobes, particularly Bacteroides 
fragilis and gram-negative enteric 
bacilli.7 Our patient is the first in whom 
C. jejuni has been isolated from an 
abscess at this site. One may speculate 
that the episode of self-limited enteritis 
was caused by C. jejuni and was subse­
quently complicated by an abscess due to 
this organism in proximity to the gastroin­
testinal tract. Similar manifestations 
(perineal, perirectal abscesses) are well- 
known in relationship to Salmonella infections.8
It is recommended that any patient with 
a perirectal abscess who has suffered ente­
ritis in the preceding few weeks and 
requires incision and drainage should 
have samples of pus sent to the microbi­
ology laboratory. The laboratory should 
be asked to culture not only aerobes and 
anaerobes, but also Campylobacter which 
requires specific media and culture con­
ditions for isolation.1
Sigmund Krajden, md, frcpc 
Department of Microbiology
Claude J. Burul, md, frcsc 
Department of Surgery
Milan Fuksa, d sc 
Department of Microbiology
University of Toronto and St. Joseph’s Health Centre,30 The Queensway,Toronto, Ont.M6R 1B5
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Tube Cecostomy
To the editors.—To evaluate the role of 
tube cecostomy, one must consider the 
purpose of the procedure, its effectiveness and its morbidity.
The purpose of tube cecostomy is to 
decompress the colon. Decompression 
involves the release of gas, liquid and 
solid material. Rosenberg and Gordon in 
the January 1986 issue of this journal 
(pages 38 to 40) showed that tube 
cecostomy is not reliably effective in 
achieving that goal. Frequent and 
unavoidable tube obstruction is the limit­
ing factor in this procedure. A mucosa- 
to-skin cecostomy without a tube may 
reduce the incidence of obstruction. 
However, the stoma may be small, diver­
sion incomplete and a second operation 
required for closure.
Rosenberg and Gordon outlined the 
morbidity associated with tube ceco­
stomy, further emphasizing the dis­
advantages of this procedure.
Are there any indications for this 
procedure, which is, at best, partially 
decompressing? The intraluminal stapler 
has made it possible to create more secure 
anastomoses in the pelvis and has reduced 
the need for proximal diversion of the 
fecal stream. If such diversion is deemed 
necessary, a loop transverse colostomy or 
a loop ileostomy will more completely 
divert gas, liquid and solid material than 
tube cecostomy. The Division of Colon 
and Rectal Surgery at the University of 
Minnesota has used proximal diversion of 
left-sided colonic anastomoses in only 
13% of 2537 cases. A cecostomy in which 
the mucosa was sutured to the skin was
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used once with good anastomotic healing; 
however, the cecostomy continued to 
drain small amounts of stool and was still 
not closed 2 years after surgery.
Cecal volvulus requires a procedure 
that will release gas from the cecum 
and prevent recurrent volvulus. Tube 
cecostomy is better suited to this role, but 
again the incidence of tube obstruction 
limits the value of this procedure. Ileoce­
cal resection is a safe and more reliable 
alternative.
Pseudo-obstruction of the colon 
requires temporary gas decompression of 
the cecum. If colonoscopic decompres­
sion has failed, a tube cecostomy may be 
considered. However, a mucosa-to-skin 
cecostomy is more reliable.
In summary, tube cecostomy is not a 
reliable means of diversion or decompres­
sion for protecting distal anastomoses. 
Cecal volvulus is best managed by resec­
tion and primary anastomosis. Tube 
cecostomy or a mucosa-to-skin cecostomy 
may still have a role in the management 
of pseudo-obstruction of the colon 
unresponsive to colonoscopic decompres­
sion. Currently there are no other indi­
cations for the use of tube cecostomy.
Stanley  M . G old berg , m d , facs 
D avid  L. M eese , md
Department of Surgery,
Division of Colon and Rectal Surgery, 
University of Minnesota Medical School,
516 Delaware St. SE,
Minneapolis, MN 55455 
USA
Organization of Trauma Care
To the editors.—Although you are to be 
commended for an excellent overview of 
trauma care systems in Canada (vol. 28, 
no. 6, November 1985), I would like to 
update you on progress being made in 
Ontario. Presently, we have one central 
air ambulance dispatch for the entire 
province and central land ambulance dis­
patch for all the major urban and regional 
centres.
With respect to the air ambulance, in 
Ontario, Bandage 1 helicopter which 
operates out of Toronto and covers cen­
tral Ontario has had paramedical staff for 
7 years. In addition, advanced life sup­
port is being introduced in the near future 
to the two helicopters and two small jets 
that operate as dedicated air ambulances 
in Northern Ontario.
J.W. C rosby , m d , fr cpc
Medical consultant,
Emergency Care Programs,
Ministry of Health,
Government of Ontario,
7 Overlea Blvd.,
Toronto, Ont.
M4H 1A8
Management of Breast 
Fibroadenoma in Women 
Under 25 Years of Age
To the editors.—Deschenes and associates 
(Can JSurg  1985; 28: 372-374) advocate 
delayed excision of breast fibroadenomas 
for women under 25 years of age with a 
cytologically confirmed tumour on the 
grounds that the risk of breast cancer is 
small and spontaneous regression may 
occur. In a retrospective study1 of 134 
patients with a clinical diagnosis of 
fibroadenoma, cancer was found in 8. 
One of these patients was only 26 years 
old. Fine-needle aspiration biopsy has a 
sensitivity of over 95% in the diagnosis 
of suspected malignant breast masses,2 
but a negative result is of no value. In two 
out of eight patients with a clinical diag­
nosis of fibroadenoma who later were 
found to have cancer, fine-needle aspi­
ration cytology gave negative results.1
The extent to which fibroadenomas 
may show spontaneous regression is 
uncertain. In one report3 only 2 of 17 
fibroadenomas observed for varying 
periods regressed. The standard treatment 
of fibroadenoma should, therefore, 
remain surgical excision1 since it is both 
diagnostic and therapeutic.
V .K. Ka p o o r , m b , bs, ms 
Formerly senior resident 
Research officer
L.K. SHARMA, MB, MS, FICS 
Professor
Department of Surgery,
All India Institute of Medical Sciences,
New Delhi — 110029,
India
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To the editors.— We fully agree with 
Kapoor and Sharma that excisional 
biopsy is the standard management of 
women with a presumptive clinical and 
cytologic diagnosis of fibroadenoma. 
Like Haagensen,1 however, we see no 
point in rushing patients under 25 years 
of age to the operating room. The risk of 
a malignant condition is, indeed, minimal 
at that age. Among our 762 patients with 
histologically confirmed fibroadenoma, 
studied in the last 8 years, 158 (20.7%) 
were in the 20- to 24-year age group and 
85 (11.2%) were under 20 years of age, 
the youngest being 15 years old. On the 
other hand, in Haagensen’s series of 6000 
patients with carcinoma of the breast1
and in our series of 1564 cases, there was 
no woman in her teens and there were, 
respectively, 9 (0.15%) and 3 (0.19%) 
patients aged 20 to 24 years. In these 12 
young patients with breast cancer, clini­
cal findings were not suggestive of a 
fibroadenoma.
Prompt surgery is justified for young 
women with a presumptive diagnosis of 
fibroadenoma who mention a rapidly 
growing lump, have a tumour measuring 
more than 15 to 20 mm in diameter or 
seem anxious. Otherwise, we recommend 
an excisional biopsy in the next few 
months at the patient’s convenience. 
Occasionally, at re-examination, the 
tumour has vanished. If a biopsy is not 
performed, it is practically impossible to 
know whether the lump was in fact a 
fibroadenoma, a small cyst depleted by 
the fine needle of the aspiration biopsy 
or a nodule associated with premenstrual 
changes in the breast.2
L u c  D e sc h £n e s , m d , frcsc  
J a c q u elin e  Fa b ia , m d , sc  d 
S imon  J a c o b , m d , fr c pc
Hopital du Saint-Sacrement,
1050, chemin Ste-Foy,
Quebec, PQ,
G1S 4L8
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
Heart Transplants Likely to Quadruple in Canada
by 1990
“ Between ages 10 and 55 years, about 
1500 to 2000 people in Canada each year 
could benefit from heart transplantation; 
if you extend the age limit to 65, the num­
ber is probably doubled,” says the man 
heading the newest heart-transplant pro­
gram in the country.
Dennis Modry, FRCSC, who spent 3 
years at Stanford and was chief of the 
transplant service in his last year there, 
received approval from the Alberta 
government on May 1 this year for a pro­
gram at the University of Alberta Hospi­
tal in Edmonton, giving the western 
provinces their first centre for heart and 
heart-lung transplants. The approval fol­
lows a pilot program in which Modry’s 
team performed three heart transplants — 
the first one on July 28, 1985 — and then 
analysed the costs and results of the care 
both in and outside the hospital.
Within 4 years, Modry expects his and 
other Canadian centres each to be per­
forming about 50 heart transplants annu­
ally. “ The goal for 1990 is to do about 
500 transplants across the country in 10 
or so centres; the centres performing 
heart-lung transplants may each do 
another 5 or 10 of those. That’s a realis­
tic number to aim for given the status of 
available donors. If legislation is enacted 
to make it incumbent upon physicians to 
approach donor families, then the trans­
plant teams could conceivably handle 
about two-thirds of the people who can 
benefit from the procedure.
“ In Edmonton, we have now accepted 
seven individuals as recipients for heart 
transplants but there are hundreds that
Contributions to this column are welcome. 
Please send your material to: Mrs. Amy 
Chouinard, Canadian Journal o f Surgery, PO 
Box 8650, Ottawa, Ont. K1G 0G8.
have been referred from British Colum­
bia, Alberta and Saskatchewan. There is 
talk of another two western centres — one 
in Vancouver — that should come on 
stream in a couple of years and one in 
Winnipeg. Most centres begin with heart 
transplantation and move into the more 
difficult heart-lung procedure. For our 
program, the next transplant could be a 
heart-lung operation as far as Em con­
cerned since Eve done several at Stanford 
and a great number in the lab.
“ Since we are just getting started in 
transplantation we haven’t assessed the 
wait list. In future, we will probably have 
actively selected 12 to 15 people at any 
one time, although there may be any­
where from 50 to 75 who are waiting to 
get on the active list.”
At present, like Modry’s group, most 
of the other centres are just gearing up, 
averaging fewer than 10 each in the past 
year. Besides the group in Edmonton, 
teams at four hospitals in Montreal, two 
in Toronto, one in London and one in 
Ottawa are performing heart or heart- 
lung transplants.
As the procedures are performed only 
on individuals with “ end-stage” disease, 
the operation’s ability to extend life has 
not been debated since survivors 
undoubtedly live longer than they would 
have without the transplant and success 
rates approach 90% in most centres.
Ottawa Team Opts for 
Artificial Heart
At the success rates typical of heart trans­
plant programs, the risk of imminent 
death for recipients is much greater before
than after transplantation — a reality that 
has prompted cardiac transplant teams 
not only to step up the numbers of ope­
rations but to seek reliable means of tem­
porary support until a human heart 
becomes available. So it was that in May, 
the University of Ottawa Heart Institute
— or rather team leader Wilbert Keon, 
FRCSC, coordinator Arvind Koshal, 
FRCSC, Alan Menkis, clinical and 
research fellow, and resident Ed Farrell
— became the first in Canada to test an 
artificial heart as a means to bridge the 
time between heart failure and receipt of 
a suitable donor heart.
Menkis has submitted for publication 
a report of the events leading up to and 
following the use of the Jarvik 7-70 in 
Noella Leclair but briefly reviewed the 
event: “ The patient was a 41-year-old 
mother of one who was asymptomatic 
before the initial infarct. During the next 
week the infarct extended to cover most 
of her left ventricle, and despite all of the 
usual and dramatic things that cardiolo­
gists and cardiac surgeons do, including 
the use of streptokinin, intra-aortic bal­
loon pumping and subsequent double 
bypass, she couldn’t come off bypass. By 
the time we put in the artificial heart she 
was effectively dead.” The decision 
proved timely and, despite some bleeding, 
she was “ in good shape when a donor 
became available” . Thus, the first reci­
pient of an artificial heart in Canada 
became the 12th to receive a human heart 
at the institute, which began its program 
2 years ago. (True to the statistics else­
where, one patient in the series died, 5 
weeks after transplantation.)
As might be expected, the technique for 
inserting the air-driven pump made of 
plastic and metal differs substantially 
from that for a human heart, so last year 
the team spent time learning the proce­
dure with the heart’s developer in Salt 
Lake City.
The Jarvik heart has now been used at 
least 12 times to maintain individuals 
awaiting human hearts, and only two 
patients have reportedly died while it was
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inserted. It has not been compared with 
other means of temporary support but 
was the method with which the Ottawa 
team felt most comfortable.
Methods of bridging will be used 
increasingly often, not only for patients 
like Leclair who deteriorate rapidly, but 
also for those who become victims of the 
competition for organs. At present, only 
about 15% of organs that could be used 
for transplantation are being donated, 
and the frustrating part, says Menkis, is 
“Every institution in Canada is capable 
of contributing donors. Whether it is 
capable of retrieving the organs is irrele­
vant, since the MORE (Multiple Organ 
Retrieval, Toronto) system will arrange 
for someone to come to the institution. 
A very small hospital can contribute 
organs if it has the intensive care facili­
ties to keep someone who is brain dead 
physiologically going.
“ When you have a recipient or donor, 
you call MORE or NATCO (North 
American Transplant Coordinating 
Agency), and the staff there make a 
preliminary match by blood type, size and 
age of the individuals. An urgency or 
status-nine list is reserved for patients in 
imminent danger of dying.”
Leclair was put on the list. The heart 
that she eventually received was from a 
44-year-old Montreal man killed in a car 
accident near London, Ont.
At one time, a heart older than 35 years 
wouldn’t have been considered because of 
the prevalence of heart disease in North 
America, but, says Menkis, “ Generally 
all the programs are relaxing their criteria 
somewhat, using chronologically older 
donors and recipients. We do an angio­
gram to confirm there is no coronary 
artery disease in older donors...the 
healthy heart of a 40-year-old is better 
than the near-dead heart of the 
recipient.”
London Multiorgan Service to 
Perform 200 Transplants
Calvin Stiller, FRCPC, chief of the mul- 
tiorgan transplant service at University 
Hospital, London, Ont., reports that the 
cardiac transplant team there performed 
19 heart transplants in the first quarter 
of this year and by the end of May had 
done more than 70.
“Although, like most transplant pro­
grams, we initially were quite restrictive 
about recipients, we are now taking 
patients on the basis of their need. We 
have performed heart transplants in 15 
older than 50 years and 10 older than 55 
years. The current success rate is over 
80% for the entire program.”
Stiller prefers to discuss the complete
multiorgan service. The statistics are 
impressive, with similar success rates 
across the board for kidney, liver and 
heart.
The teams in the service expect to per­
form transplants at the rate of about two 
kidneys, one heart and one liver each 
week this year.
Says Stiller, “About four of every five 
transplant recipients will regain their pre­
illness health at a cost to society of about 
$40 000 to $50 000 for every heart and 
liver transplant and something in the 
region of $25 000 for every kidney. Each 
of the clinical programs is preceded by 
intensive work in the laboratory. For 
instance, right now transplant programs 
for intestines, limbs and islets are in the 
preparatory period, with clinical applica­
tions expected in the next 2 to 3 years. A 
facility is now under construction to 
house the whole program; a 12-bed unit 
is being built and will open in December, 
the focus being detection and manage­
ment of rejection.”
Montreal MD Recalls Events 
Leading to His Heart 
Transplant a Year Ago
“ I had everything to contraindicate 
transplantation,” says Samir Chebeir, 
FRCSC, who at 49 years was still within 
the criteria for age, but was suffering 
from pulmonary infection, renal insuffi­
ciency and hypotension, as well as hav­
ing numerous rib fractures and a swollen 
foot from misguided medical care he had 
received days before in the Azores 
Islands.
Albert Guerraty, FRCSC, head of the 
heart-transplant team at the Royal Vic­
toria Hospital in Montreal, had to be 
pushed to perform the operation accord­
ing to Chebeir: “ I was in very bad shape; 
he told everyone I was going to die, but 
he operated on me April 29, 1985. After 
the transplant I was in a coma for 3 days, 
I had to have dialysis and I had a gastric 
hemorrhage.”
When it had all begun 1 month earlier, 
Chebeir and his wife were en route to Por­
tugal for a holiday. As the plane stopped 
to refuel in the Azores Islands, Chebeir, 
who had no history of heart disease and 
was a hard-working obstetrician- 
gynecologist, experienced a sharp, 
unmistakable stab.
He called for oxygen, and when no one 
responded he fumbled to find the plane’s 
canister. It was empty, but a flight atten­
dant noticed the commotion and began 
to chastise him before realizing his dis­
tress. A fellow traveller — a doctor from 
Toronto — took his pulse, confirmed 
arrhythmia and administered lidocaine 
hydrochloride and called an ambulance.
The first hospital sent him to a second 
where he was admitted. As he entered, he 
moved backward in time — to the days 
when defibrillators caused every muscle 
in the body to contract, when anesthetics 
were not offered and no equipment except 
an electrocardiograph was used for inves­
tigations. He watched his electrocardio­
gram charting a series of arrhythmias; he 
was given a pacemaker. He continually 
asked to be allowed to return to Canada 
for treatment.
He had no phone in his room, and the 
receptionists at the hospital spoke only 
Portuguese so relayed no messages to 
him. His request for assistance in reach­
ing specialists in Montreal was denied. 
His wife succeeded in arranging for col­
leagues at Hotel-Dieu — a cardiologist 
and cardiac surgeon — to obtain 
whatever they needed in the way of equip­
ment and medications and to rent a jet 
from New Jersey. They arrived in the 
Azores to oversee his flight home.
Back in Montreal, the investigations 
began. Besides the ischemic cardiomyopa­
thy, he had pulmonary infection, 
hypotension, renal insufficiency, an 
inflamed foot, and every day he required 
either cardiac massage or defibrillation, 
the cardiac arrests numbering more than 
100 before he underwent transplantation.
Chebeir has had no episodes of rejec­
tion; he takes cyclosporine (150 mg twice 
a day) and cortisone (10 mg daily). Peri­
odically he has also needed captopril for 
renal hypertension related to the long­
term use of cyclosporine. His serum 
creatinine levels are elevated (between 159 
and 194 /unol/L) and although he is pre­
pared to decrease his intake of cyclospo­
rine, he refuses to consider a regimen 
without the drug. “ If I switch now to 
Imuran (azathioprine), the chances of 
rejection, I think, are high, and it’s 
impossible to know beforehand. I prefer 
to diminish the dosage of cyclosporine.”
By radioimmunoassay, the levels of 
cyclosporine in his blood are within the 
range considered suitable for maintenance 
— between 90 ng and 150 ng/ml.
Chebeir is one of 19 who have received 
new hearts at the Royal Victoria Hospi­
tal. All but one are still alive and have 
Guerraty and his team to thank. To show 
his gratitude, Chebeir has been 
instrumental in obtaining support from 
the private sector for the program. Lloyd 
MacLean, FRCSC, surgeon-in-chief, 
noted that Chebeir has been able to put 
the services of a Lear jet at the disposal 
of the transplantation unit when a donor 
heart needs to be picked up, even from 
as far away as South Carolina.
Says Chebeir, “The cardiac team at the 
Royal Victoria is very capable and could 
do even more than they are doing now if 
they had some help. The government has 
not provided funds and the conditions at 
the hospital are not what one would
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expect for sophisticated surgery. The 
hospital doesn’t have anything — I had 
to bring a chair from my home for my 
room.
“ Competition with other hospitals for 
funds has been detrimental, and my aim 
is to help establish a foundation for heart 
transplantation so that everyone who 
needs a transplant can have one.”
In the meantime, Chebeir has done 
much to facilitate organ procurement and 
he would like to see the government do 
more. “ At least three or four are await­
ing heart-lung transplants at the Royal 
Victoria and another six are waiting for 
hearts. In April, the shortage was serious 
for many centres. What we need to do is 
to persuade the government to pass a law 
similar to the one in France, number 
761181 du Conseil d ’etat.” This law 
assumes that a person is willing to donate 
organs unless he or she officially opts out.
Few surgeons would disagree with Che­
beir that the pool of donors has to be 
extended, but the methods for doing so 
are widely debated.
Heart-Lung Transplants 
in Toronto Began as Treatment 
for End-Stage Lung Disease
The Toronto team performing heart-lung 
transplants, unlike the others in Canada, 
began the operation as an extension of 
their program to deal with end-stage lung 
disease.
Joel Cooper, FRCSC, who heads the 
program as part of the division of 
thoracic surgery at the University of 
Toronto, explains: “ There are two com­
ponents of the program — single-lung 
and heart-lung transplantations. The 
former is unique in that we have the only 
successes in the world after about 45 
unsuccessful tries over the past 20 years. 
We’ve done single-lung transplants in five 
patients with pulmonary fibrosis, with 
four long-term successes. The first was in 
November 1983, and that recipient is now 
61 years old, leading a normal life. The 
second was a woman who’s now touring 
Germany; she was confined to a wheel­
chair before the operation. All the sur­
vivors returned to work within 3 months.
“ However, the heart-lung operation or 
— as we refer to it — the lung-heart oper­
ation is used in most places in the world 
for an individual whose heart has failed 
in association with some narrowing of the 
blood vessels of the lung. We started 
using the operation because there are 
some people with lung failure for whom 
a single-lung operation is not suitable, for 
example, when the heart fails because of 
lung disease or when the patient has a
condition in which one needs to take out 
both lungs, such as cystic fibrosis or 
emphysema. At the moment, the only 
way we can replace both lungs is to 
include the heart, although we are work­
ing on an operation for just the lungs.
“ We have performed five heart-lung 
transplants, with four survivors. One of 
the survivors has now — a year later — 
died, probably as a result of chronic rejec­
tion. All the others are doing well. One 
was a gal from Chicago; another much- 
publicized case was a woman from Que­
bec — Diane Hebert. She had been down 
to Stanford for a couple of years and had 
come here to die. One was a chap from 
Calgary who had a congenital immune 
deficiency — agammaglobulinemia.
“At first I thought it was insane to con­
sider a transplant for him. His defect 
meant he wasn’t making B-cell antibod­
ies to protect him against bacterial infec­
tion. To take someone like that and fur­
ther suppress the immune system — do
a T-cell immunosuppression to protect 
against rejection — I thought would 
render him hopelessly vulnerable. What 
I found out was that gammaglobulin can 
now be injected intravenously once a 
month to keep this type of individual 
immune competent. That treatment 
wasn’t available before and the repeated 
infections destroyed his lungs.
“ It’s only one case so all I can tell you 
is that he probably had fewer problems 
with rejection than did anyone else, 
although some of the other recipients had 
only minimal rejection.
“ For all our heart-lung transplant 
recipients, we use primarily cyclosporine 
for immunosuppression; after the first 3 
weeks we also use prednisone — not 
before, because we feel it interferes with 
wound healing. We use azathioprine, and 
in the early days we sometimes use 
antilymphocyte globulin.”
Amy Chouinard
SESAP V Question
Item 44
Which of the following statements about operative management of pa­
tients with unresectable carcinoma of the pancreas is TRUE?
(A) Gastrojejunostomy should be performed only if duodenal obstruc­
tion is already present
(B) Cholecystojejunostomy will reliably decompress the biliary tree if 
the gallbladder is distended
(C) Choledochoenteric anastomosis should be performed if the tumor 
encroaches on the cystic duct
(D) Placement of a hepatic U tube can provide excellent palliation if 
this procedure can technically be performed
(E) Routine drainage of the obstructed pancreatic duct is usually recom­
mended
For the critique of Item 44 see page 286.
(Reproduced by permission from SESAP V Syllabus; Surgical Education and 
Self-Assessment Program No. 5. For enrolment in the Surgical Education and 
Self-Assessment Program No. 5, please apply to the American College of Sur­
geons, 55 East Erie St., Chicago, IL 60611.)
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Surgical Management of Gastric Ulcer
The charts of 139 patients operated on 
for benign gastric ulcer between 1976 
and 1980 were reviewed. Indications for 
surgery included failure of medical 
management, bleeding, perforation and 
inability to differentiate benign from 
malignant disease. Surgical management 
included hemigastrectomy 2 9 % , vagot­
omy with antrectomy 2 7 % , vagotomy 
with pyloroplasty 13% , wedge resection 
7 %  and highly selective vagotomy 4% . 
Eighty-four patients (60% ) were available 
for a minimum 4-year follow-up. Recur­
rence rates were highest in those treated 
by highly selective vagotomy (33% ) and 
wedge resection (3 0 % ). The overall 
death rate was 4 .3 % , and 7 0 %  of the 
patients were classified as Visick grades 
I or II (no or minimal symptoms).
Of the 30 patients with acute perfora­
tion, 21 were treated by omental patching; 
1 died and 3 had recurrent ulcer. Of six 
patients treated by vagotomy with antrec­
tomy, there were no deaths and no 
recurrences.
The authors conclude that lesser 
procedures are associated with an unac­
ceptable recurrence rate and that gastric 
resection is the procedure of choice for 
both elective and emergency manage­
ment of gastric ulcer.
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On a etudie les dossiers medicaux de 
139 patients qui ont ete operes pour un 
ulcere gastrique benin entre 1976 et 
1980. Parmi les indications chirurgicales, 
on notait I'echec du traitement medical, 
des saignements, une perforation et 
I'impossibilite de differencier I'ulcere 
benin d'un cancer. Les techniques chirur­
gicales comprenaient 29%  d'hemigas- 
trectomies, 2 7 %  de vagotomies avec 
antrectomies, 13%  de vagotomies avec 
pyloroplasties, 7 %  de resections cun6i- 
formes et 4 %  de vagotomies hyperselec- 
tives. Quatre-vingt-quatre patients (60% ) 
ont pu se preter pendant un minimum de 
4 ans a des examens de surveillance.
Les plus hauts taux de rechute ont 6te 
observes chez les patients traites par 
vagotomie hypers6lective (3 3 % ) et par 
resection cun6iforme (3 0 % ). La mortality 
a 6te de 4 .3 % , et 7 0 %  des patients ont 
ete cotes I ou ll a la classification de 
Visick (absence de symptomes ou 
symptomes minimes).
Des 30 patients en perforation aigue, 
21 ont ete traites par pose d'une plaque 
d'epiploon; 1 est decede et 3 ont eu une 
rechute ulcereuse. II n'y a eu ni deces ni 
recidive chez les six patients traites par 
vagotomie et antrectomie.
Les auteurs concluent que les interven­
tions limitees sont entachees d'un taux 
de rechute inacceptable et que la resec­
tion gastrique represente ('intervention 
de premier choix dans le traitement 
d'urgence ou differ de I'ulcere gas­
trique.
Peptic ulceration of the stomach has a 
number of characteristics in common 
with duodenal ulcer, especially when the 
distal antrum and pyloric region are 
involved.1 However, ulceration of the 
body of the stomach remains distinct in 
its pathogenesis, the population at risk
and potential for complications. Unlike 
duodenal ulcer, a major priority in the 
management of gastric ulcer is the early 
detection of a possible malignant lesion. 
Despite these differences, the surgical 
management of gastric ulcer is often 
based on the principles underlying duo­
denal ulcer, resulting in an inappropri­
ately high incidence o f recurrence and 
morbidity.2-4 In an effort to define the 
features of gastric ulcer that demand 
separate consideration in surgical 
management, we undertook to review a 
series o f patients treated at our insti­
tution.
Patients and Methods
The charts of all patients operated on 
for gastric ulcer at the major Dalhousie 
University teaching hospitals between 
1974 and 1980 were reviewed. Ulceration 
was confirmed radiologically, endoscop- 
ically or by pathological study. Patients 
with coexisting duodenal ulcer were 
excluded, as were those with superficial 
erosions, gastritis or malignant gastric 
ulceration.
Follow-up information was obtained 
by questionnaire and by a review of 
hospital admissions after the ulcer sur­
gery. Particular attention was paid to 
ulcer recurrence and postoperative syn­
dromes.
A modified Visick classification was 
used to grade postoperative results, as fol­
lows: Visick I — no symptoms, Visick II 
— minimal symptoms, Visick III — 
severe symptoms controlled by medica­
tion and Visick IV — uncontrolled 
symptoms.
Findings
There were 139 patients (82 men, 57 
women), with a mean age o f 57 years. A 
minimum 4-year follow-up was possible
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in 84 (60%). With respect to the surgical 
procedures performed, patient availabil­
ity for re-evaluation was as follows: gas­
tric resection 49%, vagotomy and antrec­
tomy 58%, vagotomy and pyloroplasty 
100%, wedge resection 56% and highly 
selective vagotomy 100%. Within the ser­
ies, seven (5%) patients had previously 
undergone a Nissen fundoplication for 
gastroesophageal reflux.
Diagnosis
Endoscopy, the most common means 
of diagnosis, was used in 81 (58%) 
patients and correctly localized the ulcer 
in 73. As expected, those presenting with 
acute perforation were not subjected to 
endoscopy preoperatively. In 8 of the 81 
patients the ulcer was not visualized 
endoscopically but was found at laparo­
tomy. Biopsy and cytologic specimens 
were obtained through the endoscope in 
only 29 patients. Despite this, only 2 of 
the 139 patients were subsequently found 
to have underlying malignant disease.
Upper gastrointestinal series was used 
to identify the ulcer in 74 (53%) patients; 
the remainder were located at laparo­
tomy. Acid secretory studies were carried 
out preoperatively in six patients, and, of 
these, acid secretion was normal in five 
patients and below normal in one.
The ulcer was located in the body of 
the stomach, along its lesser curvature, in 
64 patients (46%). Of these, eight had 
ulcers in close proximity to the cardia. 
Fifty ulcers (36%) were in the prepyloric 
area and 17 (12%) arose from the gastric 
antrum.
Operative Procedures
The indications for operation and the 
surgical procedures performed are set 
forth in Tables I and II. The lowest recur­
rence rates followed gastric resection with 
or without truncal vagotomy.
Acute upper gastrointestinal bleeding 
was the indication for surgery in 32 (23%) 
patients. In three the bleeding point was 
simply oversewn because other risk fac­
tors were present, and in two of these the 
bleeding recurred immediately after oper­
ation, necessitating reoperation that 
resulted in the death of one patient. Six 
patients underwent vagotomy and 
pyloroplasty, two with concurrent wedge 
resection of the ulcer. Three patients 
underwent wedge resection alone. One 
patient, subjected to vagotomy and 
pyloroplasty, had recurrent bleeding 
postoperatively and required reoperation. 
No episodes of bleeding postoperatively 
were documented in 11 patients who had 
gastric resection or in 9 subjected to 
resection with truncal vagotomy. Surgery 
for bleeding gastric ulcer was followed by 
substantial morbidity. Wound complica­
tions occurred in 13 (41%) patients and 
7 (22%) patients had respiratory compli­
cations. Overall, the postoperative death 
rate was 13%.
Thirty patients required surgery for 
acutely perforated gastric ulcer. Only 11 
(37%) of them had a history of ulcer dis­
ease and 13 (43%) were poor surgical 
risks, because of advanced age, concur­
rent medical illness and delay before sur­
gery. Free air was visible on abdominal 
films in only 52% of those in whom the 
study was carried out. The perforation 
was in the distal stomach and prepyloric 
area in 20 (67%) patients. Of 14 patients 
in whom specimens of peritoneal fluid 
were submitted for bacteriologic culture 
at the time of surgery, only 3 demon­
strated substantial growth, consisting 
mainly of enteric organisms. A patch of 
omentum was used to seal the perforation 
in 21 patients, most of whom were poor 
surgical risks or had extensive peritoneal 
contamination. Biopsies of the ulcer were 
done in 12 of these and 3 suffered recur­
rent ulceration. One patient died shortly 
after operation. Truncal vagotomy and 
distal gastric resection to include the per­
foration was carried out in six patients, 
with no deaths and no recurrences.
Postoperative morbidity following sur­
gery for perforation was again mainly in 
the form of respiratory (20%) and wound 
complications (13%). The overall death 
rate was 3%.
Overall Mortality and Morbidity
In the early postoperative period, six 
(4.3%) patients died. Acute bleeding was 
the indication for surgery in four of these, 
and in another acute perforation.
Wound complications were the most 
common source of morbidity postopera­
tively, occurring in 23 (17%) patients. 
These were followed by respiratory tract 
complications, with significant atelecta­
sis and pneumonia occurring in 20 (14%) 
patients. Cardiovascular complications 
occurred in two patients and two 
experienced delayed gastric emptying in 
the early postoperative period.
Of the 84 patients available for follow­
up, long-term morbidity was minimal, 
with 57% rated as Visick I and 13% as 
Visick II. Symptoms suggestive of the 
dumping syndrome occurred in five 
patients (6%), diarrhea in four (5%) and 
alkaline reflux gastritis in two (2%). Of 
these 11 patients with post-gastrectomy 
syndromes, truncal vagotomy had been 
carried out in 9 (82%).
Discussion
While the pathogenesis of gastric ulcer 
remains unknown, some accept that the 
basic defect is a deficiency in mucosal 
protective factors to the secretion of acid
and pepsin. Davenport5 and Du Plessis6 
suggested that ulceration results from 
duodenal alkaline reflux, with destruction 
of the gastric mucosal barrier and cellu­
lar destruction mediated by back diffu­
sion of luminal acid. Thus, one would 
expect ulcer recurrence to be a common 
phenomenon following gastric resection. 
However, as in our series, recurrence rates 
have consistently been less than 5% when 
gastric ulcer is managed by resection.7’8 
Oi and colleagues9 suggested that the 
tendency for gastric ulcer to involve the 
lesser curvature near the incisura 
angularis can be explained by the presence 
of a congenital point of least resistance 
where parietal cell mucosa borders on 
antral mucosa. The failure of wedge 
resection of the ulcer to prevent recur­
rence, as in our series, suggests that other 
factors are involved. Of interest in our 
series, was the association between gas­
tric ulcer and previous Nissen fundo­
plication, an association already 
described.10’11 Alkaline reflux into the 
stomach and esophagus and altered gas­
tric emptying with hypergastrinemia have 
been proposed as possible contributory 
factors but are unproven.
Unlike duodenal ulcer in which the risk 
of underlying malignant disease is 
minimal, as many as 10% of gastric ulcers 
are ulcerating carcinomas.12 This empha­
sizes the importance of endoscopic exami­
nation with tissue sampling in all patients 
whose gastric ulcer fails to heal rapidly 
with medical management or who demon­
strate clinical features suggestive of malig­
nant disease.
If endoscopy cannot be carried out 
preoperatively, as in acute perforation, 
gastric resection allows sampling of ade­
quate tissue to exclude the presence of a 
malignant lesion. When resection is con­
traindicated, full-thickness biopsy speci­
mens of the ulcer margins should be 
obtained before resorting to a lesser 
procedure, such as omental patching. The
Table I—Indications for Operation
Indication
% of 
patients
Intractability 37
Bleeding 23
Perforation 22
Possible malignant disease 14
Obstruction 3
Penetration 1
Table II—Procedures Performed and 
________ Postoperative Recurrences________
%
Procedure recurrence
Vagotomy and antrectomy 0
Resection 5
Vagotomy and pyloroplasty 11
Wedge resection 30
Highly selective vagotomy 33
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failure of endoscopy to detect the ulcer 
preoperatively in 10% of our cases is pos­
sibly related to those emergency situations 
with bleeding. It also suggests the 
presence of a blind spot in the stomach, 
especially on the lesser curvature, that 
should be carefully evaluated during 
endoscopic examination.
The high incidence of wound compli­
cations in our series underscores the need 
for perioperative antibiotic prophylaxis 
and peritoneal lavage in the management 
of gastric ulcer, especially in bleeding gas­
tric ulcers in which the protective action 
of luminal acid is negated by the buffer­
ing effects of blood. During the period 
of our study, antibiotic prophylaxis and 
irrigation were not in widespread use.
Gastric resection, including the ulcer 
crater, appears to be the procedure of 
choice in the elective management of 
uncomplicated gastric ulcer. Recurrence 
rates of less than 5% have consistently 
been reported with acceptable postoper­
ative morbidity and death rates.7-8 Addi­
tion of a truncal vagotomy is indicated 
by the presence of a coexisting duodenal 
ulcer, the location of the ulcer in the 
prepyloric antrum or by preoperative acid 
studies suggesting hypersecretion. Vagot­
omy is not required for the treatment of 
proximal gastric ulcers or in patients with 
hyposecretion, as it can itself cause addi­
tional operative and postoperative 
problems.
Truncal vagotomy and pyloroplasty, 
when used to treat gastric ulcer is 
associated with recurrence rates higher 
than those seen when the procedure is 
used for duodenal disease.4,13,14 Also, the 
incidence of late postoperative problems 
is similar to that observed following trun­
cal vagotomy with antrectomy. It is, 
however, indicated for a potentially 
difficult duodenal stump or in the surgi­
cal management of a bleeding or perfo­
rated prepyloric ulcer in an unstable 
patient, after adequate biopsy samples 
have been obtained. The addition of ulcer 
excision did not improve the recurrence 
rate in our series, as one of the nine 
patients so treated had recurrent ulcer.
Highly selective vagotomy has gained 
a place in the management of uncompli­
cated duodenal ulcer,15,16 but recur­
rence rates following this procedure for 
gastric ulcer are unacceptable.2,3,15,16 
Although Reid and colleagues,17 in a 
randomized clinical trial, found no differ­
ence in recurrence rates between Billroth 
I resection and resection of the ulcer with 
highly selective vagotomy, the recurrence 
rate in the gastrectomy group was 
unusually high compared with those of 
most other series. Prepyloric and pyloric 
canal ulcers appear to be especially resis­
tant to resolution by highly selective 
vagotomy.2,3 Our series corroborates 
these data, with a 33% recurrence rate
following the use of highly selective 
vagotomy for gastric ulcer.
Although wedge resection of the ulcer 
provides enough tissue to exclude malig­
nant disease, the recurrence rate in our 
series was far greater than that following 
gastric resection, with the same potential 
for postoperative suture-line leakage and 
infection. Damage to the adjacent nerves 
of Latarjet is not unexpected and could 
account for the two cases of delayed gas­
tric emptying following wedge resection 
in our series.
Acutely perforated gastric or duodenal 
ulcers present a similar clinical picture, 
but in addition to the potential for malig­
nancy in gastric ulcer, the often-advanced 
age of the patient, with associated medi­
cal disease, may contraindicate aggressive 
surgical management. Always a consider­
ation in the management of visceral per­
foration is the degree of intraperitoneal 
contamination with the potential for 
intra-abdominal sepsis and suture-line 
breakdown. Of interest in our series was 
the high incidence of negative cultures 
from intraperitoneal fluid, even in 
patients with a history indicative of per­
foration 12 hours or more before surgery. 
A similar incidence of negative cultures 
has been noted by Boey and colleagues,18 
suggesting that extensive or long-standing 
peritoneal contamination does not con­
traindicate a definitive procedure for per­
forated peptic ulcer.
Because of the high recurrence rate 
after omental patching, gastric resection 
is clearly the operation of choice for gas­
tric perforation. However, when resection 
is contraindicated as in the unstable 
elderly patient with underlying medical ill­
ness, patching may be the only alterna­
tive.19 Intraoperative biopsy and then 
long-term therapy with histam ine2 
blockers are suggested before more defini­
tive surgery is considered in the event of 
recurrence.
A substantial number of perforated 
gastric ulcers are located in the antrum 
and prepyloric area where they share the 
physiologic characteristics of duodenal 
ulcer. In these circumstances the addition 
of a truncal vagotomy is appropriate, 
despite the risk of complications post- 
operatively.
When surgery is required for bleeding 
gastric ulcer, our series suggests that any­
thing less than resection of the ulcer, as 
a gastrectomy, results in a high incidence 
of recurrent bleeding in the early post­
operative period. This must be kept in 
mind when choosing a lesser procedure 
in high risk, unstable or elderly patients 
in whom the operative death rate of a 
second procedure can be extremely high. 
As in duodenal ulcer, optimal manage­
ment of bleeding gastric ulcer depends on 
prompt recognition and the timing of 
surgery.
Conclusions
When considering operative treatment 
for gastric ulcer in either elective or emer­
gency situations, the surgeon must recog­
nize the possibility of malignant disease 
and rule it out by tissue sampling en- 
doscopically or at laparotomy. Gastric 
resection is the procedure of choice in 
both emergency and elective situations, 
with the addition of truncal vagotomy, 
when indicated by location of the ulcer 
or the results of preoperative acid secre­
tory studies. In the emergency setting, 
when the patient is unstable or a poor 
risk, a less-definitive procedure may be 
undertaken providing the increased inci­
dence of ulcer recurrence is anticipated.
References
1. Johnson  HD, Love AHG, Rogers NC, et al: Gastric 
ulcers, blood groups, and acid secretion. Gut 1964; 5: 
402-412.
2. AMDRUP E, ANDERSEN D, HO STROP H: The Aarhus 
County vagotomy trial. I. An interim report on primary 
results and incidence of sequelae following parietal cell 
vagotomy and selective gastric vagotomy in 748 patients. 
World J  Surg 1978; 2: 85-90
3. Gleysteen JJ , Condon  RE, Ta ppe r  EJ: Prospective 
trial of proximal gastric vagotomy. Surgery 1983; 94: 
15-20
4. MADSEN P, SCHOUSEN P: Long term results of truncal 
vagotomy and pyloroplasty for gastric ulcer. Br J  Surg 
1982; 69: 651-654
5. Davenport HW: Is the apparent hyposecretion of acid 
by patients with gastric ulcer a consequence of a broken 
barrier to diffusion o f hydrogen ions into the gastric 
mucosa? Gut 1965; 6: 513
6. DU PLESSIS DJ: Pathogenesis of gastric ulceration. Lan­
cet 1965; 1: 974-978
7. DAVIS Z, VERHEYDEN CN, VAN HEERDEN JA, et al: 
The surgically treated chronic gastric ulcer: an extended 
followup. Ann Surg 1977; 185: 205-209
8. Thomas WEC, T hom pson  MH, W illia m so n  RCN: 
The long-term outcome of Billroth I partial gastrectomy 
for benign gastric ulcer. A nn Surg 1982; 195: 189-195
9. Ol M, OSHIDA K, Sugim ura  S: The location o f gastric 
ulcer. Gastroenterology 1959; 36: 45-46
10. BUSHKIN FL, WOODWARD ER, O’LEARY JP: Occur­
rence of gastric ulcer after Nissen fundoplication. A m  
Surg 1976; 42: 821-826
11. BREMNER CG: Gastric ulceration after a fundoplication 
operation for gastroesophageal reflux. Surg Gynecol 
Obstet 1979; 148: 62-64
12. KUKRAL JC: Gastric ulcer: an appraisal. Surgery 1968; 
63: 1024-1036
13. DUTHIE HL, MOORE TH, BARDSLEY D, et al: Surgical 
treatment of gastric ulcers. Controlled comparison of 
Billroth-I gastrectomy and vagotomy and pyloroplasty. 
Br J  Surg 1970; 57: 784-787
14. O’Leary JP, w oodw ard  ER, Hollenbeck h i , et al: 
Vagotomy and drainage procedure for duodenal ulcer: 
the results of seventeen years’ experience. Ann Surg 1976; 
183: 613-618
15. Stoddard  CJ, Johnson  AG, Duthie  HL: The iour 
to eight year results of the Sheffield trial of elective duo­
denal ulcer surgery—highly selective or truncal vagotomy? 
Br J  Surg 1984; 71: 779-782
16. KNIGHT CD JR, VAN HEERDEN JA, Kelly  KA: Prox­
imal gastric vagotomy: update. A nn Surg 1983; 197: 
22-26.
17. Reid DA, Duthie  HL, Bransom CJ, et al: Late follow­
up of highly selective vagotomy with excision of the ulcer 
compared with Billroth I gastrectomy for treatment of 
benign gastric ulcer. Br J  Surg 1982; 69: 605-607
18. BOEY J, WONG J , ONG GB: Bacteria and septic com­
plications in patients with perforated duodenal ulcers. Am  
J  Surg 1982; 143: 635-639
19. Feliciano DV, Bitondo CG, Burch JM , et al: Emer­
gency management of perforated peptic ulcers in the 
elderly patient. A m  J  Surg 1984; 148: 764-767
VOLUME 29, NO. 4, JU L Y  1986 /  THE CANADIAN JOURNAL OF SURGERY 235
Recent Research Suggests...
DALA
(clindamycin phosphate)
1. clindamycin
©  © f  •
2. clindamycin concentrating in PMN lysosomes
4. the invading bacteria
3. clindamycin-laden PMN moving 
toward the site of infection
C Phosphate S.S.
enhances 
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within 
the PMN in amounts greater than are found outside of the PMN.1 The 
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also 
enhanced by the presence of this antibiotic.2^ 3 These characteristics may 
help explain clindamycin’s outstanding record of clinical efficacy in both 
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of 
an infection, selection of antibiotics based on host defense parameters 
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144(5)
2) Johnson JD, et a! (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease 
(eds. J Nelson, C Grassi) Am Soc Microbiol Vol 2
5. phagocytosis of the bacterium 6. degranulation and killing
by antibiotic-enhanced PMN of engulfed bacterium
For prescribing information see page 238
8401 REGISTERED TRADEMARKS DALACIN 
TRADEMARK DALACIN C  CE 3950.1 LB
antibiotic i THE UPJOHN COMPANY OF CANADA 
research _ j 865 YORK MILLS ROAD/DON MILLS, ONTARIO
P A A B
C C P P
Dalacin C Phosphate S.S.
(c lin d am yc in  phosphate)
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by 
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections 
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic 
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium 
species and microaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms 
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when 
the patient is intolerant of, or the organism resistant to other appropriate antibiotics. 
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in 
patients previously found to be hypersensitive to th is compound, the parent compound, clindamycin, or 
clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride) has 
not been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have 
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn 
(infants below 30 days of age), or in pregnant women.
Mtarnings: Some cases of severe and persistent diarrhea have been reported during or after therapy with 
Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with 
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been 
performed, some of these cases have shown pseudomembrane formation.
If  significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, 
continued only w ith close observation. Significant diarrhea occurring up to several weeks post-therapy 
should be managed as if antibiotic-associated.
If co litis  is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may 
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration 
or pseudomembrane formation, should be managed with fluid, electrolyte, and protein supplementa­
tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent 
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis 
should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal 
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this 
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco­
mycin were administered orally four times a day for 5 -1 0  or more days, there was a rapid observed 
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
Is should be noted that serious relapses have occurred up to one month after apparently successful 
treatment. A relatively prolonged period of continuing observation is therefore recommended 
Precnitlons: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with 
caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration) 
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly 
yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the 
clinical situation.
As w ith  all antibiotics, perform culture and sensitivity studies in conjunction w ith drug therapy. 
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic 
liver function tests should be performed during prolonged therapy. Blood counts should also be 
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in 
patients w ith impaired hepatic function is greater than that found in normal patients, the dose of 
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not 
effective means of removing the compound from the blood. Periodic serum levels should be determined 
in patients w ith  severe hepatic and renal insufficiency.
Adverse Reactions: Local.
(a) Intramuscular Injections: 01404 patients treated w ith Dalacin C Phosphate (clindamycin phos­
phate) intramuscularly (w ith a solution containing 150 mg/mL), six (1.5%) demonstrated local 
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the 
injection site and two developed sterile abscesses.
(b) Intravenous Infusions: Of 192 patients treated w ith Dalacin C Phosphate by intravenous infusion, 
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and 
one patient developed both superficial and deep thrombophlebitis. The majority of these cases 
developed in conjunction with the use of indwelling I V. catheters and it is d ifficu lt to know how much 
the drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at 
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated w ith  Dalacin C Phosphate (clindamycin 
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as 
follows:
Number o f Patients
R ash .................................................................................................................................................................. 7
U rt ic a r ia ..........................................................................................................................................................  1
P ruritus.............................................................................................................................................................  1
Fever, Leucocytosis ....................................................................................................................................  1
Nausea, w ith or w ithout vo m itin g ..............................................................................................................  1
Diarrhea (See also under “W arn ings").....................................................................................................  4
Hypotension ...................................................................................................................................................  1
H ypertension...................................................................................................................................................  1
Shortness of Breath ....................................................................................................................................  1
S uperin fec tion*..............................................................................................................................................  4
Cardiac arrest** ............................................................................................................................................ 1
Bad and bitte r taste in m ou th ...................................................................................................................... 5
* Superinfection is a complication of antibiotic therapy in general and is not necessarily a true 
side effect of clindamycin phosphate.
'*  Due to underlying myocarditis in this patient.
Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate 
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology, 
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned 
to normal during therapy w ith Dalacin C Phosphate, while others were normal initially and became 
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does not 
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal 
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver 
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and 
there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Trnatment of Omrdosagt: No cases of overdosage have been reported. No specific antidote 
is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been 
given without adverse effects.
DOSAGE AND ADMINISTRATION 
Adults
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 .3  or 4 equal doses. Intramuscular injections of more than 
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to I.V. 
administration to a dilution of 300 mg in 50 ml of diluent (6 mg/ml) or more, and infused in not less 
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended. 
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each 
infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over 
20 minutes or longer, in life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip 
or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and Infusion rates:
Dose Diluent Time
300 mg 50 ml 10 min.
600 mg 100 ml 20 min.
900 mg 150 ml 30 min.
1200 mg 200 ml 45 min.
Alternatively, drug maybe administered in the form of a single rapid infusion of the first dose followed 
by continuous I.V. infusion as follows:
To maintain serum Rapid Maintenance
clindamycin levels infusion rate infusion rate
Above 4 mcg/ml 10 mg/min. for 30 min. 0.75 mg/min.
Above 5 mcg/ml 15 mg/min. for 30 min. 1.00 mg/min.
Above 6 mcg/ml 20 mg/min. for 30 min. 1.25 mg/min.
Children: (Over one month of age)
Intramuscular injection: 10 to 15 mg/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration:
Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each 
infused over 20 minutes or longer. In severe infections, it is recommended that children be given no less 
than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in the same 
manner as for adults.)
Dilution and Compatibility:
4 ml (600 mg) Dalacin C Phosphate when diluted with 1000 ml of the following commonly used in­
fusion solutions was found to be physically compatible and demonstrated no significant change in pH 
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection 
Dextrose 5% in water 
Dextrose 5% in saline 
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride 
Dextrose 214% in Lactated Ringer's Solution (Hartmann's Solution)
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is 
not recommended that Dalacin C Phosphate be mixed w ith any infusion solution containing B vitamins. 
Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg 
Benzyl alcohol 5 mg 
Disodium edetate 0.5 mg 
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH 
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.1C
8401 REGISTERED TRADEMARKS DALACIN 
TRADEMARK DALACIN C CE 3950.1LB
T H E  U P J O H N  C O M P A N Y  O F  C A N A D A
8 6 5  Y O R K  M IL L S  R O A D /D O N  M IL L S , O N T A R IO
PRODUCT OF
U p j o h n
ANTIBIOTIC 
I RESEARCH |
MEMBER
PAAB
Denis Bernard, m d , frcsc; Stephen Morgan, m d , frcsc; Daniel Tasse, m d , frcsc
Colonoscopic Assessment of Radiologic Strictures
of the Colon
The authors studied 47 patients with 
radiologic evidence of stricture to deter­
mine whether colonoscopy in this situa­
tion increased the accuracy of diagnosis 
and how this procedure might influence 
patient management. Colonoscopy 
increased to 81% the diagnostic 
accuracy, which was established at 38% 
with the single-contrast enema. Failure 
of both techniques to establish a precise 
diagnosis was 19%.
From the clinical and radiologic data, 
surgical exploration for the 47 strictures 
would have been necessary in 28, not 
indicated in 9, and indicated solely for 
diagnostic purposes in 10. The addition 
of colonoscopy prevented unnecessary 
laparotomy in 5 (18%) of the first group 
and in 8 (80%) of the last. The authors 
conclude that colonoscopy should be 
complementary to the standard radiologic 
examination for colonic strictures, espe­
cially when carcinoma is suspected or if 
roentgenography does not provide a 
definitive diagnosis.
Devaluation par coloscopie de 47 
stenoses radiologiques du colon a ete 
faite pour etablir une correlation entre les 
diagnostics radiologiques, endoscopiques 
et finaux et pour determiner si la con- 
duite therapeutique a pu etre influencee 
par I'addition de la coloscopie. Le diag­
nostic radiologique a ete exact et precis 
dans 18 cas (38%). L'addition de la 
coloscopie a permi d'accroitre ce taux
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d'exactitude a 81%  (20 cas addi- 
tionnels).
L'indication chirurgicale qui avait ete 
posee 28 fois sur des criteres ciiniques 
et radiologiques a ete infirmee par la 
coloscopie chez cinq et differee chez 
neuf autres. De plus, une intervention 
chirurgicale a pu etre evitee a raison huit 
fois mais a tort une fois chez 10 patients 
ou l’indication chirurgicale ne reposait 
que sur un doute diagnostique radiolo­
gique.
A cause d'un taux residuel de 19% de 
diagnostic inexact ou imprecis, on doit 
considerer la coloscopie comme com- 
piementaire a la radiologie dans les 
stenoses et I'eiement clinique ne doit pas 
etre ignore.
Strictures of the large bowel seen radio- 
logically may or may not represent a seri­
ous pathologic condition. Spasm, muscu­
lar thickening, fibrosis, inflammation and 
carcinoma can all be manifested by nar­
rowing of the colonic lumen. Although 
there may be typical radiologic features 
for each lesion, in many cases a diagnos­
tic dilemma persists,1,2 especially when 
carcinoma cannot be ruled out. Before 
the advent of colonoscopy, the only 
approaches to these strictures were to 
observe the patient by repeated barium 
enema roentgenography or to operate, 
both of which had obvious disadvantages. 
Even with the more widespread use of air- 
contrast enemas, the tortuous sigmoid 
colon, the commonest site of strictures,1 
is not easily completely demonstrated.3
The purpose of this paper is to deter­
mine the extent to which colonoscopy can 
add to the diagnostic accuracy and 
influence subsequent surgical manage­
ment of the patient.
Patients and Methods
Between 1980 and 1984, we attempted 
colonoscopy in every patient under our 
care who had radiologic evidence of 
colonic stricture. We excluded those with 
the typical symptomatic annular, “ apple- 
core” lesion, because there is no doubt 
as to the diagnosis of carcinoma, and the 
typical filiform narrowing in patients who
had recurrent Crohn’s disease. There were 
47 patients (20 men, 27 women) whose 
mean age was 59 years.
Single-contrast radiologic examinations 
were performed initially with barium, or 
water-soluble material in acute cases. The 
opinions were those of the radiologist’s 
written report. Colonoscopy was subse­
quently performed with an Olympus CF- 
LB3R instrument (Olympus Corp. of 
America, New Hyde Park, NY) with x- 
ray films on display during the procedure. 
Fluoroscopy was not used. The diagno­
sis was established in all but one patient, 
either by surgical exploration and patho­
logical examination of the resected bowel, 
endoscopic biopsy or, in non-operated 
cases, through a combination of history, 
endoscopic findings and follow-up (e.g., 
asymptomatic normal bowel).
Before colonoscopy an indication for 
surgery was made from the clinical fea­
tures (persistent or disabling symptoms, 
presence of a mass, signs of bowel 
obstruction) or the radiologic diagnosis 
or a suspicion of carcinoma; the indica­
tion in each case was considered to be 
either present, absent or doubtful (when 
no diagnosis could be made). After 
colonoscopy we reassessed our findings 
to determine if surgery was indeed neces­
sary, not necessary, necessary but could 
be delayed, or whether the colonoscopic 
findings were inconclusive.
Findings
As expected the sigmoid colon was the 
most common site of stricture in 33 (7097o) 
patients (Table I). A summary of all 
cases, with radiologic diagnoses, colonos­
copic findings, final diagnosis and indi-
Table 1-Site of Stricture in 47 Patients
Site
No. of 
patients (%)
Sigmoid colon 33 (70.2)
Descending colon 7(14.9)
Splenic flexure 2 (4.3)
Transverse colon 1 (2.1)
Ascending colon 1 (2.1)
Cecum 1 (2.1)
Ileocolonic anastomosis 2 (4.3)
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cation for surgery before and after 
colonoscopy are shown in Table II. A 
definitive diagnosis of diverticulitis was 
made radiologically in 11, and of carci­
noma in 9, but in most other cases the 
radiologic findings were equivocal and 
offered a wide variety of diagnoses. 
Figures 1 to 6 illustrate the varying radi­
ologic findings in these patients. The dis­
tribution of final diagnoses established by
laparotomy, endoscopic biopsy or a com­
bination of history, endoscopy and 
follow-up are shown in Table III.
The radiologic diagnosis correlated 
with the final diagnosis in 18 cases (38%). 
The endoscopist was right in 14 of these 
cases, uncertain in 2 (cases 12 and 41) and 
could not reach the stricture in 2 cases of 
carcinoma (cases 15 and 16). The radiol­
ogist’s opinion did not correlate in 13
cases. The colonoscopist made the correct 
diagnosis in nine of these, erred in two 
(cases 24 and 39), one of which was a 
patient with carcinoma, remained doubt­
ful in one (case 40) and could not reach 
the stenosis in one (case 17, normal bowel on barium follow-through). Finally, bar­
ium enema examination was not diagnos­
tic in 16 (34%) (cases 25 to 34 and 42 to 
47). Of these, colonoscopy resulted in the
Table 11-Summary of Diagnostic Investigations in 47 Cases of Colonic Stricture
Case
no. Sex
Age,
y r Site of stenosis
Radiologic
diagnosis
Colonoscopic
impression Final diagnosis
Surgical indication 
Before After 
c o lo n o s c o p y t  c o lo n o s c o D v l
i M 63 Sigmoid DIV DIV DIV
2 F 61 Sigmoid DIV DIV DIV
3 M 68 Sigmoid DIV DIV DIV4 F 76 Sigmoid DIV DIV DIV5 F 42 Sigmoid DIV DIV DIV + D6 F 57 Sigmoid DIV DIV DIV + D7 F 70 Sigmoid DIV DIV DIV + D8 M 69 Sigmoid DIV DIV DIV + D 
+ D9 F 63 Sigmoid DIV DIV DIV
1 0 F 61 Sigmoid DIV Anastomotic
stenosis
Anastomotic
stenosis11 F 56 Sigmoid DIV N N ? o12 F 73 Sigmoid CA ? not diagnostic CA +
13 M 63 Sigmoid CA CA CA
14 F 67 Sigmoid CA CA CA
15 M 75 Transverse colon CA Not reached CA
16 M 63 Descending colon CA Not reached CA
17 F 78 lleotransverse
anastomosis
CA Not reached N + 0 §
18 F 67 Splenic flexure CA N N 0
o19 F 47 Descending colon CA N N
20 M 77 Sigmoid CA DIV DIV + o21 F 63 Sigmoid DIV and CA DIV and CA DIV and CA +22 M 61 Descending colon Lymphoma DIV DIV
23 F 61 Sigmoid DIV and polyp DIV DIV
24 M 70 Sigmoid DIV and polyp DIV and polyp DIV + -*
25 M 48 Sigmoid DIV or CA DIV DIV + + D26 F 78 Sigmoid DIV or CA DIV DIV + D27 F 67 Sigmoid DIV or CA DIV CA +
28 M 62 Sigmoid DIV or CA DIV Foreign-body
perforation
+ +
29 M 60 Sigmoid DIV or CA N N ? o30 M 29 Descending colon Inflammation or CA Crohn's disease Crohn's disease +
31 M 55 Descending colon Inflammation or CA Ischemic colitis Ischemic colitis + 032 F 47 Sigmoid Crohn's disease or CA Crohn's disease Crohn's disease ? 033 M 37 Descending colon Inflammation or ischemia Inflammation Pancreatitis ? ?
34 F 65 Sigmoid Inflammation or fibrosis Radiation stenosis Radiation stenosis
35 M 37 lleotransverse
anastomosis
Anastomotic stenosis Crohn's disease Crohn's disease + + D
36 F 71 Sigmoid Postop changes Anastomotic band Anastomotic band
37 F 61 Descending colon Ulcerative colitis Ulcerative colitis Ulcerative colitis + +
38 F 44 Sigmoid Spasm Fibrosis Fibrosis after seat 
belt injury
? 0
39 F 72 Sigmoid Extracolonic origin Extracolonic CA ? 0
40 F 39 Sigmoid Extracolonic origin Extracolonic Endometriosis + +  041 M 19 Ascending colon Extracolonic origin Extracolonic Unknown* ? 042 M 56 Sigmoid ? not diagnostic CA Extracolonic
(carcinomatosis)
+ +
43 F 38 Sigmoid ? not diagnostic DIV Endometriosis + +
44 F 48 Cecum ? not diagnostic Crohn's disease Crohn's disease _
45 M 75 Sigmoid ? not diagnostic Anastomotic
stenosis
Anastomotic
stenosis
? 0
46 F 58 Splenic flexure ? not diagnostic N N ? 047 M 62 Sigmoid ? not diagnostic N N ? 0
DIV - diverticulitis, CA =  carcinoma, A - anastomosis, N -  normal bowel.
'Congenital bands suspected because of age, location, no intraluminal disease, no symptoms; surgery not indicated, 
t  + -  present, -  -  absent, ? = doubtful, indicated for diagnostic purpose only.
1+ “  still present, -  -  still absent, 0 -  no longer present, +0 -  still present but delayed.
§Final diagnosis established by barium follow-through examination.
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correct diagnosis in 11, but was incorrect 
in 4 (cases 27, 28, 42 and 43) and was 
equivocal in 1 (case 33).
Barium enema examination alone re­
sulted in the correct diagnosis in 18 out 
of 47 patients. When the 20 correct diag­
noses obtained at colonoscopy in the 
remaining 29 are added, the combined 
accuracy of both techniques totals (81 Wo) 
(38 of 47).
As to management of the patients, the 
indication for surgery was present before 
colonoscopy in 28 patients, absent in 9 
and doubtful or indicated for diagnosis
FIG. 1—Case 31. Radiologic appearance 
suggests inflammatory condition but carci­
noma could not be ruled out. Endoscopic and 
histologic features were consistent with 
ischemic colitis and stricture.
FIG. 2—Case 33. Inflammation or ischemia 
was suggested radiologic diagnosis. Endoscopic 
findings were of inflammation of unknown 
cause. Subsequent exploration revealed pan­
creatitis and extrinsic compression.
only in 10. In the 28 patients for whom 
surgery was initially indicated, that indi­
cation was still present after colonoscopy 
in 14, it was still present, but could be 
delayed to a more appropriate time in 9, 
and was no longer present in 5 (normal 
bowel 3, cases 17, 18, 19; diverticulitis, 
case 20; ischemic colitis, case 31). In the 
nine patients presenting no indication for 
surgery before colonoscopy, none was 
established later. Finally in the other 10 
patients in whom the indication for sur­
gery was doubtful, it was considered not 
indicated in 8, indicated in 1 (case 42) and 
remained doubtful in 1 (case 33) follow­
ing colonoscopy. Further investigation of 
the last patient led to a diagnosis of 
chronic pancreatitis and surgical explora­
tion was carried out.
FIG. 3—Case 41. Radiologic and endoscopic 
diagnosis was extracolonic disease. There was 
no known final diagnosis, but congenital bands 
were suspected because of patient’s young age 
(19 years), location of stricture and because 
there were no symptoms and no intraluminal 
disease. Patient was not operated on.
FIG. 4—Case 19. Findings are suggestive of 
carcinoma but bowel appeared normal at 
endoscopy.
Discussion
Most important in the diagnosis and 
treatment of stenotic lesions of the large 
bowel is to establish the presence or 
absence of a malignant condition. Both 
diverticular disease and carcinoma occur 
most commonly in the sigmoid colon 
where they may coexist and be very 
difficult to differentiate. In our study, 
roentgenography established a diagnosis 
of diverticulitis in 12 cases, later con­
firmed in 10. Colonoscopy suggested the 
correct diagnosis in all 12 but was defini­
tive in only 2, neither being a carcinoma. 
This is contrary to the experience of 
Boulos and associates4 who reported 
coexistent neoplasia, benign or malig­
nant, in 31% of radiologically demon­
strated diverticular disease. Carcinoma
FIG. 5—Case 27. Roentgenography could 
not differentiate diverticulitis from carcinoma 
and endoscopic examination suggested a diag­
nosis of diverticulitis. Final diagnosis was car­
cinoma.
FIG. 6—Case 25. Radiologic appearance 
suggested either diverticulitis or carcinoma. 
Endoscopy ruled out carcinoma.
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(or lymphoma) was thought to be present 
on 11 contrast enema examinations: 5 
were subsequently proven incorrect, 4 by 
colonoscopy (cases 18, 19, 20 and 22). 
The suspicious area in the fifth could not 
be reached by colonoscopy. These find­
ings are comparable to the experience of 
Hunt and colleagues1 who disproved the 
presence of carcinoma in 30 (57%) of 53 
“ malignant strictures” . Filoche and 
colleagues5 also reported colonoscopic 
exclusion of carcinoma in 7 of 13 (54%) 
suspected cases. Diverticulitis could not 
be differentiated from carcinoma in five 
instances: carcinoma was present in one 
but was missed at colonoscopy (case 27, 
Fig. 5); in the other four, suspected car­
cinoma was not present (Fig. 6). This fol­
lows the experience of Rozen’s group;6 
in 18 similar situations Filoche and 
colleagues5 found only one case of car­
cinoma.
A limitation of colonoscopy in stric­
tures is well demonstrated in the study of 
Dean and Newell3 in which there were 17 
(47%) inadequate examinations of the 
diseased segment in 36 cases of divertic­
ulitis. Their main reasons for failure were 
sharp angulation, inability to distend the 
narrow lumen and persistent fecal soiling 
through the obstructed segment. Filoche 
and colleagues5 established at 20% the 
number of strictures that could not be 
examined over their whole length. In our 
study, an accurate diagnosis by en­
doscopy failed in three situations: when 
the segment was too narrow to permit 
thorough examination (cases 12, 27 and 
39), when it was impossible to reach the 
level o f the stricture (cases 15,16 and 17) 
and when extraluminal disease was 
present (cases 28, 33 and 40 to 43).
We were particularly concerned about 
seven (15%) patients with normal bowel 
who underwent colonoscopy because 
some form of narrowing had been seen 
on roentgenograms; in four carcinoma
Table Ill-Final Diagnosis in 47 Cases of 
Colonic Stricture
Diagnosis
No. of
patients (%)
Diverticulitis (Fig. 61 15(32)
Carcinoma (Fig. 5) 7(15)
Diverticulitis and carcinoma 1 (2)
Anastomotic stenosis 2 (4)
Endometriosis 2 (4)
Crohn's disease 4 (9)
Ulcerative colitis 1 (2)
Ischemic colitis (Fig. 1) 1 (2)
Radiation stenosis 1 (2)
Anastomotic band or bridge 1 (2)
Ingested foreign-body perforation 1 (2)
Fibrosis after seat belt injury 1 (2)
Extrinsic 3 (6)
Pancreatitis (Fig. 2) 1
Carcinomatosis 1
? (congenital bands) (Fig. 3) 1
Normal bowel (Fig. 4) 7(15)
had either been diagnosed or suspected 
(Fig. 4). Colonoscopy showed normal 
bowel in six, and in the other (case 17) 
we relied on the result of barium follow- 
through examination. Hunt and associ­
ates1 had a similar experience. Another 
important asset of colonoscopy in stric­
tures is the clarification of nondescript 
radiologic pictures. Among 16 (34%) 
such cases, colonoscopy was decisive in 
11; extracolonic disease was present in 4. 
In the remaining case (no. 27 in Table II) 
carcinoma was present but not seen at 
endoscopy.
Neither roentgenography nor en­
doscopy could establish the correct diag­
nosis in nine cases (19%). Every clinician 
knows that the interpretation of radio- 
logic and endoscopic findings must take 
into account the clinical picture. A deci­
sion on the management of a patient with 
stricture must follow these principles.
Colonoscopy influenced the surgical 
decision in two clinical settings. First, it 
allowed surgery to be deferred to a more 
appropriate time. In most of these cases 
the patients had diverticulitis or other 
inflammatory conditions in the acute 
phase. The delay allowed for a more 
favourable surgical condition. Second, 
colonoscopy removed the need for surgi­
cal exploration that would have been 
undertaken either because carcinoma was 
suspected or for diagnostic purposes only. 
Both Hunt and associates1 and Rozen 
and colleagues6 have stated the useful­
ness of colonoscopy in avoiding unneces­
sary laparotomies.
To our knowledge colonoscopy 
wrongly influenced the surgical decision 
in only one patient (case 27, Fig. 5) in 
whom carcinoma was suspected but mis­
takenly ruled out. Surgery was eventually 
performed but after a 2-month delay. 
Filoche and associates5 mentioned a 
similar case, illustrating the need to con­
sider radiology and endoscopy as com­
plementary procedures in the investiga­
tion of a patient clinically suspected of 
having large bowel disease.
Summary and Conclusions
Narrowing of the colonic lumen may 
result from a wide range of diseases. In 
our study of 47 patients, radiologic 
demonstration of colonic stricture by 
single-contrast examination gave the cor­
rect diagnosis in 38%. Colonoscopy 
increased the accuracy of diagnosis to 
81%. Both radiologic and colonoscopic 
examinations failed to achieve the right 
diagnosis in 19%.
The decision to operate based on clini­
cal or radiologic criteria may lead to 
unnecessary laparotomies or untimely 
surgery. Colonoscopy did not confirm the 
indication for operation in 18% of such 
cases and afforded a useful delay in 32%.
Colonoscopy also avoided an unnecessary 
laparotomy in 80% of patients in whom 
surgical exploration was being considered 
for diagnostic purposes.
Colonoscopy should complement a 
contrast enema in every case of colonic 
stricture.
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Palliative Percutaneous Transhepatic Biliary Drainage: 
Assessment of Morbidity and Mortality
The results o f palliative percutaneous 
transhepatic biliary drainage were 
assessed retrospectively in 16 cases and 
prospective ly in 7 between 1982 and 
1985. Causes o f biliary obstruction were 
m etasta tic cancer (nine), pancreatic 
cancer (nine), cholangiocarcinoma (three) 
and gallbladder cancer (two). Internal 
drainage was established in 7 8 .3% . In 
the 19 patients w ho  died, the mean dura­
tion  o f drainage was 3 .6  m onths. Early 
m orb id ity  was 17 .4% . Late septic m or­
b id ity  occurred in 11 patients (48% ) (a 
to ta l o f 28 episodes). Late deaths 
(31 .2% ) resulted from  upper gastro intes­
tina l hemorrhage, hepatic abscess, septic 
shock, subhepatic abscess and perito­
n itis .
Percutaneous transhepatic biliary 
drainage is associated w ith  substantial 
m orb id ity  (67 .4% ) and m orta lity  (35.5% ) 
from  in fection. Palliation was modest; 
on ly e ight patients spent more than half 
the ir survival tim e at home, and 10 
patients never le ft hospital. Clinical trials 
are required to  assess the risk-to-benefit 
ra tio  and role o f percutaneous trans­
hepatic biliary drainage versus surgical 
bypass in patients w ith  lesions amenable 
to  surgery, and biliary drainage versus no 
trea tm ent in patients whose tum our can­
not be bypassed.
Les resultats pallia tifs du drainage biliaire 
transhepatique percutane ont ete evalu6s 
rdtrospectivem ent dans 16 cas et pros- 
pectivem ent dans 7 autres cas traitds 
entre 1982 et 1985. Parmi les causes 
d 'obstruc tion  biliaire, on note les metas- 
tases (neuf cas), le cancer du pancreas 
(neuf), le cholangiocarcinome (trois) et le
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cancer de la vesicule biliaire (deux). Un 
drainage interne a ete 6tabli dans 7 8 .3 %  
des cas. Chez les 19 patients qui sont 
decedes, la durge moyenne de drainage a 
ete de 3 .6  mois. Une m orbidity precoce 
a ete vue dans 17 .4%  des cas. Des in c i­
dents septiques retardes sont survenus 
chez 11 patients (48% ) (un to ta l de 
28 episodes). Les deces tard ifs (31 .2 % ) 
on t ete causes par une hgmorragie gas- 
tro in testina le  superieure, un abc&s hepa- 
tique, un choc septique, un abcfes sous- 
hepatique et une peritonite.
Le drainage biliaire transhepatique per­
cutane est entache d 'une m orbidity 
(67 .4% ) et d 'une m orta lite  (35 .5% ) 
im portantes resultant de I'in fection.
L 'e ffe t pa llia tif fu t modeste; seulement 
hu it patients ont passe plus de la m oitig  
de leur tem ps de survie a domicile, e t 10 
autres n 'o n t jamais qu ittg  I'hopita l. Des 
essais cliniques sont juggs necessaires 
pour gtablir le rapport risques/bgngfices 
et prgciser le role du drainage biliaire 
transhgpatique percutang par rapport a la 
dgrivation chirurgicale chez les pa tients 
opgrables; de m§me. il faudra it evaluer 
les m grites respectifs du drainage b ilia ire 
et de I'absence de tra item ent chez les 
patients dont la tum eur ne permet pas 
une opgration de pontage.
The use of percutaneous transhepatic 
biliary drainage to treat malignant 
obstruction of the bile ducts has gained 
popularity in the last decade. Since Mol- 
nar and Stockum1 reported the first suc­
cessful case of internal drainage in 1974, 
radiologists have developed and refined 
techniques to decompress the biliary 
tree.2-6
McPherson and colleagues7 and Elli­
son and associates8 have cautioned that 
while this procedure has gained rapid 
acceptance, the risk-to-benefit ratio must 
be carefully assessed. Further, its mor­
bidity and mortality have yet to be com ­
pared with those of other modes o f treat­
ment for malignant obstruction o f the 
biliary tree, in a prospectively randomized 
controlled clinical trial.
The present report considers the mor­
bidity and mortality associated with per­
cutaneous transhepatic biliary drainage in 
23 cases of malignant obstruction o f the 
biliary tree. We paid particular attention 
to the palliative benefit o f the procedure
and to the morbidity from infectious and 
other complications.
Patients and Methods
We reviewed the charts o f 16 patients 
who had undergone percutaneous trans­
hepatic biliary drainage between August 
1982 and June 1984. We also studied 
prospectively seven patients who had 
undergone the same procedure between 
July 1984 and January 1985. In all there 
were 15 men and 8 women with a mean 
age o f 68.6 years (range from 31 to 94 
years). All had malignant obstruction of 
the biliary tract (Table I).
The data collected concerned previous 
surgery, the cause and location of 
obstruction, the date, duration and type 
o f drainage, the occurrence o f all com­
plications and the date and circumstances 
o f death. To identify biliary microbiol­
ogy and the pathogens involved in infec­
tion, we took serial bile samples for aer­
obic and anaerobic culture on the day o f  
biliary drainage and then at the time o f  
monthly catheter changes or when other­
wise clinically indicated in the prospective 
group. Whenever possible, we recorded 
microbiologic findings on the retrospec­
tive cases.
Finally, the benefit o f percutaneous 
transhepatic biliary drainage was assessed 
with respect to the amount o f time spent 
at home between the day of drainage and 
death and the number of hospitalizations 
required during this time.
Drainage Technique
We used a modification o f the techni-
Table 1-Causes of Obstructive Jaundice
Cause No. of patients*
Metastatic cancer 9(4)
Colon 4(2)
Stomach 3(2)
Breast 1
Prostate 1
Pancreatic cancer 9(6)
Cholangiocarcinoma 3(3)
Gallbladder cancer 2(2)
Total 23(16)
"Numbers in brackets represent patients with
tissue diagnosis of the 
jaundice.
cause of obstructive
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que previously described by Ferrucci and 
colleagues,5 Nakayama and associates,6 
and Ring’s group.9 Standard fine-needle 
cholangiography was first performed to 
identify the location and assess the extent 
of obstruction. The modified Cope cathe­
ter system (20 gauge) was used to gain 
access to the biliary tree. If there was no 
cholangitis, internal drainage was attemp­
ted. If that was unsuccessful a straight 
catheter was left in the most dependent 
segment of the biliary tree and another 
attempt made in 2 to 4 days, with exter­
nal drainage in the interim. Whether or 
not the catheter had been placed beyond 
the obstruction, external drainage was 
maintained for the first 24 hours, follo­
wed by progressive clamping, resulting, 
in successful cases, in complete internal 
drainage within 8 days. During this time, 
catheters were flushed four times daily 
with 10 ml of normal saline, the fre­
quency was reduced to once daily when 
internal drainage was established. Cathe­
ters were changed each month on an out­
patient basis unless otherwise indicated. 
Antibiotics were not given prophylacti- 
cally unless patients had had a previous 
episode of catheter-related cholangitis, 
known bactibilia, or previous biliary tract 
surgery.
Findings
In 9 of the 23 patients percutaneous 
transhepatic biliary drainage was under­
taken because a surgical bypass could not 
be done. Laparotomy to assess the pos­
sibility of surgical bypass was not perfor­
med in 14 patients, 7 of whom had 
metastatic biliary tract obstruction. Of the 
remaining seven, two were pre-terminal 
(both died within 6 weeks of presenta­
tion), two were shown radiologically to 
have lesions that could not be bypassed 
(obstruction at the porta hepatis), one 
refused surgery and two underwent biliary 
drainage because of the surgeon’s prefe­
rence, despite radiologic evidence that 
surgical bypass might be possible. Two of 
these 14 patients subsequently had ope­
rative bypass when biliary drainage fai­
led, and their courses are described below.
There were no failures of insertion of 
the transhepatic catheters in 23 attempts. 
Internal drainage was established initially 
in 15 patients and within 4 days in 3 
others for an overall success rate of 
78.3% (18 of 23). Five patients (21.7%) 
had external drainage only.
The average duration of drainage was 
3.6 months (range from 4 days to 14 
months) among the 19 patients who died. 
Two of the four patients alive at the time 
of reporting have been drained for 1 and 
4 months respectively. A third patient has 
undergone surgical bypass, despite metas­
tatic gastric cancer, for repeated attacks 
of cholangitis. The fourth patient, ini­
tially drained percutaneously because of
surgeon’s preference, underwent surgical 
bypass because of persistent fever and 
intrahepatic abscesses.
Complications
Early complications of percutaneous 
transhepatic biliary drainage included 
catheter dislodgement, cholangitis and 
fatal acute hemorrhagic pancreatitis 
(Table II). None of these complications 
required operative intervention. The early 
morbidity was 17.4% (4 of 23) and the 
rate of early death 4.3% (1 of 23).
Thirty late complications occurred in 
22 patients (1.4 complications per 
patient). Late morbidity from catheter 
blockage and dislodgement occurred in 
34.9% and 13.0% of patients respecti­
vely. Cholangitis occurred late 19 times 
in 11 patients (1.7 episodes per patient) 
and was associated with bacteremia five 
times, resulting in the death of one 
patient. Three episodes of cholangitis 
occurred within the first 3 weeks of drai­
nage in the patient with metastatic sto­
mach cancer mentioned above; operative
choledochoenterostomy resolved the 
infections. Eight months later, the intra­
hepatic bile ducts became obstructed from 
progression of disease, and two catheters 
were required to treat recurrent cholan­
gitis due to the original organism (Kleb­
siella).
Five patients had septic-related deaths. 
At autopsy two were found to have intra­
hepatic abscesses and a third had a sub- 
hepatic abscess. Autopsy was not 
performed on the other two, but in both 
the catheters were known to be providing 
inadequate drainage of the left-sided bile 
ducts in one case and of both left and 
right-sided ducts in the other.
The late death rate related to percuta­
neous transhepatic biliary drainage was 
31.2% (7 of 22) (Table II). An eighth 
patient died of acute myocardial infarc­
tion while recovering from an episode of 
cholangitis.
Bile cultures in 16 patients at the time 
of initial drainage were negative in 11 
(68.8%) patients and positive in 5 (31.3%) 
(Table III). Cultures were not obtained 
in the other seven patients. Three of the
T a b le  I I — C o m p lic a t io n s  o f  P e r c u ta n e o u s  T r a n s h e p a t ic  B il ia ry  D ra in a g e
C o m p lic a t io n
E a r ly ,
n o . o f  e p is o d e s !  
n o . o f  p a t ie n ts
L a te ,
n o . o f  e p is o d e s !  
n o .o f  p a t ie n ts D e a t h s *
M in o r
C a th e t e r  b lo c k a g e 0 1 2 1 8 —
C a th e t e r  d is lo d g e m e n t 111 3 /3 —
M a jo r
C h o la n g it is 2 / 2 1 9 /1 1 —
B a c te r e m ia — 5 /5 1
H e p a t ic  a b s c e s s - 2 1 2 2
S u b h e p a t ic  a b s c e s s - 1 /1 1
P u ru le n t  a s c ite s - 1 /1 1
A c u te  p a n c r e a t i t is 111 - 1
U p p e r  g a s tr o in te s t in a l t r a c t
h e m o rrh a g e - 2 /2 2
* 0 n e  o th e r  p a t ie n t  re c o v e r in g  f r o m a n  e p is o d e  o f  c h o la n g it is  d ie d  o f  a c u te  m y o c a rd ia l in f a r c t io n .
T a b le  I l l - M ic r o o r g a n is m s  F o u n d  in  B ile *
O rg a n is m D a y  o f  d ra in a g e
P o s t
d ra in a g e
K le b s ie lla  sp 2  (2 ) 1 0 ( 7 )
E n t e r o b a c t e r 1 1 0 ( 6 )
E s c h e r ic h ia  c o l i 2 7 ( 5 )
E n te ro c o c c u s 3 ( 2 ) 7 ( 6 )
P r o t e u s  m ir a b il is 0 6 ( 5 )
P s e u d o m o n a s  a e r u g in o s a 0 6 ( 2 )
S t r e p t o c o c c u s  s p , L a n c e f ie ld
g ro u p  D , n o n  e n te r ic 1 4 ( 1 )
S ta p h y lo c o c c u s  e p id e r m id is 0 4 ( 0 )
C lo s t r id iu m  p e r f r in g e n s 1 (1 ) 3 ( 2 )
C o r y n e b a c te r iu m  sp 0 3 ( 0 )
A c in e t o b a c t e r  sp 0 2 ( 0 )
C it r o b a c t e r  sp 0 1 (2 )
M ic r o a e r o p h il ic  s tr e p to c o c c i 0 1 ( 1 )
A e r o m o n a s  h y d r o p h ila 0 1 (0 )
H a t n ia  sp 0 2 ( 2 )
S ta p h y lo c o c c u s  a u r e u s 1 1 (1 )
S t r e p t o c o c c u s  s p , L a n c e f ie ld
g ro u p  B 0 1 ( D
‘ N u m b e r s  in  b r a c k e ts  in d ic a te  th e  n u m b e r  o f  t im e s  a  m ic ro o rg a n is m  w a s  im p lic a te d  
o f  c h o la n g it is .
in  a n  e p is o d e
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five positive cultures were in patients who 
had undergone previous biliary tract 
surgery.
Bile cultures remained negative in 3 of 
the 11 patients, but became positive in 6, 
representing a conversion rate of 54.5%. 
In the remaining two cases, follow-up cul­
tures were not obtained. The biliary trees 
that remained sterile were in patients who 
died within 3 weeks of drainage.
The palliative effects of percutaneous 
transhepatic biliary drainage with respect 
to improvement in hyperbilirubinemia, 
pruritis and anorexia are shown in Table 
IV and the duration of time spent at home 
in Table V.
Discussion
All patients who underwent percutane­
ous transhepatic biliary drainage in this 
series had malignant obstruction of the 
biliary tract. Internal drainage was estab­
lished in 18 (78.3%) of 23 patients which 
compares favourably with the rates of 
72% and 64.3% reported by Mueller and 
associates2 and Clark and colleagues10 
respectively. The average duration of 
drainage was 3.6 months compared with 
4.3 months and 3.3 months reported by 
Ferrucci and colleagues5 and Pollock’s 
group4 respectively. Early morbidity 
(17.4%) and mortality (4.3%) also com­
pared favourably with those of other 
studies.10,11
The single early death due to pancrea­
titis represents the only one reported to 
date from this complication, although at 
least three other cases of pancreatitis 
related to percutaneous transhepatic 
biliary drainage have been reported.3-12 
Early death from bleeding (five patients), 
pneumothorax with bilious pleural effu­
sion (one) and septic shock (one) have 
also been reported .2’3'10'13 Intra­
abdominal hemorrhage, hemobilia, 
bilothorax or bile leak, reported by others 
did not occur in our series. This might be 
accounted for in part by the use of a 
smaller (20 gauge) needle for cannulation.
Late morbidity from cholangitis 
occurred in 50% of patients, somewhat 
higher than previously reported (range of 
14.5% to 36.5%2"4,6’7,11’13). The 30-day 
mortality, related to biliary drainage was 
35.0% (8 of 23) and compares with rates 
quoted for surgical bypass, which range 
from 6% to 30%.14'15
The prophylactic use of antibiotics has 
been advocated by several investiga­
tors, 3,9~n none of whom have been able 
to demonstrate a decreased incidence of 
morbidity from infection. Nevertheless, 
antibiotics should be given prophylacti- 
cally to patients with a history of biliary 
tract surgery or instrumentation, with a 
periprocedural history suggestive of 
cholangitis, and to those who undergo 
catheter change or manipulation. As 
Keighley and colleagues16-17 and Wayne 
and Whelan18 have pointed out, mor­
bidity from contaminated bile can be 
important; thus Wayne and Whelan 
recommended prophylaxis with a combi­
nation of an aminoglycoside and 
ampicillin.
Our practice has been to use a first- 
generation cephalosporin for initial 
prophylaxis and for subsequent manipu­
lations in patients who have experienced 
no morbidity from infection. The 
appropriate antibiotic(s) in those who 
have suffered infectious morbidity should 
be directed by the most recent bile or 
blood culture. Based upon the paucity of 
anaerobes cultured in either bile or blood 
of our patients, anaerobic coverage was 
not warranted and is not recommended.
The average duration of drainage of 3.6 
months is misleading, since patients fell 
into three distinct groups with respect to 
survival (Table V). Eight patients lived 
less than 1 month after biliary drainage 
and only one was discharged from hospi­
tal before death. Five patients lived from 
1 to 4 months. While two were home for 
at least 51% of their remaining days, the 
other three never left hospital. Of the 
eight patients who lived for 4 or more 
months, 6 spent a minimum of 51% of
their remaining days at home, whereas the 
other one spent only 6.6% of such time 
at home. These eight patients required an 
average of 1.4 hospitalizations after their 
drainage procedures, to treat cholangitis. 
The palliative benefit of drainage is most 
evident in this group of patients. While 
they had serious morbidity (eight episodes 
of tube blockage, nine episodes of cholan­
gitis, three episodes of bacteremia and 
two hepatic abscesses), four spent more 
than 75% of their remaining days out of 
hospital and two others between 51 % and 
75%.
The morbidity from infection after per­
cutaneous transhepatic biliary drainage is 
high enough in this and other series7-11-13 
to cast doubt on its overall palliative 
benefit in all but a select group of patients 
likely to survive for several months.
Of patients presenting with carcinoma 
of the pancreas or periampullary region, 
less than 20% have surgically resectable 
lesions.14,15 Operative bypass is possible 
in another 30%. Thus approximately 
50% of patients are left with a palliative 
drainage procedure or no treatment for 
their disease. For patients who have 
biliary obstruction due to metastatic dis­
ease, curative resection is inappropriate, 
and in less than 30% will surgical bypass 
be possible because of the higher inci­
dence of associated portal lymph-node 
involvement. Therefore, more than 50% 
of these patients may be candidates for 
a palliative drainage procedure of some 
sort.
The ideal trial would randomize 
patients with surgically bypassable lesions 
to surgery or a nonoperative drainage 
procedure. For those in whom surgical 
bypass cannot be performed safely, ran­
domization between a nonoperative 
drainage procedure and no treatment 
should be undertaken. Since morbidity 
and mortality from infection using per­
cutaneous transhepatic biliary drainage is 
high, it would be prudent to set out strin­
gent guidelines concerning catheter inser­
tion, irrigation and daily care, in an 
attempt to keep complications at a mini­
mum. The role of intraductal yttrium, 
biliary endoprostheses and radiotherapy 
for these lesions in selected patients has 
yet to be determined.
While percutaneous transhepatic biliary 
drainage plays a beneficial role in some 
patients, its precise role in the treatment 
of malignant obstruction of the bile ducts 
remains to be defined.
References
1. Molnar W, Stockum AE: Relief of obstructive jaun­
dice through percutaneous transhepatic catheter — a new 
therapeutic method. Am  J  Roentgenol Radium Ther Nucl 
Med 1974; 122: 356-367
2. MUELLER PR, VAN SONNENBERG E, FERRUCCI JT JR: 
Percutaneous biliary drainage: technical and catheter- 
related problems in 200 procedures. AJR  1982; 138: 17-23
3. BERQUIST TH, May GR, JOHNSON CM, et al: Per­
cutaneous biliary decompression: internal and external 
drainage in 50 patients. A JR  1981; 136: 901-906
T a b le  IV — B e n e f i ts  o f  P e r c u ta n e o u s  T r a n s h e p a t ic  B il ia ry  D ra in a g e
S y m p to m s /r e s p o n s e H y p e rb il iru b in e m ia P r u r i t is A n o r e x ia
P re s e n t  in i t ia lly 2 3 1 9 2 1
Im p ro v e d 1 8 8 5
N o  c h a n g e 1 3 8
N o t e v a lu a b le 4 8 8
T a b le  V — P a llia t iv e  B e n e f i t  o f  B il ia ry  D ra in a g e
T im e  a t  h o m e , % *
T o ta l  d u ra t io n  o f
d r a in a g e , m o N o , o f  p a t ie n t s  0 <  2 5 2 5 - 5 0  5 1 - 7 5 >  7 5
<  1 8  7 1 -  - —
1 -  4 5  3 — 1 1
>  4 8 1 1 2 4
T o t a ls 2 1  1 0 2 1 3 5
“ T im e  f r o m  d ra in a g e  t o  d e a th .
VOLUME 29, NO. 4, JU L Y  1986 /  THE CANADIAN JOURNAL OF SURGERY 245
BOOK REVIEWS
POLLOCK TW, RING ER, OLEAGA JA, et al: Percutane­
ous decompression of benign and malignant biliary 
obstruction. Arch Surg 1979; 114: 148-151 
Ferrucci JT jr , MUELLER PR, Harbin WP: Per­
cutaneous transhepatic biliary drainage: technique, 
results, and applications. Radiology 1980; 135: 1-13 
Nakayama T, IKEDA A, Okuda K: Percutaneous 
transhepatic drainage of the biliary tract: technique and 
results in 104 cases. Gastroenterology 1978; 74: 554-559 
McP herson GAD, Benjam in  IS, Habib n a , et al: 
Percutaneous transhepatic drainage in obstructive jaun­
dice: advantages and problems. Br J  Surg 1982; 69: 
261-264
Ellison EC, Van Aman ME, Carey LC: Preoperative 
transhepatic biliary decompression in pancreatic and peri­
ampullary cancer. World J  Surg 1984; 8: 862-871 
RING EJ, Oleaga JA, Freiman DB, et al: Therapeu­
tic applications of catheter cholangiography. Radiology 
1978; 128: 333-338
Clark RA, Mitchell SE, Colley DP, et al: percuta­
neous catheter biliary decompression. AJR  1981; 137: 
503-509
CLOUSE ME, Evans D, Costello P, et al: Percutane­
ous transhepatic biliary drainage. Complications due to 
multiple duct obstructions. Ann Surg 1983; 198: 25-29 
P robst P, Castaneda-Zuniga w r , AMPLATZ K: 
Percutaneous transhepatic drainage catheter: a valuable 
therapeutic aid in obstructive jaundice. ROFO 1978; 128: 
443-445
Hansson JA, HOEVELS J, SlMERT G, et al: Clinical 
aspects of nonsurgical percutaneous transhepatic bile 
drainage in obstructive lesions of the extrahepatic bile 
ducts. Ann Surg 1979; 189: 58-61 
Buckwalter JA, Lawton RL, T idrick RT: Bypass 
operations for neoplastic biliary tract obstructions. Am  
J  Surg 1965; 109: 100-106
Feduska NJ, Dent TL, Lindenauer SM: Results of 
palliative operations for carcinoma of the pancreas. Arch 
Surg 1971; 103: 330-334
Keighley MR, Wilson G, Kelly JP: Fatal endotoxic 
shock of biliary tract origin complicating transhepatic 
cholangiography. Br Med J  1973; 21: 147-148 
Keighley MR, Graham NG: Infective complications 
of choledochotomy with T-tube drainage. Br J  Surg 1971; 
58: 764-768
Wayne PH m, Whelan JG jr : Susceptibility testing 
of biliary bacteria obtained before bile duct manipula­
tion. AJR  1983; 140: 1185-1188
FLEXIBLE SIGMOIDOSCOPY. Ronald M. 
Kalon, Emmet B. Keeffe and Clifford S. 
Melnyk. 158 pp. Illust. Grune & Stratton, 
Inc., Orlando, Fla., 1985. $34.50 (US). 
ISBN 0-8089-1701-3.
This complete manual presents even more than 
is necessary to learn the essentials of flexible 
sigmoidoscopy.
Eleven chapters cover all aspects of history, 
technique, indications and complications. 
Comparisons are made between the various 
brands of sigmoidoscopes, offering the physi­
cian who wishes to purchase a sigmoidoscope 
an objective means of making comparisons 
away from the persuasion of a salesman. 
Unfortunately, the newest endoscopes are not 
mentioned. The tip of the new instruments con­
tains a microelectronic sensor that transmits 
an image to a television monitor; thus, the 
fiberoptic system is obviated. The cost of the 
new system is high, but maintenance will be 
much cheaper. The fiberoptic systems 
described in this book are all fragile, and the 
life of the fiberoptic system is the life of the 
entire sigmoidoscope.
The chapter on technique is the strongest 
one—by reading and following the instruc­
tions, the novice could become a self-taught 
sigmoidoscopist. The diagrams of the tech­
nique for sigmoidoscopy are most valuable. 
Words cannot express the value of the infor­
mation provided by the line drawings illustrat­
ing the introduction and advancement of the 
sigmoidoscope. However, they go to far. If the 
sigmoidoscope is truly a screening tool, a dis­
cussion of electrocoagulation and electrosnar- 
ing is beyond the province of a diagnostic tech­
nique. Complete colonoscopy is almost always 
necessary whenever electrosurgery is indicated, 
and complete colon preparation makes elec­
trosurgery safer with respect to explosion from 
hydrogen and methane. Furthermore, should 
a complication occur, the better-prepared 
bowel for colonoscopy will likely spare the 
patient a colostomy. Often a perforation in 
poorly prepared bowel will necessitate exteri­
orization of the perforation or proximal 
diversion.
The chapter on indications again brings the 
colonoscope into a conflict with the sigmoido­
scope. Most doctors use the flexible sigmoido­
scope as an office technique, specifically for 
screening asymptomatic patients. The moment 
the patient has blood in the stool, the finding 
of occult blood, a mass or a change in bowel 
habit, colonoscopy is required. Thus, the 
expense of a flexible sigmoidoscopy is avoided. 
To be cost-effective, duplication of diagnos­
tic procedures must be prevented. Flexible sig­
moidoscopy is not necessary if barium enema 
examination or colonoscopy is to be per­
formed.
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Microbiologic Features and Treatment of Persistent Peritonitis 
in Patients in the Intensive Care Unit
The charts of 25 patients who died in 
the intensive care unit of persistent 
peritonitis after abdominal operations 
were reviewed to determine the micro­
bial flora and the efficacy of antibiotic 
treatment. All patients had undergone 
two or more surgical procedures for 
abdominal sepsis and 23 had at least 
three-system organ failure. The most 
common organisms cultured were: Staph­
ylococcus epidermidis, 24 cultures from 
16 patients, Candida albicans, 19 cul­
tures from 10 patients, Pseudomonas 
aeruginosa, 16 cultures from 12 
patients, Enterobacter, 16 cultures from 
8 patients and enterococcus, 14 cul­
tures from 8 patients. The classic iso­
lates, Escherichia coli (11 cultures from 
six patients) and Bacteroides fragiiis (4 
cultures from three patients) were found 
infrequently. To  determine the adequacy 
of antimicrobial therapy for this "new " 
flora, we examined the ability of 
appropriate agents to eradicate the 
micro-organism upon subsequent culture. 
Candida sp. were eradicated in 54% (6 
of 11) of the assessable cases, while 
enterococcus and S. epidermidis were 
cleared in only 25%  and 28%  respec­
tively. The spectrum of intra-abdominal 
organisms cultured from critically ill sur­
gical patients in the intensive care unit
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differs from that seen in those with 
acute peritonitis. Despite administration 
of appropriate antimicrobial agents, these 
organisms tend to persist, probably 
reflecting impaired host defences with 
multiple-system organ failure rather than 
antimicrobial failure.
On a etudie les dossiers m£dicaux de 25 
patients qui sont decedes a I'unite des 
soins intensifs, des suites d'une perito- 
nite persistante consecutive & une opera­
tion abdominale, dans le but de determi­
ner la nature de la flore microbienne et 
I'efficacite de I'antibiotherapie. Tous les 
patients avaient subi au moins deux 
interventions chirurgicales pour sepsie 
abdominale et 23 presentaient au moins 
trois insuffisances fonctionnelles. Les 
microorganismes les plus souvent culti- 
ves ont ete: Staphylococcus epidermidis, 
24 cultures chez 16 patients, Candida 
albicans, 19 cultures chez 10 patients. 
Pseudomonas aeruginosa, 16 cultures 
chez 12 patients, Enterobacter, 16 cultu­
res chez 8 patients, et I'enterocoque, 14 
cultures chez 8 patients. Les isolats clas- 
siques, Escherichia coli (11 cultures chez 
six patients) et Bacteroides fragiiis (4 
cultures chez trois patients), ont ete 
retrouves plus rarement. Afin d'etablir 
l'efficacit§ des traitements antimicro- 
biens sur cette "nouvelle" flore, on a 
etudie la capacity des antibiotiques 
appropries a faire disparaTtre les microor­
ganismes lors de cultures subsequentes. 
L'espece Candida a ete elimin6 dans 
54%  (6 sur 11) des cas ^valuables, alors 
que I'enterocoque et S. epidermidis dis- 
paraissaient dans seulement 2 5 %  et 
28%  des cas respectivement. Le spectre 
des microorganismes intra-abdominaux 
cultives chez les patients chirurgicaux 
tres malades alors qu'ils sont dans le 
service de soins intensifs diffdre de celui 
qu'on retrouve dans les autres cas de 
peritonite. Malgre I'utilisation des antibio­
tiques appropries, ces organismes ont 
tendance & persister, refletant probable- 
ment de la sorte une atteinte des defen­
ses immunitaires et une insuffisance mul- 
tifonctionnelle, davantage que I'echec de 
I'antibiotherapie.
The microbiologic chacteristics of perito­
nitis after perforation of the gastrointes­
tinal tract are remarkably consistent.1'3 
The infections are usually polymicrobial 
and dominated by Escherichia coli, Bac­
teroides fragiiis, streptococci (both aero­
bic and anaerobic) and eubacteria. Fur­
thermore, blood cultures in these patients 
most often contain B. fragiiis or E. coli, 
demonstrating the invasiveness o f the micro-organisms.1 The predictability of 
this flora has permitted the development 
of an empiric antimicrobial regimen used 
in conjunction with surgery in the treat­
ment o f peritonitis. Clinical and ex­
perimental studies have clearly demon­
strated that antibiotics directed against 
both aerobic and anaerobic organisms 
should be given.4’5
The advent of intensive-care-unit (ICU) 
monitoring, total parenteral nutrition and 
broad-spectrum antibiotics have pro­
duced a subgroup of critically ill patients 
able to survive their initial abdominal 
procedure, but whose postoperative 
course is characterized by prolonged ICU 
care, multiple surgical procedures and the 
development o f multiple-system organ 
failure. The death rate in these patients 
is high, ranging from 60% to 80%.6,7 
The microbiologic features and optimal 
antimicrobial therapy in such patients 
with persistent peritonitis is unclear. To 
clarify our impression that the bacterial 
spectrum of abdominal infection is radi­
cally altered during treatment, we 
reviewed the charts o f patients who died 
in our surgical ICU o f persistent intra­
abdominal sepsis. The study revealed that 
the organisms cultured from these 
patients differed markedly from those 
found in patients who present with acute 
peritonitis.
Patients and Method
We reviewed the charts of 17 men and 
8 women admitted over the 18-month 
period from July 1982 to December 1983 
to the surgical ICU of the University of 
Minnesota Hospitals and who died with 
persistent intra-abdominal infection. Per­
sistent peritonitis was deemed to be 
present in patients who required two or
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more interventions (either operative or 
percutaneous drainage) for intra-abdo­
minal sepsis.
In addition to standard demographic 
data, the review determined the microbi- 
ologic features of the intra-abdominal 
collections, the incidence of concurrent 
bacteremias and the ability of adequate 
antibiotic therapy to produce a microbi- 
ologic cure of the intra-abdominal infec­
tion. Adequate antibiotic therapy was 
defined as treatment with amphotericin 
B for Candida sp., ampicillin or van­
comycin plus an aminoglycoside for 
enterococci and vancomycin for Staph­
ylococcus epidermidis for at least 7 days. 
Cultures were taken for both aerobic and 
anaerobic bacteria. They did not rep­
resent cultures taken from drains in situ 
for a prolonged period, but rather cul­
tures recovered either at reoperation or 
insertion of a fresh percutaneous drain.
Chart Findings
The mean age of the 25 patients studied 
was 61 years (range from 26 to 88 years). 
The initial operative site was small intes­
tine (six patients), colon (four), biliary 
tract (four), pancreas (four), stomach 
(three), genitourinary tract (three) and 
peritoneum (one) for a necrotic infected 
intraperitoneal tumour. Two biliary tract 
procedures involved anastomoses to the 
small intestine (Whipple operation in one 
and choledochojejeunostomy in the 
other). One genitourinary procedure in­
volved the formation of an ileal conduit 
followed by dehiscence of the small bowel 
anastomosis; another, a uretoureteros- 
tomy, was complicated by a postopera­
tive sigmoid leak.
The average time between the initial 
operation and death was 55 days (range 
from 6 to 131 days). The average num­
ber of reoperations (or postoperative 
cutaneous drainages) was 3.1 (range from 
1 to 8). Twenty-two patients received 
antibiotics effective against both faculta­
tive gram-negative bacilli and anaerobes.
Multiple-system organ failure during 
the course of the illness was frequent
Table 1—Multiple-System Organ Failure in 
Patients Dying of Persistent Peritonitis*
System failure
% of 
patients
Pulmonary (requiring ventilatory 
support) 80
Renal (dialysis required) 72
Central nervous system (decreased 
consciousness) 96
Hepatic (elevated bilirubin and 
alkaline phosphatase levels) 80
Cardiovascular (necessitating 
inotropic support, measurements 
indicating sepsis) 80
'Present during the course of the illness and 
not just pre-terminal events.
(92%) (Table I). In our ICU, during an 
overlapping period,8 the need for dialy­
sis was associated with a 6.3% survival 
rate while prolonged ventilatory support 
(7 days or longer) was similarly associated 
with a poor outcome (19.2% survival).
The microbial flora of persistent intra­
abdominal infection is shown in Table II. 
These cultures were dominated (in 
decreasing order of frequency) by S. 
epidermidis, Candida albicans, Pseudo­
monas aeruginosa, Enterobacter and 
enterococcus while the classic microbial 
isolates (E. coli and B. fragilis) were less 
common.
The ability of an organism to produce 
a bacteremia is associated with its 
pathogenicity. To examine the invasive­
ness of this “ new” flora, positive blood 
cultures were correlated with the presence 
of the bacteremic organism in the 
abdominal cultures. Twelve of the 25 
patients had a total of 23 positive blood 
cultures during their postoperative course 
(or at autopsy in 2 patients). Three were 
polymicrobial and 20 monomicrobial. 
The common bacteremic organisms were 
S. epidermidis (nine), Enterobacter 
(four), enterococcus (three), B . fragilis 
(three) and C. albicans (three). In 18 of 
the 23 positive cultures, the bacteremic 
organism was present simultaneously in 
the peritoneal fluid culture, but not so in
3. The remaining two blood cultures had 
some, but not all, organisms present in 
the abdominal cultures. Of note, in the 
nine with S. epidermidis bacteremia, is 
that none had simultaneous positive cul­
tures of central venous catheters. These 
results suggest that the intra-abdominal 
organisms demonstrated invasiveness by 
producing a bacteremia.
To assess the adequacy of antimicrobial 
therapy for the “ new” flora in these crit­
ically ill patients, we examined the abil­
ity of appropriate agents to eradicate the 
micro-organism on subsequent cultures. 
These results are shown in Table III. Only 
amphotericin B, used to treat Candida sp. 
demonstrated at least moderate success 
(54%). Ampicillin and vancomycin were 
ineffectual in ridding enterococci from 
the cultures while S. epidermidis cleared 
equally well with or without antibiotics.
Discussion
At any given time the gastrointestinal 
tract contains more than 1012 bacterial 
organisms comprising over 400 species.9 
When the continuity of the tract is 
breached and bacteria are released, host 
defences eliminate most of these organ­
isms. The resulting peritonitis contains a 
well-defined and consistent flora,13 
which is invariably polymicrobial, domi-
Table II—Microbiology of Persistent Peritonitis
Organisms
No. of positive 
cultures
No. of 
patients
Aerobes
Staphylococcus epidermidis 24 16
Enterococcus 14 8
Alpha hemolytic streptococcus 4 3
Lactobacillus 1 1
Pseudomonas aeruginosa 16 12
Facultative gram negative bacilli
Escherichia coli 11 6
Klebsiella (pneumonia and oxytoca) 8 6
Enterobacter (cloacae and aerogenesl 16 8
Citrobacter freundii 1 1
Anaerobes
Bacteroides fragilis 4 3
Clostridium (perfringens, clostridiformis
and unidentified species) 5 3
Fusobacterium nudeatum 1 1
Corynebacterium sp 1 1
Fungus
Candida albicans 19 10
C. glabrata 10 5
C. tropica Us 2 2
Aspergillus 1 1
Table III—The Ability of the Appropriate Antibiotic to Effect Microbiologic Cure
Appropriate therapy Inappropriate therapy
Organism
Patients
assessable*
No. of 
patients
Organism
cleared
No. of 
patients
Organism
cleared
Candida sp 14 11 6 3 0
S. epidermidis 12 4 1 8 4
Enterococcus 7 7 2 - -
'Patients received at least 7 days therapy with the appropriate antimicrobial agent and a follow-up 
culture was available to assess efficacy of therapy.
248 VOLUME 29, NO. 4, JU LY 1986 /  THE CANADIAN JOURNAL OF SURGERY
nated by E. coli, enterococci, B. fragilis, 
anaerobic streptococci and eubacteria. 
The management of these infections is 
also well defined, combining surgical cor­
rection of the underlying disease with the 
administration of broad-spectrum anti­
biotics.10 The need to provide antibiotic 
therapy, active against both aerobic and 
anaerobic bacteria, has been demon­
strated, both experimentally and clini­
cally.4,5 Using a rat peritonitis model, 
Weinstein and colleagues11 demonstrated 
a biphasic response to fecal contamina­
tion of the peritoneal cavity. This model 
closely mimics the clinical setting of bowel 
perforation in man. The first or perito­
nitis phase, was associated with a death 
rate of 40%. Bacteria recovered included 
mainly E. coli, enterococci and B. fragilis. 
The death rate correlated with the initial 
inoculum size of E. coli.12 The survivors 
entered the second, or abscess phase, and 
were found to have abscesses at autopsy. 
The flora of these abscesses was domi­
nated by the three bacteria just mentioned 
plus Fusobacterium sp. Gentamicin 
prevented death and clindamycin pre­
vented abscess formation while the two 
drugs combined prevented both death and 
abscess formation.5
The findings from clinical studies cor­
roborated these experimental findings. 
Thadepalli and colleagues4 compared 
cephalothin and kanamycin to clindamy­
cin and kanamycin in 100 patients with 
penetrating abdominal trauma. The aer­
obic infection rate was identical, but 
anaerobic infections developed in 11 of 
52 patients treated with cephalothin and 
kanamycin versus 1 of 48 patients treated 
with clindamycin and kanamycin. Simi­
larly, Berne and colleagues13 showed that 
the combination of gentamicin and clin­
damycin in treating perforated appendi­
citis resulted in fewer septic complications 
than either cefamandole or cefoperazone 
alone, both cephalosporins with poor 
anti-anaerobic activity. Thus, the most 
favourable results in peritonitis are 
achieved when antibiotics are directed 
against both the aerobic (usually E. coli) 
and the anaerobic (usually B. fragilis) 
components.
Progress in metabolic and hemody­
namic support in conjunction with con­
ventional treatment has improved initial 
survival from peritonitis. However, these 
patients may subsequently manifest mul­
tiple-system organ failure. In the critically 
ill surgical patient, such failure is a 
predominant cause of late death after ini­
tial resuscitation.14 We reviewed patients 
who died in our surgical ICU of persis­
tent intra-abdominal infections to deter­
mine whether intensive therapy may have 
altered the microbial flora of these infec­
tions and also to see if appropriate adjust­
ments of antimicrobial therapy could 
effect a microbiologic cure.
As expected, from a defined group of 
patients who died of sepsis in the surgi­
cal ICU, a high percentage (92.5%) had 
at least three-system organ failure during 
their clinical course. Studies from our 
institution8 have shown that surgical 
ICU patients suffering renal or pulmo­
nary failure have extremely high death 
rates (95% and 80% respectively). Fry 
and associates15 dem onstrated that 
patients with abdominal abscesses 
manifesting organ failure in three or more 
systems had greater than 80% mortality. 
They also showed that recurrent abscesses 
correlated significantly with an increas­
ing likelihood of death.
The most frequently isolated organ­
isms were S. epidermidis, C. albicans, P. 
aeruginosa, Enterobacter sp. and 
enterococcus. The classic microbial iso­
lates, E. coli and B. fragilis were found 
much less frequently. Since almost all 
patients received broad-spectrum antibi­
otics, one would expect these relatively 
resistent micro-organisms to appear. The 
pathogenicity and origin of these organ­
isms need to be considered.
The pathogenic roles of P. aeruginosa 
and Enterobacter sp. are above question 
and gram-negative bacteremias are 
associated with a 40% death ra te .16 
Pseudomonas aeruginosa is one of the 
most frequently recovered organisms in 
the neutropenic bacteremic patient.17 On 
the other hand, the virulence of S. epider­
midis, enterococcus and C. albicans, espe­
cially when isolated from intra-abdominal 
sources, is not as clear.
Pathogenicity has been judged by the 
ability to cause bacteremia. O f the 25 
patients in this study 48% had bactere­
mias (or candidemias) and cultures from 
these patients were dominated by S. 
epidermidis, C. albicans and entero­
coccus, indicating that these organisms 
have a propensity for invasion. Entero- 
coccal bacteremias have been associated 
with death rates of 34% to 68% .18~21 
Dougherty and colleagues,19 focusing on 
bacteremias originating from in tra­
abdominal sites, reported the highest 
death rate (68%). Their data also sug­
gested that antienterococcal therapy may 
improve survival. Conversely, the data of 
Garrison and colleagues20 demonstrated, 
as did our present study, that antibiotics 
specifically directed against enterococcus 
neither reduced the death rate nor ef­
fected cure. The death rate in patients 
with S. epidermidis bacteremia has ranged 
from 27% to 46%.22,23 Burchard and 
colleagues23 showed that specific antibi­
otic therapy reduced the death rate from 
49% to 10%. In the patients in that study, 
central venous catheters represented the 
main focus of infection. We were unable 
to demonstrate a role for therapy directed 
against S. epidermidis in our patients. In 
fact, 50% of the bacteremias cleared
without treatment. It is difficult to draw 
conclusions concerning the role of 
antimicrobial therapy against entero­
coccus and S. epidermidis isolated from 
intra-abdominal sites in these critically ill 
patients. We continue to administer 
drugs, based on the scanty evidence in the 
literature of their ability to reduce deaths 
and that enterococcemia may lead to 
enterococcal endocarditis.19 We believe 
that these low virulence organisms 
represent markers, reflecting global 
depression of host immune defences in 
the critically ill patient but do not exert 
a specific pathogenicity.
The im portance o f Candida  in 
intraperitoneal infections is better 
defined. Solomkin and colleagues24 
retrospectively reviewed 56 episodes of 
intraperitoneal infection in which various 
Candida sp. were identified. They showed 
the colonization of three or more sites 
with Candida predisposed to blood inva­
sion. Furthermore, patients treated with 
amphotericin B, before candidemia, had 
a better survival rate than those not 
treated. They suggested that colonization 
of three sites was sufficient rationale for 
instituting amphotericin B therapy. In a 
subsequent paper6 these same authors 
included 22 patients with organ failure in 
their assessment of antifungal therapy. 
They found that the survival rate was 
much lower (18%) in patients with organ 
failure before treatment than in patients 
without organ failure (78%). With such 
poor survival, it is difficult to justify 
antifungal therapy. The paper did not 
specifically examine the ability of 
amphotericin B to sterilize colonization 
sites in these critically ill patients. Our 
review suggests it is only moderately 
effective (54% sterilization) and that the 
risk of candidemia probably persists 
despite therapy.
It is interesting to speculate on the ori­
gin of the flora of these persistent intra­
abdominal infections. In 9 of the 25 
patients, there was a fistulous communi­
cation to the gastrointestinal tract or 
biliary system. In the remaining patients 
it is possible that the organisms recovered 
were residual organisms spilled at the ini­
tial episode of peritonitis and, by selec­
tive antibiotic therapy, they survived and 
ultimately infected the collection. En­
terococci, S. epidermidis and C. albicans 
fall into the holes of antibiotic therapy. 
P. aeruginosa and Enterobacter sp. tend 
to be relatively antibiotic resistant. Evi­
dence is increasing that these organisms 
originate from the gastrointestinal tract 
by the phenomenon of “ bacterial trans­
location” .25 Wells and colleagues26 
showed that B. fragilis abscesses in rats 
attracted (and were ultimately colonized) 
by enterococci and S. epidermidis from 
the gastrointestinal tract. Stone and 
associates27 observed Candida dissemina-
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tion in dogs whose gastrointestinal tracts 
were inoculated with high doses of Can­
dida. Bacterial translocation is en­
couraged by impairment o f host cellular 
immune response.28 The fact that this 
defect is present in patients with multiple- 
system organ failure supports this con­
cept.29 Further studies are needed to 
define the route by which bacteria (and 
yeast) leave the gastrointestinal tract to 
colonize sites o f inflammation and 
produce systemic spread.
In summary, the microbial flora of crit­
ically ill patients with persistent intra­
abdominal infection differs radically 
from that in patients admitted with acute 
peritonitis. It is dominated by organisms 
that tend to be multiple-antibiotic resis­
tant and that individually are often con­
sidered low in virulence. Specific anti­
microbial therapy, although still rec­
ommended, did not sterilize these cul­
tures, probably reflecting impaired host 
defences in patients with multiple-system 
organ failure.
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Presidential Address, 1985: Collecting
We are all collectors — collecting and 
organizing information being a very 
important part of medical practice. View­
ing and collecting medical data are just 
the same as collecting stamps, and the 
personal computer has made it much 
easier for us. But we must get started, 
decide what to collect and how to dis­
play it. In vascular surgery, primary and 
secondary patency have been used to 
display results. In the author's opinion, 
the concept of actual palliation (a living 
patient with a patent graft) gives a much 
better reflection of what has actually 
been accomplished. In the “ high-tech” 
future surgeons must know more about 
their collections than anyone else — or 
they will be directed by those who do. 
Let's accept the challenge now.
Nous sommes tous des collectionneurs 
puisque la collection et I'organisation de 
I'information constituent une partie 
importante de la pratique medicate. 
L'examen et la collection des donnees 
medicates s'apparentent a la collection 
de timbres et I'ordinateur personnel nous 
a rendu la tache beaucoup plus facile. II 
faut neanmoins se lancer, decider de ce 
qui sera collectionne et de quelle fapon 
cela sera visualise. En chirurgie vascu- 
laire, la permeability primaire et secon- 
daire a servi a visualiser nos resultats. 
Selon I'auteur, le concept de palliation (un 
patient vivant qui a une greffe permea-
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ble) illustre beaucoup mieux ce qui a ete 
accompli. Dans un avenir oil prevaudra la 
haute technologie nous devrons mieux 
connaitre nos collections que quiconque; 
sinon, ceux qui sauront nous meneront. 
Acceptons le defi. Des maintenant.
To collect is defined in Webster’s Diction­
ary as to gather together or assemble.
All of us collect — if only information 
for income tax! Any memorabilia or 
knick-knack can make a good collection 
and may be profitable. Most of us have 
collected stamps or coins to some degree. 
I still have all my Popular Mechanics and 
Lionel trains, collecting dust and my 
wife’s wrath, and I’ll bet most of you 
have your favourite old ski in the base­
ment. These are a little like the old doc­
tor with a series of one case — interest­
ing but hardly a collection.
What is a collection? Unsoaked stamps 
have been saved, but they are definitely 
not a collection. Collections are 
organized, attractively displayed and have 
a common theme. The whole point of the 
collection is that it can be observed, 
enjoyed, refined and, if organized, under­
stood.
In postgraduate training we collect a 
great deal of information. One of the 
important aims is to infuse the trainee 
with enthusiasm for adding in some way 
to medical knowledge or development. 
Two people, particularly, influenced me
in this regard. Charles Rob had one of the 
most incisive minds I have ever encoun­
tered. There were hooks all over it, ask­
ing questions and looking for answers, 
collecting and organizing. Rounds were 
exciting. His surgery had the same preci­
sion and flair.
The second person was Professor 
Milnes Walker of Bristol who was a world 
authority on surgical control of portal 
hypertension. A humble and most gra­
cious host, he had two sets of bar graphs 
displayed on his office walls; one showed 
patients after portacaval shunting and the 
other after transesophageal ligation of 
their varices. He extended the bar graph 
on each follow-up visit and coded 
“ rebleeds” , hepatic encephalopathy and 
death. The up-to-date results in his area 
of major interest were there for all to see: 
a brilliant surgeon and an academic col­
lector.
Then, as now, treatment of femoro- 
popliteal occlusive disease was a very hot 
topic. I first did a femoropopliteal vein 
graft in June 1964, and I have collected 
results of vein grafting procedures ever 
since. My collection was organized as bar 
graphs, and I marked revision with a line, 
occlusion with an X and death with a 
cross. I kept this on the wall of my office, 
soon covered by a curtain so that it didn’t 
frighten patients. As the follow-up time 
increased the early cases looked a little 
like Flanders fields, with its crosses row 
on row!
Then the day of the main-frame com­
puter was upon us. Henry Litherland 
recognized its value to the collector and 
developed a form to collect pertinent data 
associated with the surgery of occlusive 
vascular disease.1 A year later Henry 
Hildebrand drew up a form for 
aneurysms. Using these forms we started 
a prospective study of vascular disease at 
St. Paul’s Hospital in Vancouver in 1967, 
back loading my femoropopliteal collec­
tion at that time. There have been a few
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revisions in the last 18 years, one to 
improve collection of data on “ redo” 
cases and the other, a format change to 
satisfy the “ data punchers” . The point 
is, that by making the decision to collect, 
we now have an organized prospective 
data base of patients, their surgical com­
plications and subsequent operations 
since 1967. The fact that a few things have 
been changed has not been a real 
problem.
What To Collect
Several problems confront any collec­
tor and the most important is what to col­
lect. In the field of stamp collecting, each 
collector makes decisions. Some collec­
tors collect stamps from all over the 
world, but they are rarely able to sustain 
interest or input for such a wide collec­
tion. Even the stamp collector who 
specializes has decisions to make. Will he 
collect every existing ultra-rare stamp in 
his area? — a good “ Penny Black” is 
worth $100 000.! Does it ruin the collec­
tion not to have it? A mistake I made was 
to stop collecting Canadian stamps 
prospectively about the end of World 
War II, they were just so common. Re­
trospective stamp collecting is a much 
more expensive exercise.
Without making tedium of the compar­
ison, collecting medical data is no differ­
ent. We must get started and decide what 
to collect; we can be satisfied with a data 
base that provides us with complete infor­
mation on say 90% of the group as long 
as we can identify the missing informa­
tion and find it. In writing up 100 cases,
I would hope to pull no more than 15 
charts and should go directly to them for 
one or two pieces of information. As 
numbers increase or interest focuses, new 
categories are necessary and a good data 
collection form has some leeway to accept 
them. Clearly, there is no need to look up 
all the vein grafts to pick out the in-situ 
grafts, so we changed a few numbers 
recently to identify them.
Storage and Access
The next problem confronting the col­
lector is where to keep the collection and 
how to gain access to it. Valuable collec­
tions are often locked up in a bank vault, 
but active portions of the collection, 
where one is completing a page or adding 
to a contemporary area, must be availa­
ble. Obtaining information from a main­
frame computer through the interface of 
a programmer can be a little like borrow­
ing money from a difficult banker, you 
may not get what you want! The great 
advantage of the personal computer is 
that it is interactive, which means that as 
you change an entry it is immediately visi­
ble on the screen or rejected with a dis­
couraging beep. Linked mathematical 
changes are instantaneous. You can ask 
the computer what will happen if your 
next 10 patients fail or succeed. The inter­
face between the collector and the per­
sonal computer is software. Good soft­
ware programs are termed friendly. 
Compatible computers with friendly pro­
grams often lead to collectors being mar­
ried to their computers.
Medical literature has become an over­
whelming collection. Reports are being 
abstracted daily and are available to all 
of us on-line through a personal computer 
and modem. There is no question that this 
is the educational route of the future. The 
most up-to-date literature is available at 
one’s finger tips the evening before a
presentation or the arrival of a visiting 
professor. The microcomputer was 
refined for business purposes only 2 years 
ago and has become a fact of life in that 
short time.
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FIG. 3--Big brother will be watching.
FIG. 1—Actual pallation curve (graft patent and patient alive) truly reflects patient bene­
fit from operation.
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HG. 2—Menu-driven software program to analyse patient data base on personal computer 
the stamp album for the vascular collector.
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Organization
The final problem is organizing the col­
lection. The stamp collector buys an 
album with organized pages, ponders 
over the stamps and enters the best one. 
The more sophisticated collector divides 
the collection into mint and used or may 
have special interest in topics or cancels. 
The better and larger the collection, the 
more important is the organization and 
the display.
I have been particularly interested in 
displaying the results of medical collec­
tions. Much like stamps, our patients 
change as they progress through treat­
ment. The patient who is being assessed 
is like the mint stamp; the patient after 
successful surgery, very fine used; after 
reoperation, socked on the nose; and 
treatment failure, faulty.
For our purpose in vascular surgery we 
can condense these phases into: primary, 
that is the durability of the original con­
struction; secondary, our ability to keep 
it functioning with revisionary operations; 
and actual palliation, which we define as 
the combination of a successful graft and 
a living patient. With this display format 
for an aortofemoral collection, the results 
are informative and should influence 
future management (Fig. 1). They can be
compared to results of femoropopliteal 
grafting for the same complaint.2 It is 
difficult to say which curve is the most 
valuable, but in my opinion it is the actual 
palliation curve that best reflects patient 
benefit from the operation.
Over the last 2 years I have developed 
a menu-driven software program for the 
personal computer that analyses a patient 
data base and produces life tables and 
graphs under the above headings (Fig. 2). 
The end point for primary patency is 
usually revision or thrombectomy, but 
any late occurrence, reconstruction above 
or below, or false aneurysm, can qualify, 
depending on the study. Graft occlusion 
(failure) ends the secondary patency. 
Patient groups can be selected on the basis 
of outflow, symptoms, age, sex or any 
combination of factors the collector has 
entered. When combined with the data 
collection form, this is the stamp album 
for the vascular collector.
If we can define the exact criteria and 
aim of a study before we start, collecting 
can be very efficient. This was possible 
in the annual vascular surgery audit for 
which we decided to utilize only informa­
tion that was easily retrievable in 
retrospect and to use hospital morbidity 
as the cut-off date, thereby eliminating 
long-term follow-up.3
Future
What does the future hold for medical 
collectors? Undoubtedly, we will all end 
up with computer access directly from our 
offices, whether it be a personal computer 
or a dumb terminal connected to a mini- 
or main-frame computer. Hospitals are 
gradually breaking down their computer 
fear. Medical records departments are 
great savers of questionable information. 
Perhaps through more direct input from 
medical personnel, we can identify what 
is important to us and delegate some of 
the leg work to those who are trained to 
do it.
Some collectors are born and others are 
made. In the “ high-tech” future we are 
all involved and big brother will be watch­
ing (Fig. 3). It behooves us to know more 
about our collections than any one else, 
or we will be directed by those who do.
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Edwards Foundation Lecture. 
Femoropopliteal and Infrapopliteal Reconstruction:
State of the Art 1985
A review of recent reports in the surgical 
literature and the author's recent 
experience suggest that autogenous vein 
grafts remain the best method for arterial 
reconstruction below the inguinal liga­
ment. The in-situ vein graft appears 
superior to reversed grafts for femoro- 
infrapopliteal reconstruction. Bypass 
grafts of polytetrafluoroethylene or 
human umbilical vein have not achieved 
satisfactory long-term patency even in 
the femoropopliteal position and should 
probably be used sparingly.
La revue des dernieres communications 
dans la presse chirurgicale ainsi que 
I'experience recente de I'auteur indiquent 
que la greffe de veine autogene demeure 
la meilleure technique de reconstruction 
arterielle sous le niveau du ligament 
inguinal. La greffe veineuse in situ paraft 
etre superieure a la greffe inversee dans 
les cas de reconstruction f6moro- 
infrapoplitee. Les derivations a I'aide de 
tubulure de polytetrafluoroethylene ou de 
veine ombiiicale humaine n'ont su assu­
rer une permeabilite satisfaisante a long 
terme, meme en position femoropoplitee, 
et doivent probablement etre utilisees 
avec parcimonie.
Arterial reconstruction below the ingui­
nal ligament, particularly that of the 
infrapopliteal vessels, remains a problem
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in vascular surgery. There is widespread 
agreement that the most effective means 
of treating femoropopliteal and femo- 
rotibial arterial occlusive disease is bypass 
grafting with autogenous vein. However, 
the late results of reversed saphenous vein 
grafting in the lower extremities have 
generally been inferior to those achieved 
with repair of occlusive disease of the aor- 
toiliac system, the internal carotid arter­
ies, the renal arteries, or the great vessels 
arising from the aortic arch.
The major cause of vein-graft failure 
is myointimal hyperplasia of the graft 
itself. Experimental evidence suggests that 
these lesions are the direct result of 
intimal injury, often occurring at the time 
the graft is harvested.1 Recent work by 
LoGerfo and colleagues2 indicated that 
careful handling of autogenous 
saphenous vein,, when it is removed in 
preparation for grafting, coupled with the 
use of papaverine to prevent venous 
spasm, may reduce the incidence of 
intimal damage and subsequent hyper­
plastic lesions. Some clinical reports also 
suggest that careful handling of the vein 
may yield improved results for 
femoropopliteal and infrapopliteal vein 
grafts.2,3
In-Situ Grafting
There still remains the problem of size 
discrepancy using reversed saphenous 
vein, when the small distal end is attached 
proximally to the circumferentially larger 
and often thick wall of the common 
femoral artery. This situation frequently 
leads to a narrowing at the proximal 
anastomosis with damage to the intima 
distal to that point because of resulting 
flow disturbance and shear stress. This 
problem can be solved by the use of the 
saphenous vein in situ and, stimulated by 
the excellent results of the Albany 
group,4 many surgeons have adopted the 
in-situ grafting technique with valve inci­
sion using instruments developed by 
Leather and associates.5 The in-situ tech­
nique is also thought to cause less intimal 
damage to the vein because it is left in its
natural bed and is perfused by arterial 
blood at physiologic pressure.
The early and intermediate results of 
the in-situ vein grafting technique in 
femoropopliteal and fem oro-infra- 
popliteal reconstructions have been 
gratifying in our hands and in those of 
other surgical groups.6-7 We found that 
the cumulative 2i-year patency rate of 
femoropopliteal m-situ vein grafts was 
82% in a series of 54 grafts and for 
femoro-infrapopliteal in-situ vein grafts 
87% for a series of 47 grafts. These results 
are at least as good as those achieved on 
our service with the reversed saphenous 
vein graft in the femoropopliteal position 
and are superior to those in the femoro- 
infrapopliteal position.
The in-situ operation takes no longer 
to perform than reversed vein grafting 
and actually reduces the operating time 
for femoro-infrapopliteal bypasses in 
most instances. The technique has also in­
creased our use of vein grafts. Previous 
experience indicated that the use of 
reversed autogenous vein grafts of less 
than 4 mm external diameter was accom­
panied by too high a graft failure rate to 
be worthwhile. However, the use of 3-mm 
diameter veins is feasible with the in-situ 
technique. This is probably because the 
larger end of the vein is anastomosed to 
the large common femoral artery and the 
smaller end to a small thinner-walled dis­
tal artery, and also because the incidence 
of myointimal hyperplasia in the vein 
graft itself is lower. For these reasons we 
believe that the in-situ vein graft is now 
the preferred method of arterial recon­
struction below the inguinal ligament.
Polytetrafluoroethylene Grafts
Management of the patient who has 
limb-threatening ischemia and whose 
saphenous vein is either too diseased for 
use or has already been removed remains 
a problem. There has been widespread 
interest over the past decade in infrain- 
guinal bypass grafts of polytetrafluoro­
ethylene. The early enthusiasm for this 
material has been tempered considerably
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by the late results reported from a num­
ber of vascular surgical services.8,9 Our 
experience suggests that bypasses of poly- 
tetrafluoroethylene grafts to the tibial ves­
sels stay patent on the average for such 
a short period as to be contraindicated. 
The 5-year patency rate of 30% for 230 
femoropopliteal polytetrafluoroethylene 
grafts is discouraging when compared 
with the results achieved using autoge­
nous vein.
One problem with polytetrafluoroethy­
lene grafts, in concert with other artifi­
cial prostheses crossing the knee joint, is 
buckling of the graft when the knee is 
flexed to 90° and beyond. Manufacturers 
have attempted to prevent this problem 
by incorporating external rings into the 
graft material. However, the grafts then 
appear to buckle the popliteal artery and 
failure rates, in our experience, have not 
lowered. Polytetrafluoroethylene grafts, 
both experimentally and clinically, are 
also associated with the development of 
a myointimal hyperplastic lesion at the 
distal anastomosis that appears to begin 
in the wall of the artery opposite the 
anastomotic suture line and to expand to 
involve the entire circumference of the 
artery and the lower portion of the graft 
itself.10 The reason for this complication 
is not known, but it may be that the com­
pliance mismatch between a stiff poly­
tetrafluoroethylene tubing and a compli­
ant host artery is responsible for damage 
to the arterial intima.
It has been suggested that the use of 
antiplatelet agents may improve the long­
term patency of polytetrafluoroethylene 
grafts. The only experimental evidence 
supporting this concept is a report from 
Green and associates,11 in which a small 
number of patients treated with antiplate­
let agents were compared with those 
treated with placebo. It was found that 
only those patients with polytetrafluoro­
ethylene grafts placed above the knee 
joint appeared to benefit from such ther­
apy. A controlled double-blind study in 
which our service participated, failed to 
show improved patency of polytetraflu­
oroethylene grafts in patients treated with 
antiplatelet agents when compared with 
those treated with a placebo.12
In any event, the discouraging long­
term patency rates of polytetrafluoroethy­
lene in the infrainguinal position reported 
by a number of experienced surgeons sug­
gest that grafts of this material should be 
used sparingly. The late results are simi­
lar, to those reported in the early 1960s for 
Dacron prostheses in the infrainguinal 
region, and these grafts are now rarely 
used for femoropopliteal reconstruction.
There are reports suggesting that 
human umbilical vein may be superior to 
polytetrafluoroethylene for grafting in the 
femoropopliteal position.9 We have been 
unable to duplicate these results on our 
service and have found that patency rates
with umbilical vein are essentially the 
same as those with polytetrafluoroethy­
lene. The umbilical vein graft is more 
difficult to use technically, is subject to 
unpredictable early failure, is very 
difficult to thrombectomize successfully, 
and is associated with late aneurysm for­
mation.13
Alternatives
Since none of the artificial materials 
appear to be an alternative to autogenous 
vein grafts for femoral-distal popliteal 
and infrapopliteal reconstruction, a num­
ber of surgeons have turned to compo­
site grafts for patients whose saphenous 
veins are unsuitable or missing. Conduits 
of polytetrafluoroethylene or Dacron 
above the knee are attached to shorter 
segments of autogenous vein to carry the 
graft below the knee joint. There is some 
evidence that composite grafts have a 
patency superior to that of artificial 
prostheses a lone .14,15 However, the 
Achilles’ heel of a composite graft is the 
proximal prosthesis, which continues to 
have the disadvantages noted, even 
though it is attached distally to an 
autogenous venous graft. Our experience 
suggests that the results with composite 
are better than those of plastic prostheses 
alone when used below the knee. How­
ever, we believe that attaching the vein to 
the prosthesis by an end-to-end anasto­
mosis should be avoided; this appears to 
result in buckling of the compliant vein 
by the non-compliant prosthesis with each 
pulse beat. A better technique is to 
anastomose each separately to a segment 
of popliteal artery above the knee joint 
if possible, or to use an end-to-side 
anastomosis of the vein to the prosthesis.
We believe an attempt should be made 
to use autogenous arm-vein grafts, which 
have been shown by several groups to 
have satisfactory long-term patency in the 
infrainguinal position, or composite 
venous grafts formed of arm vein and 
lesser saphenous vein, which is frequently 
ignored by vascular surgeons although it 
is usually intact and of adequate calibre. 
Use of such grafts, combined with prox­
imal endarterectomy of the superficial 
femoral artery, will often permit satisfac­
tory infrapopliteal reconstruction in 
patients whose saphenous veins have been 
removed or destroyed. There has been a 
rekindling of interest in the use of a more 
extensive endarterectomy of the superfi­
cial femoral and popliteal arteries, partly 
the result of a new motor-driven endar­
terectomy instrument that appears to do 
a better job than the old-fashioned loop 
strippers. The late results reported by one 
surgical group16 using this technique, 
rival those achieved with autogenous 
venous grafts. At present, if at all possi­
ble, autogenous tissue reconstruction 
should be used below the inguinal liga­
ment if a high late failure rate is to be 
avoided.
The Future
Hope should not be abandoned that a 
satisfactory small-vessel prosthesis will 
ultimately be developed. Modern tech­
niques of endothelial cell culture, partic­
ularly recent advances in the purification 
and utilization of endothelial cell-growth 
factor, have opened the way towards the 
clonal expansion of endothelial cells har­
vested from short segments of autogenous 
vein for use in the lining of a prosthesis. 
Advances in polymer chemistry also sug­
gest that the construction of an appropri­
ately compliant prosthesis to accept an 
autogenous endothelial lining may be 
feasible in the near future. Perhaps an 
even more attractive idea is the growth in 
tissue culture of a totally autologous 
prosthesis composed of an endothelial- 
lined smooth-muscle tube, which has 
been found experimentally to be feasible 
if not commercially practical.
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Utility and Application of Pulmonary Artery Catheterization
in Aortic and Aortoiliac Disease
To determine how useful pulmonary 
artery catheterization is in abdominal aor­
tic surgery and which patients are most 
likely to benefit from the procedure, the 
author studied 28 patients with aneu­
rysms and 22 with obstructive disease. 
Patients with multiple risk factors, 
except those with leaking aneurysms, 
were assessed before operation by pul­
monary artery catheterization and 
volume loading (15 ml of 5 %  albu- 
min/kg over 12 hours). All patients who 
underwent operation were assessed and 
monitored by pulmonary artery catheteri­
zation, beginning immediately postopera- 
tively.
In 26 patients the procedure made a 
substantial contribution to assessment or 
care of their condition, not suggested by 
the usual clinical and technical modali­
ties. In four patients the proposed sur­
gery was affected; it was cancelled in 
one, delayed in two and replaced by a 
lesser procedure in one. Tw o other 
patients, thought to have unacceptable 
cardiac function, were considered suita­
ble for operation after catheterization 
was done. Eleven patients with subop- 
timal cardiac index and 2 with volume 
overload were recognized early after sur­
gery. Tw o  patients with oliguria follow­
ing repair of a ruptured aneurysm had 
optimal cardiac indices and renal perfu­
sion assured by pulmonary artery cathe­
terization, which helped to identify 
unsuspected pulmonary hypertension in 
three patients, bleedir g in one and intes­
tinal infarction in one.
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Twenty-seven patients were challenged 
before surgery with 5 %  albumin and 
their response was analysed. In 7 there 
was no response to the colloid challenge 
and they suffered much more morbidity 
than the 20 patients who had a positive 
hemodynamic response to challenge.
Multiple regression analysis of disease 
and risk factors among the 50 patients 
showed that age and cardiac status were 
independent and were the most 
dominant of all variables in determining 
the likelihood of benefit from pulmonary 
artery catheterization.
Dans le but de determiner I'utilite du 
catheterisme de I'artere pulmonaire dans 
la chirurgie de I’aorte abdominale et 
d'identifier les patients les plus suscepti- 
bles de beneficier de cette intervention, 
I'auteur a etudie 28 patients souf- 
frant d'an6vrisme et 22 de maladie 
occlusive. Les patients presentant des 
facteurs de risque multiples, a I'excep- 
tion de ceux qui avaient un anevrisme 
suintant, ont ete evalue avant I'operation 
par catheterisme de I'artere pulmonaire 
et charge de volume (15 ml d'albumine 
a 5%/kg sur une periode de 12 heures). 
Tous les patients qui ont subi I'operation 
ont ete evalues et surveilles par cathete­
risme de I'artere pulmonaire en commen- 
cant des la fin de I'intervention.
Chez 26 patients, I'intervention a con- 
tribue de facon importante a revaluation 
des soins apportes a leur etat, contribu­
tion que n'auraient pu apporter les 
moyens cliniques et techniques habi- 
tuels. Dans quatre cas, I'operation envi- 
sagee a ete modifiee; une chirurgie a ete 
annuiee, deux ont ete retardees et une a 
ete remplacee par une intervention 
reduite. Deux patients que I'on croyait 
inaptes a I'operation en raison d'une 
insuffisance de la fonction cardiaque se 
sont qualifies au catheterisme, Onze 
patients ayant un index cardiaque sous- 
optimal et deux ayant une surcharge de 
volume ont ete identifies peu apres I'ope­
ration. Deux patients presentant une oli- 
gurie apres reparation d'un anevrisme
rupture ont montre au catheterisme de 
I'artere pulmonaire, un index cardiaque 
optimal et une bonne perfusion renale; 
ceci a permis d'identifier une hyperten­
sion pulmonaire insoupconnee chez trois 
patients, du saignement chez un et un 
infarctus intestinal chez un autre.
Avant I'operation, 27 patients ont ete 
mis a I'epreuve a I'aide d'albumine a 5%  
et leur reponse a ete analysee. Sept 
d'entre-eux n'ont pas reagi a cette 
epreuve au colloide; on a constate chez 
eux une morbidite beaucoup plus consi­
derable que chez les 20 qui ont repondu 
positivement a I'epreuve hemodyna- 
mique.
Chez 50 malades, une analyse de 
regression multiple portant sur la maladie 
et les facteurs de risque a montre que 
I'age et I'etat de la fonction cardiaque 
etaient independants; de toutes les varia­
bles, elles etaient les plus importantes 
pour determiner la probabilite de benefi­
cier d'un catheterisme de I'artere pulmo­
naire.
The role o f invasive hemodynamic 
monitoring in patients who undergo 
major vascular surgery remains con­
troversial. These patients tend to be 
elderly, many have critical vascular dis­
ease in other areas and many have chronic 
lung disease. The basic monitors of pulse 
rate, blood pressure and urinary excretion 
rate in patients who undergo surgery are 
often unreliable in the patient with aortic- 
vascular disease, as a result of preopera­
tive beta blockade, aortic clamping and 
operative diuretic therapy. Central venous 
pressure is not a reliable monitor of the 
rapid changes that may take place and is 
often misleading, especially in the 
presence of pulmonary artery hyperten­
sion. On the other hand, pulmonary 
artery catheterization adds complexity to 
the care of the aortic surgical patient and 
is associated with a morbidity of its 
own.1
This study was undertaken to deter­
mine how useful pulmonary artery cathe­
terization is in aortic surgery, the nature
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of the benefits, and to see if patients 
deriving benefit could be identified.
Methods
Fifty consecutive patients, 28 with 
aneurysmal disease and 22 with obstruc­
tion, were assessed by pulmonary artery 
catheterization. Patients (33 of the 50) 
with multiple clinical risk factors, exclud­
ing those with ruptured aneurysms, 
underwent baseline studies preopera- 
tively. Twenty-seven of this group were 
challenged with 5% albumin solution (15 
ml/kg over 12 hours) to evaluate cardiac 
performance and optimize preload before 
operation. All who had direct aortic sur­
gery (48 patients) were assessed immedi­
ately after by pulmonary artery catheteri­
zation and monitored for at least 48 
hours.
As each patient was assessed and 
treated, the substantial contributions 
made by catheterization to the assessment 
or care of that patient, not indicated by 
other clinical or technical modalities, were 
noted prospectively and classified accord­
ingly as major (3), intermediate (2) or 
minor (1).
After identifying patients in whom 
catheterization was considered useful, our 
group developed a statistical model that 
included individual variables, to see if we 
could identify those patients likely to der­
ive benefit from pulmonary artery cathe­
terization. The variables included age, 
sex, cardiac status (New York Heart 
Association, 19732), clinical risk factors 
of renal, cerebral, respiratory and meta­
bolic origin, and the presence preopera- 
tively of hypertension; these were consi­
dered together with the nature of the 
disease treated, obstructive or aneu­
rysmal.
Apart from benefits in individual 
patient care, the initial preoperative infor­
mation obtained from catheterization, 
with the response to challenge with 5% 
albumin, was examined to see if outcome 
and morbidity were predictable by that 
initial assessment.
Results
Usefulness o f  Pulmonary Artery Cathe­
terization
In 26 of 50 patients the procedure made 
substantial contributions to assessment or 
patient care (Table I). These were major 
in 10 cases, intermediate in 7 and minor 
in 9.
Cancellation o f  surgery.—A 74-year- 
old man with chronic obstructive pulmo­
nary disease, aortoiliac obstruction and 
ascending aortic aneurysm had his surgery 
cancelled because the catheterization 
indices deteriorated after challenge with 
5% albumin.
Alteration o f  a planned procedure.— 
In one 70-year-old man with an ascend­
ing aortic aneurysm whose catheterization 
indices deteriorated following challenge 
with 5% albumin, the aneurysm surgery 
was cancelled and axillobifemoral graft­
ing carried out 6 days later.
Delay o f  surgery.—Two patients whose 
initial assessment revealed marginal 
cardiac indices and elevated pulmonary 
capillary wedge pressures had their oper­
ations postponed. Digitalis was prescribed 
and 7 days later when their condition was 
improved the aortic operations were per­
formed.
Upgrading o f  fitness assessment.—Two 
patients were considered poor candidates 
for aortic surgery by medical assessment. 
Following pulmonary artery catheteriza­
tion and a good response to 5% albumin 
challenge they were considered to be at 
less risk and they subsequently underwent 
uncomplicated aortic surgery.
Optimal cardiac index and renal 
insufficiency.— Two patients had persis­
tent oliguria after repair of ruptured 
abdominal aneurysms. Optimal renal per­
fusion was assured by pulmonary artery 
catheterization in circumstances in which 
overload and adult respiratory distress 
syndrome were potential hazards.
Recognition o f  volume /preload defi­
ciency.—In three patients volume defi­
ciencies were recognized postoperatively
Table 1—Contribution of Pulmonary Artery Catheterization to 
Individual Care of 50 Patients with Aortic Aneurysms or Obstruction
Contribution No. of patients Weighting*
Cancellation of surgery 1 3
Replacement by lesser operation 1 3
Delay of operation 2 3 x 2
Upgrading of fitness assessment 2 1 x 2
Assurance of optimal cardiac index
in oliguric patients 2 2,3
Recognition of:
Volume/preload deficiency with
hypertension 11 1 x 5, 2 x 4, 3 x 2
Volume overload 2 2 x 2
Pulmonary artery hypertension 3 3 x 3
Postoperative bleeding 1 1
Intestinal infarction 1 1
*1 -  minor benefit, 2 -  intermediate benefit, 3 -  major benefit.
by pulmonary artery catheterization, but 
the information obtained from basic 
monitoring was within the normal range. 
These patients required an average of 630 
ml of red blood cells and plasma to 
restore normal catheterization indices. 
Twenty-seven patients had moderate 
hypertension early after operation; in 8 
of them, relative volume/preload defi­
ciency was exposed after vasodilator ther­
apy for increased systemic vascular 
resistance—an average of 890 ml of red 
blood cells and plasma corrected the 
abnormality with return to normal 
indices. The volume deficiencies in these 
patients, in the absence of pulmonary 
artery catheterization data, might not be 
evident until renal recovery from opera­
tive diuretic therapy and oliguria 
occurred.
Volume overload.—Two patients who 
suffered interstitial pulmonary edema and 
had evidence of respiratory failure after 
aortic surgery were found by cathe­
terization to have volume overload. The 
clinical distinction between respiratory 
failure, pneumonia and adult respiratory 
distress syndrome may be difficult 
without pulmonary artery catheteri­
zation.3
Pulmonary artery hypertension.— 
Three patients had serious pulmonary 
artery hypertension, with systolic pres­
sures over 35 mm Hg. Lesser degrees of 
pulmonary artery hypertension were fre­
quent. Those with severe hypertension are 
at special risk because they are more sen­
sitive to volume overload and have an 
increased susceptibility to adult respira­
tory distress syndrome; in some instances 
pulmonary hypertension can impair left 
ventricular performance.4’5
Early recognition o f  bleeding.—A 
69-year-old man with infrarenal aortic 
obstruction and renal artery stenosis had 
hypertension, treated with (3-blockers. 
Two hours after repair of the obstructed 
abdominal aneurysm and aortorenal 
bypass, pulmonary artery hypotension 
developed and there was a drop in cardiac 
index without systemic hypotension. With 
volume infusion, the catheterization 
indices returned to normal, but after 1 
hour the previous abnormal indices of 
pulmonary artery catheterization were 
again noted. The patient was returned to 
the operating room and suture-line bleed­
ing controlled. At no time did the patient 
manifest systemic hypotension, tachy­
cardia or a decrease in urine volume. Pul­
monary artery catheterization in this 
instance served as an early warning 
system.
Intestinal ischemia.—As a result of a 
hemodynamic failure of a cross-femoral 
graft a 74-year-old man underwent oper­
ation for aortoiliac obstruction. He had 
coronary artery disease and had had a 
myocardial infarction. At operation, in
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addition to aortobifemoral grafting, a 
stricture of his small intestine was 
resected. Forty-eight hours later he 
became hypotensive and tachycardiac. 
His cardiac index (6.3) on pulmonary 
artery catheterization was double that of 
the early postoperative value (3.1), his 
systemic vascular resistance index had 
dropped from 1065 to 878 and his arteri­
ovenous oxygen difference was 2. At 
laparotomy total colectomy was required 
for colonic infarction. In a patient such 
as this who is still on the respirator and 
heavily sedated 48 hours after operation, 
other causes of hypotension, cardiac- or 
volume-related, would be difficult to 
exclude without pulmonary artery 
catheterization.
Colloid Challenge with 5% Albumin: 
Relationship to Outcome
In addition to the individual contribu­
tions by pulmonary artery catheterization 
to patient assessment and care, the rela­
tionship between the response to chal­
lenge by 5% albumin to outcome after 
operation was examined. The 27 patients 
challenged by 5% albumin who subse­
quently had aortic surgery responded in 
one of two ways. In 20 patients (group 
1), the mean cardiac indices increased 
(from 2.93 ± 0.4 m l/m in»m r2 to 3.6 ± 
0.62 ml/min*m~2); in the other 7 
patients (group 2) cardiac indices did not 
increase (3.18 ± 0.21 ml/min*m~2 ver­
sus 2.98 ± 0.3 m l/m in*m -2). In 
Fig. 1 the net change in cardiac index is 
shown for each patient together with the 
mean change and standard deviation for 
all 27 patients. The cardiac index in all 
group 2 patients fell below one standard 
deviation from the mean.
Outcome.—In group 1 patients there 
was major morbidity in two but no deaths 
(Fig. 2). One patient required reoperation 
for bleeding and the other a colectomy for 
intestinal ischemia. In group 2, there was 
major morbidity in four patients. One 
patient had cardiac arrest in the operat­
ing room and a second experienced ven­
tricular fibrillation in the intensive care 
unit shortly after surgery. A third patient 
had recurring cardiac failure and died at 
home 60 days after operation. A fourth 
suffered from adult respiratory distress 
syndrome and sequential organ failure 
and died 14 days after operation. This 
was the only death in the series in electi- 
vely treated patients.
Characterization o f  Patients Deriving 
Benefit From Pulmonary Artery Cathe­
terization
From initial overview of our 50 
patients, those with aneurysms (8 of 22) 
and obstruction with multiple risk factors 
(8 of 22) appeared more likely to benefit 
from pulmonary artery catheterization.
However, when benefit was quantified 
(from 1 to 3) and interacting terms were 
examined by multiple regression analysis, 
the common features were those of age 
and cardiac status as independent and 
dominant variables in the models. The 
R2 in this analysis was 50.84.
When unruptured aortic aneurysms 
and obstructions were examined, both 
separately and together, the variables 
became part of a more homogeneous pat­
tern with higher R2 values, from 63 to 
70; again age and cardiac status appeared 
as the dominating factors.
Since pulmonary artery catheterization 
is essentially a cardiac assessment, a fur­
ther model was constructed interacting 
cardiac status with all other variables. The 
stepwise regression process again showed 
age and its interaction with cardiac sta­
tus to be the important variables. The for­
mula in Fig. 2 characterizes precisely 
(with R2 = 50.17) those patients deriv­
ing benefit from pulmonary artery 
catheterization and the degree of benefit 
they might expect.
Cardiac index,
mL/min-nT^
FIG. 1—Response to 5% albumin challenge 
over 12 hours. Mean increase in cardiac index 
was 390 ± 300 ml/min.m'2. All patients in 
group 2 are below one standard deviation from 
mean.
HINETAB PACKAGE
STEPWISE LINEAR MULTIPLE REGRESSION -  FORWARD SELECTION
DEPENDENT INDEPENDENT
Helpful contribution
FORMULA: Helpful contribution < 1-3) by pulaonery ertery c e th e te r lu t lo n  -
-2.5018 ♦ 0.0053 (age * cardiac statue) * 0.048 age
EXAMPLE: Patient aged 75 yeare, cardiac statue *
Helpful contribution by pulnonary artery catheterisa tion  - 
-2.5018 ♦ 0.0053 (75 x 4) + 0.048 (75) - 2.69
FIG. 2—Characterization of group deriving 
benefit from pulmonary artery catheterization.
Discussion
In our group of patients who required 
abdominal aortic surgery, pulmonary 
artery catheterization was frequently 
beneficial, especially for elderly patients 
with cardiac impairment. In studies of 
survivors of critical illness, it has been 
shown that those with the capacity to pro­
vide above-normal performance (“ op­
timal goals versus normal values” ) with 
respect to cardiac index, oxygen delivery 
and other indices, are more likely to sur­
vive.6'7 It may be that those who cannot 
improve their cardiac performance sub­
stantially above a resting baseline level are 
poor candidates for major aortic surgery. 
They could be identified by constructing 
cardiac performance curves, but this is 
difficult, time-consuming and is only 
valid if end-diastolic volumes are meas­
ured.8 Observing cardiac response, by 
pulmonary artery catheterization, to a 
standard colloid challenge may be more 
practical and simple.
In older patients with cardiac impair­
ment who are candidates for aortic sur­
gery, assessment and monitoring by pul­
monary artery catheterization will 
frequently be of benefit and should help 
to minimize the increased morbidity and 
mortality of that group.
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Low-Dose Intra-arterial Streptokinase Infusion Therapy 
of Peripheral Arterial Occlusions and Occluded Vein Grafts
To study the effectiveness of low-dose 
thrombolytic therapy the authors report 
their experience with local, low-dose, 
intra-arterial streptokinase infused at a 
rate of 5000 units/h in four patients with 
occluded vein grafts and eight with 
peripheral arterial occlusions presenting 
with limb-threatening ischemia. The 
patients had had symptoms for 4 hours 
to 6 weeks. The streptokinase infusion 
successfully declotted two occluded vein 
grafts and restored distal blood flow in 
five patients with peripheral arterial 
occlusion. Complications resulting in 
early withdrawal of thrombolytic therapy 
included surgical wound hematomas in 
two patients. Tw o patients had severe 
bleeding at the arterial puncture site 
leading to the death of one of them. 
Treatment after cessation of thrombo­
lytic therapy included femoropopliteal 
bypass in three patients, percutaneous 
transluminal balloon dilatation of a 
stenotic popliteal artery in one patient 
and thromboembolectomy in three 
patients. Two patients required below- 
knee amputation because of irreversible 
ischemia.
The authors conclude that in carefully 
selected patients, intra-arterial infusion 
of streptokinase locally in low dosage is 
an important adjunct in the treatment of 
limb-threatening ischemia caused by 
occluded vein grafts and acute arterial 
thrombosis. They warn that selective 
thrombolytic therapy with streptokinase 
must be used with caution since it may 
be associated with serious complica­
tions.
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On decrit les resultats d'une etude sur 
I'efficacitS d’un traitement thrombolyti- 
que par perfusion locale intra-arterielle de 
streptokinase a faible dose. Le produit a 
ete administre a raison de 5000 uni- 
tes/h chez quatre patients ayant une 
occlusion de greffe veineuse et chez huit 
souffrant d'occlusion artdrielle peripheri- 
que qui ont ete vus pour une ischemie 
susceptible d'entrafner la perte d ’un 
membre. Les symptomes etaient pre­
sents depuis des periodes allant de 4 
heures a 6 semaines. La perfusion de 
streptokinase a permis de dissoudre le 
caillot dans deux cas d'occlusion de 
greffe veineuse et a retabli la circulation 
sanguine distale chez cinq patients souf­
frant d'occlusion artdrielle peripherique. 
Chez deux patients, un hdmatome au 
point d'incision a entraine I'arret precoce 
du traitement thrombolytique. Deux 
autres patients ont eu une hemorragie 
importante au point de piqure arterielle, 
ce qui a cause la mort de I'un des deux. 
A I'arret de la th£rapie thrombolytique, le 
traitement s'est poursuivi par pontage 
fdmoropoplitd chez trois patients, dilata­
tion transluminale percutanee par ballon- 
net dans un cas de stdnose de I'artSre 
poplitee et thromboembolectomie dans 
trois cas. Deux patients ont du subir une 
amputation en dessous du genou a 
cause d'une ischgmie irreversible.
Les auteurs concluent que chez des 
patients soigneusement choisis, la perfu­
sion locale intra-arterielle de streptoki­
nase a faible dose contribue de faqon 
importante au traitement de I'ischemie 
causee par I'occlusion d'une greffe vei­
neuse ou par thrombose arterielle aigue, 
mettant en peril la survie du membre. Ils 
mettent en garde contre I'utilisation sans 
precaution du traitement thrombolytique 
seiectif a la streptokinase, car celui-ci 
peut etre relie & des complications 
serieuses.
The effectiveness o f regional administra­
tion o f thrombolytic agents at low dosage 
to treat peripheral arterial occlusions has 
been confirmed by reports o f  several 
authors.1-8 Hargrove and associates9 
reported successful recanalization o f 
totally occluded femoropopliteal vein
grafts in four patients receiving low-dose 
streptokinase infusion. Current concepts 
and guidelines for the use o f thrombolytic 
agents are well established and have been 
reviewed in detail by Bell and M eek.10 
We evaluated this treatment in 12 patients 
with limb-threatening ischemia, consi­
dered ideal candidates for local, low-dose, 
thrombolytic therapy.
Patients and Method
Four patients with occluded fem oro­
popliteal vein grafts and eight with arte­
rial occlusions were treated with local, 
low-dose, streptokinase infusion at the 
Health Sciences Centre in Winnipeg 
between September 1982 and March 1985.
F IG . 1— Preoperative angiogram of 
occluded left femoropopliteal vein graft (left). 
Completely declotted vein graft after 43 hours 
of intra-arterial streptokinase infusion (right).
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Of the 12 patients, 8 were men and 4 
women, ranging in age from 52 to 80 
years. All had acute limb-threatening 
ischemia. The duration of symptoms 
ranged from 4 hours to 6 weeks. Screen­
ing eliminated any contraindications to 
thrombolytic therapy.
Coagulation studies, including platelet 
count, thrombin, prothrombin and par­
tial thromboplastin times were measured 
before, during and after therapy. Trans- 
femoral angiography identified the sites 
of occlusion, except in one patient in 
whom a transaxillary approach was used.
After the site of occlusion had been 
visualized angiographically, a no. 4 or 5 
French angiographic catheter was placed 
through the same arterial puncture site, 
under fluoroscopic control, as close to the 
thrombus as possible to deliver the max­
imum concentration of streptokinase to 
the site of thrombosis. Streptokinase was 
administered at a rate of 5000 units/h for 
up to 72 hours. To avoid catheter throm­
bosis, we found that dilution of strep­
tokinase to 1000 units/ml with normal 
saline by way of a sage pump was most 
satisfactory. Vital signs and arterial punc­
ture sites were monitored in the intensive 
care unit. Coagulation studies were per­
formed every 12 hours and when 
necessary.
Patients were assessed frequently by 
Doppler and pressure measurements. 
Follow-up arteriographic studies were 
performed 24 to 72 hours from the onset 
of therapy. Moderate arterial lesions 
remaining after therapy were treated 
by direct surgery or transluminal 
angioplasty.
When streptokinase infusion was suc­
cessful the patient was placed on heparin 
followed by oral anticoagulation for 3 to 
6 months.
The following three case reports illus­
trate the typical course of patients with 
arterial lesions and occluded vein grafts 
treated by streptokinase infusion.
Case Reports
Case 1
A 68-year-old woman had a 10-hour history 
of acute pain in the left leg.
Thirty-two months earlier, because of rest 
pain, she had undergone femoropopliteal 
bypass grafting below the knee, using reversed 
saphenous vein and proximal superficial place­
ment of a femoral artery onlay patch to the 
left common femoral artery.
Physical examination revealed a pale, cool, 
left leg with a 4 + femoral pulse but no palpa­
ble distal pulses. Motor and sensory functions 
were intact. Arterial flow at the ankle was 
undetectable by Doppler. Left transfemoral 
arteriography, performed immediately after 
admission, demonstrated complete occlusion 
of the left femoropopliteal bypass graft with 
a patent common femoral artery (Fig. 1). A 
no. 5 French infusion catheter was inserted 
through the same arterial puncture site by 
means of a guide wire and the catheter tip 
advanced approximately 3 cm into the occluded 
femoropopliteal vein graft under fluoroscopic 
control.
A continuous infusion of streptokinase at 
5000 units/h produced complete lysis of the 
clot in 43 hours with resumption of good flow 
(Fig. 1).
No lesion requiring surgical correction was 
demonstrated on the follow-up arteriograms. 
Coumadin was prescribed and at the time of 
discharge the ankle pressure was 92 mm Hg 
with a brachial pressure of 160/90 mm Hg.
The graft became occluded again after 15 
months and was treated successfully with strep­
tokinase infusion. The graft has remained 
patent for the past 14 months.
Case 2
A 62-year-old white man presented at a local 
hospital with rest pain of sudden onset in the
Fig- 2a Fig. 2b Fig. 2c
FIG. 2—(a) Angiogram of occluded distal superficial femoral artery and interposition vein graft, (b) Angiogram 33 hours after strep­
tokinase therapy shows completely declotted occluded segment but aneurysmal dilatation of distal superficial femoral artery, (c) Angiogram 
at end of operation showing reconstruction with polytetrafluoroethylene interposition graft.
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left leg. He was treated with heparin 
intravenously for 3 days before transfer to the 
Health Sciences Centre in Winnipeg.
The patient had undergone bilateral popliteal 
aneurysm resections and interposition grafting 
with reversed saphenous vein, 9 and 6 years 
earlier respectively. Aortoiliac bifurcation 
grafting had been performed 3 years before 
when an abdominal aortic aneurysm was 
resected. He had been a smoker for many years 
and had suffered myocardial infarction 2 
months before admission.
On examination the left leg was pale and 
cool with intact motor and sensory functions. 
There was 4+ femoral pulse but no palpable 
distal pulses. A left transfemoral arteriogram 
demonstrated both a distal superficial femoral 
artery and interposition vein-graft occlusion 
(Fig. 2a).
A no. 4 French intra-arterial infusion 
catheter was placed, under fluoroscopic con­
trol, proximal to the occlusion site and a con­
tinuous intra-arterial streptokinase infusion 
(5000 units/h) begun. The saphenous vein 
interposition graft was completely declotted 
after 33 hours of continuous infusion. In the 
follow-up post-infusion arteriogram there was 
a proximal aneurysm in the superficial femoral
artery and stenosis at the proximal anastomo­
sis (Fig. 2b). An interposition polytetra- 
fluoroethylene graft was placed to correct the 
lesion (Fig. 2c).
Postoperatively, the patient had good, pal­
pable, pedal pulses, and his ankle pressure was 
110 mm Hg with a brachial pressure of 129/79 
mm Hg.
Coumadin therapy was prescribed, and at 
follow-up 11 months later the graft was still 
patent.
Case 3
A 71-year-old white man experienced sud­
den onset of rest pain in his left leg. A left 
transfemoral angiogram (Fig. 3a) revealed 
proximal occlusion of the left popliteal artery. 
He was transferred to the Health Sciences 
Centre 3 weeks later.
His relevant medical history included chronic 
hypertension, renal insufficiency, cardiac 
arrhythmia and a myocardial infarction 
suffered 4 years earlier. Physical examination 
revealed a pale, cool, left leg with intact motor 
function and decreased sensation. There was 
a normal femoral pulse but no distal pulses.
A no. 4 French infusion catheter was inserted 
by the transfemoral route on the same side and 
its tip advanced under fluoroscopic control to 
the occlusion site. A continuous intra-arterial 
infusion of streptokinase (5000 units/h) opened 
the popliteal artery and distal vessel, all the way 
to ankle and foot, in 48 hours (Fig. 3b).
After the infusion, ankle pressure was 140 
mm Hg with a brachial pressure of 175/95 mm 
Hg. The patient was discharged on coumadin 
therapy and 33 months postoperatively the left 
limb vessels were patent.
Results
In six of seven patients (Table I) throm­
bolytic therapy was successful, the arter­
ies were patent and the limbs preserved. 
One patient (no. 7) required below-knee 
amputation owing to distal thrombosis, 
even though proximal lysis was obtained. 
In four patients streptokinase was discon­
tinued because of hematoma formation. 
Two large retroperitoneal hematomas 
arose from the angiography puncture site 
above the inguinal ligament and one 
patient died as a result.
Discussion
Streptokinase is a product of /3- 
hemolytic streptococci, group C, and 
produces clot lysis by activating the 
human fibrinolytic system.11 It combines 
with the inactive proenzyme plasminogen 
to form an activator complex that in turn 
enzymatically converts available plas­
minogen to plasmin, the active fibrino­
lytic enzyme.12 Streptokinase has two 
half-lives: the first is 18 minutes and 
represents clearance after binding with 
antistreptokinase antibodies, and the 
second is 83 minutes.
Operative intervention in late occlusion 
of vein grafts has often been unsatisfac­
tory because of difficult thrombectomy 
or the presence preoperatively of uniden­
tified lesions such as a valve cusp steno­
sis.13 Lysis of the clot is less traumatic 
than thrombectomy and a lesion  
precipitating the occlusion may be iden­
tified. In one patient with a vein graft 
there was no demonstrable cause for graft 
occlusion after lysis had been accom­
plished. In five patients with arterial 
occlusions, lysis of the clot permitted 
identification of lesions such as arterial 
stenosis and aneurysm as causes of acute 
arterial thrombosis that were treated suc­
cessfully by surgical reconstruction or bal­
loon dilatation. When arterial thrombo­
sis occurs with severe distal disease, lytic 
therapy may be preferable to surgery. 
However, infusion time required for com­
plete lysis may be up to 72 hours so if 
ischemia is severe, limb viability may 
preclude lytic therapy. If there is good 
motor function and only minor sensory 
deficit in the limb, lytic therapy may be 
initiated under close observation. It 
would appear safe to operate within 2
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Fig- 3a Fig. 3b
FIG. 3—(a) Angiogram of occluded left popliteal artery, (b) Patent popliteal artery after 
48 hours of intra-arterial streptokinase infusion therapy.
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hours of cessation of the streptokinase if 
lysis is unsuccessful or if ischemia 
progresses. There are a number of con­
traindications to streptokinase therapy. 
They are: surgery within the past 10 days 
(including invasive biopsy, thoracentesis 
and paracentesis); an intra-arterial diag­
nostic procedure within the past 10 days 
(excluding uncomplicated arterial blood- 
gas measurement employing a 22-gauge 
or smaller needle); active gastrointestinal 
bleeding and conditions in which there is 
a high potential for bleeding (e.g., ulcer­
ative colitis or diverticulitis); defective 
hemostasis (including coagulation-factor 
deficiency or thrombocytopenia); a recent 
(within 2 months) stroke or a condition 
involving potential central-nervous- 
system embolism (e.g., mitral-valve dis­
ease with atrial fibrillation or subacute 
bacterial endocarditis); recent trauma 
with possible internal injuries or external 
cardiac massage; intracranial neoplasms; 
severe hypertension (diastolic pressure 
more than 125 mm Hg); active and 
progressive cavitating lung disease; acute 
or chronic hepatic or renal insufficiency; 
ulcerative cutaneous or mucous- 
membrane lesions; a history of severe 
allergic reaction to the thrombolytic 
agent.10
Low-dose local infusion is associated 
with a low frequency of hemorrhagic 
complications. Nevertheless patients must 
be monitored in an intensive care unit and 
clotting parameters assessed, particularly 
thrombin, prothrombin and partial 
thromboplastin times. In spite of close
monitoring, hemorrhage occurred in five 
of our patients. Two were treated within 
6 days of surgery with resulting forma­
tion of wound hematomas that forced us 
to withdraw treatment. We do not recom­
mend use of this therapy earlier than 1 
month after major surgery. Two patients 
bled severely from their initial arterio­
graphy puncture site. For this reason we 
recommend that if one contemplates 
streptokinase therapy, the initial puncture 
site should be planned with the introduc­
tion of the infusion catheter in mind.
Systemic complications such as fever or 
anaphylaxis were not a problem in this 
group of patients.
We have observed the development of 
clot around the catheter, due to stasis in 
the arterial segment being infused and 
because of this the catheter must some­
times be repositioned. The tip of the infu­
sion catheter should be placed in the clot 
initially and may be advanced as lysis 
occurs to maintain a high dose at the site 
of the thrombus. Fragmentation of the 
clot with distal embolization has been 
observed and could account for worsen­
ing of the ischemia in one patient.
It should be emphasized that all 
patients who had successful clot lysis were 
placed on intravenous heparin therapy 4 
hours after cessation of the streptokinase 
infusion. Patients who do not have sur­
gically correctable lesions are placed on 
oral anticoagulation before discharge 
from hospital.
Streptokinase can be used with success 
for the lysis of clot in acute arterial occlu­
sion when surgery may be contraindicated 
because of systemic or local factors. 
Patients being treated should be closely 
monitored in an intensive care unit as life- 
threatening hemorrhage may occur even 
with local low-dose infusion of strep­
tokinase. Surgically correctable lesions 
may be demonstrated and appropriately 
treated after clot lysis.
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Microvascular Surgery as an Adjunctive Tool 
in Renal Transplantation
There has been a serious shortage of 
suitable kidneys for transplantation since 
this procedure became the treatment of 
choice for many patients with end-stage 
renal failure. Some harvested kidneys are 
discarded due to complicated or injured 
renal vasculature and some potential liv­
ing related donors are judged unsuitable 
because their kidneys have multiple ves­
sels. The authors review the basic 
microsurgical techniques they have used 
in such situations to salvage kidneys for 
transplantation. They emphasize the ex- 
vivo, "bench", microsurgical method for 
protecting the kidney from prolonged 
warm ischemia time (as with multiple 
complicated in-situ anastomoses).
Several illustrative case reports from 
their recent experience are presented. 
The authors conclude that microvascular 
surgery is an important adjunct to the 
armamentarium of the transplant 
surgeon.
Depuis que la greffe renale est devenue 
le traitement de premier choix de I'insuf- 
fisance renale terminale, on observe une 
serieuse penurie d'organes convenables 
pour la transplantation. Certains des 
reins recueillis doivent etre rejetes a 
cause de la complication du reseau vas- 
culaire renal ou d'une lesion de celui-ci. 
et certains donneurs potentiels apparen- 
tes sont juges inadequats parce que 
leurs reins poss&dent de multiples vais- 
seaux. Les auteurs passent en revue les
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techniques de microchirurgie qu'ils ont 
utilisees dans de telles circonstances afin 
de r6cuperer des reins pour la greffe. Ils 
soulignent I'utilite de la methode de 
microchirurgie ex-vivo sur "banc 
d'essai” pour proteger le rein d'une 
periode d'ischemie (comme il en survient 
dans les cas d'anastomoses in situ com- 
pliquees). Ils decrivent plusieurs cas tir6s 
de leur experience personnels recente 
pour illustrer le cas. Les auteurs con- 
cluent que la chirurgie microvasculaire 
est un complement important de I'arse- 
nal therapeutique du chirurgien specia- 
liste de la greffe.
Renal transplantation is now the treat­
ment of choice in the majority of patients 
with end-stage renal disease. Although 
approximately 60 people in every million 
annually in North America suffer renal 
failure and require definitive replacement 
therapy, the number of kidneys harvested 
annually is only about 23 per million peo­
ple. This means that only one-third of 
those requiring a cadaver kidney are likely 
to receive one. Within this group of har­
vested kidneys, about 10% are discarded 
for various reasons, some with multiple 
vessels. A number of living related donors 
are also considered unsuitable because of 
multiple vessels. In view of the economic 
advantage and improvement in health of 
the recipient, an attempt should be made 
to salvage kidneys with reparable vascu­
lar damage (incurred primarily during 
harvesting) and those with anatomic vas­
cular variations.1 With microsurgery, 
such organ salvage procedures can be 
safely and reliably performed.2-4 We 
review the surgical techniques applicable 
to various vascular arrangements and 
present illustrative examples from our 
recent experience.
Surgical Equipment
Standard microsurgical instruments
and monofilament nonabsorbable sutures 
(Ethilon, Prolene, Surgilene) of 7-0, 8-0, 
9-0 and 10-0, are used, depending on the 
diameter of the lumen and thickness of 
the vessel wall. An operating microscope 
providing 10 x magnification is used to 
anastomose finer vessels (2 mm diameter 
or less) and opthalmologic loupes yield­
ing 3.5 x magnification for larger ves­
sels. Ex-vivo, “ bench” , microvascular 
surgery is performed with the kidney 
cooled in a basin of iced saline.
Multiple Renal Arteries
Over 20% of patients have multiple 
renal arteries unilaterally and approxi­
mately 10% bilaterally. For cadaveric 
donors, a Carrel aortic patch containing 
the origins of all renal arteries and 
anastomosed end-to-side to the recipient 
external iliac artery is preferred. 
However, an aortic patch should not be 
taken from a living donor. Occasionally, 
the origins of the cadaver donor renal 
arteries are far apart and would necessi­
tate a large Carrel patch and a very long 
anastomosis; in such instances the arter­
ies are best taken separately from the 
donors and microvascular arterioplasty 
performed ex vivo before transplantation. 
Following are examples, with illustrative 
case reports, of the common vascular 
arrangements.
Arteries o f  Comparable Calibre
The preferred method for anastomos­
ing two arteries of approximately equal 
size is the side-to-side technique to cre­
ate a common opening and a single 
arterial anastomosis to the recipient. The 
side-to-side anastomosis is done with a 
double-armed 7-0 vascular suture running 
up both cut edges of the vessels (Fig. 1), 
with reinforcing sutures at the apex and 
near the end of the new single-vessel 
opening. This procedure is done in the
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cold basin, thus warm ischemic time is 
minimized with the single anastomosis 
required for revascularization. The com­
mon opening is also hemodynamically 
preferrable to two separate smaller 
openings.
Case 1.—A 38-year-old woman underwent 
nephrectomy donation for her 35-year-old 
brother who had rejected two cadaveric renal 
grafts. A renal arteriogram of the donor rev­
ealed double right renal arteries and a single 
left artery with early branching (0.5 cm) (Fig. 
2). To minimize the risk to the donor, the left 
arterial branches were ligated distal to the 
branching. The two vessels were then 
anastomosed ex vivo to create a single open­
ing before revascularization end to side to the 
recipient external iliac artery. The rewarm 
ischemic time (venous and arterial anastomo­
sis) was 30 minutes. Both donor and recipient 
did well. The recipient’s serum creatinine value 
2 months postoperatively was 100 /unol/L.
Arteries o f  Unequal Calibre
Although some surgeons5,6 maintain 
that small upper pole branches may be 
ligated, we believe that these small 
branches should be revascularized 
whenever possible to avoid potential seg­
mental renal infarction, urinary fistula, 
postoperative hypertension and graft rup­
ture. A lower pole branch should 
definitely be revascularized to protect the 
ureteral blood supply.
The preferred method is end-to-side 
implantation of the smaller polar artery, 
which is first spatulated into the main 
artery (Fig. 3). Interrupted 8-0, 9-0 or 
10-0 monofilament sutures are used, 
depending on the size of the polar branch. 
A small plastic cannula (e.g., 24-gauge 
Angiocath) passed through the opening 
of the main artery into the anastomotic 
site may prevent injury to the back wall 
of the side branch during anastomosis. 
The single renal artery is anastomosed as 
with a standard transplant.
Case 2.—A 62-year-old man received a cada­
veric kidney harvested at another hospital. The 
donor became hypotensive during the multior­
gan harvest (heart, kidneys and liver) and in 
the hurried dissection, the anatomy was not 
well appreciated. The left kidney had three 
arteries, two of comparable size and a third 
smaller mid-pole vessel (Fig. 4). The smaller 
artery was ligated and the two larger ones were 
divided separately. A branch of the upper pole 
artery was partially caught in a ligature. The 
ligature was released and the vessel was 
reanastomosed end-to-side to the upper pole 
artery with 10-0 sutures. The mid-pole vessel 
was trimmed and anastomosed likewise to the 
upper pole artery with interrupted 9-0 sutures 
(Fig. 4). The two arteries of comparable size 
were joined side-to-side, creating a single open­
ing. A single anastomosis, end-to-end, to the 
recipient hypogastric artery was performed. 
Anastomosis rewarm time was 28 minutes with 
excellent kidney perfusion. The patient did well 
and 3 months after transplantation had a serum 
creatinine level of 160 /tmol/L.
Alternative methods of dealing with 
multiple renal arteries include using the 
recipient inferior epigastric artery5 for a 
separate lower-pole arterial anastomosis 
and branches of the recipient’s hypogas­
tric artery for branch anastomoses.2,3 
This branched autogenous vascular graft 
method has been found useful by some 
surgeons.2,3 Atherosclerotic disease of 
the recipient artery would render the 
method less attractive, although endar­
terectomy has been advocated.4
In addition, several in-situ revascular­
ization techniques have been used for kid­
neys with multiple arteries.6 These 
include: multiple separate in-situ arterial 
anastomoses end-to-side to the external 
iliac artery; one branch end-to-side to the 
external iliac artery and one branch end- 
to-end to the hypogastric artery; and 
separate anastomoses to branches of the 
hypogastric artery. The main disadvan­
tage of these methods is that the rewarm 
ischemic time is prolonged. This is cru­
cial in cases in which cyclosporine is used 
as the immunosuppressive agent as it has 
been found that prolonged warm ischemic 
time (greater than 45 minutes) com­
pounds the nephrotoxic effect of 
cyclosporine.7 Multiple in-situ vascular 
anastomoses are also cumbersome and 
the likelihood of technical error is 
increased.
Multiple Renal Veins
Smaller venous branches can safely be 
ligated. However, double veins of equal 
size should be anastomosed as with two 
arteries of equal calibre to avoid venous 
outflow obstruction.
Case 3.—A 43-year-old woman received a 
cadaveric kidney with two equal-sized arteries 
widely spaced along the aorta and with two 
equal-sized veins. A common caval patch with 
the two veins was not used as it would have 
been too wide. A single ostium was created 
from the two arteries with 8-0 Prolene. The two 
veins were then anastomosed side-to-side in a 
similar fashion, using a double-armed 7-0 Sur- 
gilene suture. The warm ischemic reanastomo­
sis time with the resultant single artery and sin­
gle vein was 32 minutes. The nadir of serum 
creatinine was 190 gmol/L, but the recipient 
had multiple rejection episodes. His condition 
stabilized with a serum creatinine value of 270 
/unol/L 1 month postoperatively.
FIG. 1—Side-to-side anastomosis of two 
vessels of comparable calibre to create single 
ostium.
Fig. 2a
FIG. 2—(a) Renal arteriogram of live donor 
showing double right renal arteries (white 
arrows) and single left renal artery with very 
early branching (black arrow), (b) Schematic 
drawing of left donor nephrectomy. Two 
arterial branches were taken separately and 
reconstructed ex vivo.
FIG. 3—End-to-side anastomosis of two ves­
sels of unequal calibre.
FIG. 4—Schematic drawing of harvested left 
kidney and its microsurgical reconstruction.
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Vascular Injury During Harvesting
When an unsuspected polar vessel or 
a small, early branch is severed, the tech-
Fig. 5c
FIG. 5—(a) Repair of kidney with severed 
upper pole branch and area of “non-clearing” . 
Lower pole branch was damaged by ligature, 
(b) Arterial anastomoses before revasculariza­
tion. (c) Kidney in patient with patent 
anastomoses.
niques mentioned for dealing with mul­
tiple vessels are applicable. An additional 
problem may be loss of vessel length as 
a result of the injury.
Fig. 6c
FIG. 6—(a) Digital intravenous angiogram 
of transplanted kidney showing normal vas­
culature after microvascular reconstruction. 
Subtraction angiogram of same kidney show­
ing (b) arterial and (c) capillary phase.
Severed Side Branches Without 
Loss o f Length
Both ends of the severed vessels should 
be examined carefully and trimmed. They 
are reanastomosed using interrupted 9-0 
or 10-0 sutures, preferably with the aid 
of the operating microscope. Often an 
area of “ non-clearing” is evident on the 
renal surface where the initial flushing 
with preservation fluid does not reach the 
segment supplied by the severed branch. 
Efforts should be made to flush out the 
small branch either before or after 
microsurgical repair.
Severed Side Branch or Polar Vessel 
With Loss o f Length
If length of a vessel is lost or a portion 
damaged by ligatures and the side branch 
does not reach its original ostium, the 
small vessel can often be reimplanted end- 
to-side to the main renal artery at a site 
closer to the renal hilum.
The following case demonstrates situ­
ations in which side branches are severed 
with and without loss of vessel length.
Case 4.—A 55-year-old diabetic man 
received a cadaveric kidney from a 39-year-old 
donor, harvested elsewhere. At the time of har­
vesting, a lower-pole branch with early take­
off was severed. The distal end was damaged 
by a ligature. At the time of flushing, an area 
2 x 2 cm in the upper pole did not clear (Fig. 
5). On closer examination, a small upper pole 
branch obscured by perinephric fat had been 
sharply transected. There was no loss of ves­
sel length from this upper pole branch. The 
lower pole branch with some loss of length was 
reimplanted into the side wall of the main 
artery with 8-0 interrupted Ethilon sutures at 
a site closer to the renal hilium. The upper pole 
branch was reanastomosed end-to-end with 
interrupted 10-0 Ethilon sutures. The main 
renal artery was then flushed in the cold basin 
to ensure watertight anastomoses and to flush 
out the “ non-cleared” area in the upper pole. 
Surgical anastomosis rewarm ischemic time was 
38 minutes. The recipient had acute tubular 
necrosis, lasting 3 weeks, before the kidney 
started functioning but did well. His serum 
creatinine value 5 months after operation was 
150 /unol/L.
In cases in which loss of length from 
the severed vessel precludes direct anasto­
mosis to the main renal artery, interposi­
tion of a vascular graft (preferably 
autogenous) or use of the inferior epigas­
tric artery may be feasible.5
Clinical Outcome
We have used microsurgical angio­
plasty techniques to handle kidneys with 
multiple vessels. In the past 8 months, 11 
such repairs on transplant kidneys were 
performed. The average ex-vivo operat­
ing time was 45 minutes. Kidneys that 
required extensive microvascular recon­
struction were repaired ex vivo before the 
recipient was anesthetized. Repairs that
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were less complex (e.g., side-to-side 
anastomosis o f double arteries) were per­
formed just before vascular anastomosis 
o f the recipient vessels.
We did not routinely perform arteriog­
raphy to assess the microvascular repair, 
because o f the inherent risks. Radioactive 
nuclear scans of all transplanted kidneys 
have demonstrated prompt perfusion 
with no segmental filling defects. Digital 
intravenous angiography and standard 
arteriography on selected patients demon­
strated normal vasculature (Fig. 6). There 
was no case of hemorrhage, calyceal 
fistula formation or immediate postoper­
ative hypertension.
Discussion
Discarding a donor organ is a waste of 
precious material and discouraging to 
donor hospitals. Efforts to reduce this 
wastage must be pursued. In the past, 
organs may have been discarded because 
of multiple arteries or vascular injury. We 
believe the majority of kidneys can be sal­
vaged by applying the basic microsurgi- 
cal techniques outlined. Moreover, mul­
tiple renal vessels requiring multiple (and 
often cumbersome) in-situ anastomoses
can be modified structurally to facilitate 
the revascularization procedure. The ex- 
vivo microvascular techniques are not 
complex and do not require elaborate sur­
gical equipment. A combination of the 
basic anastomotic techniques is often 
required to deal with various vascular 
arrangements. This portion of the surgery 
can be performed ex vivo in the cold basin 
before the recipient is anesthetized, so 
that patient anesthetic time is not 
prolonged. More importantly, the vascu­
lar anastomoses to recipient vessels are 
much simpler. The warm ischemic time 
is shortened, compared with the time 
required for multiple in-situ anastomoses, 
which is of paramount importance in 
patients receiving a nephrotoxin like 
cyclosporine. The Canadian Multicentre 
Transplant Study Group7 observed that 
the cyclosporine nephrotoxicity effect is 
exacerbated by a warm ischemic time 
exceeding 45 minutes.
In summary, we have outlined the var­
ious clinical situations in which microsur- 
gical repair can be used to salvage some 
kidneys for transplantation and to facili­
tate revascularization in other kidneys. 
We conclude that microvascular surgery 
is an important adjunct to the armamen­
tarium of the transplant surgeon.
We thank Ms. N. Somerville, Division of 
Nephrology, University Hospital, for her 
expert, artistic illustrations.
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Les complications du traitement du cancer 
du col uterin par radiotherapie
Le traitement du cancer du col ut6rin par 
radiotherapie a conduit 6 des complica­
tions soit digestives, urologiques ou 
gynecologiques chez 275 des 939 
malades (29 .3% ) traitees a I'hopital 
Notre-Dame de Montreal, de 1979 a 
1981.
Dans 55 cas (5 .9 % ), il a fallu recourir 
a un traitement chirugical pour pallier a 
73 complications: 42 complications 
digestives sous forme d'occlusions (25), 
de fistules (13) et de perforations (4); 22 
complications urologiques sous forme 
d'occlusions (16), de fistules (5) et 
d'hemorragie (1); 6 complications 
gynecologiques, sous forme d'hemor- 
rhagie (3) ou de necrose uterine (3); 1 
necrose cutanee, 1 vasculaire et 1 
osseuse.
Les auteurs n'ont pas trouve de corre­
lation directe entre I'incidence des com­
plications et certains facteurs favorisants 
tel que le type de radiotherapie adminis­
tree, I'age des malades trait6s, le stade 
de la neoplasie et la presence de chirur- 
gie gynecologique anterieure au traite­
ment radiotherapeutique. Par contre, la 
relation entre I'incidence des complica­
tions et la dose de rayons administree et 
la presence de chirurgie gynecologique 
posterieure au traitement radiotherapeu­
tique est hautement significative.
Dans le groupe des complications trai­
tees par la chirurgie, la morbidity a ete 
elevee: les 55 malades ont du subir en 
moyenne 2.36 interventions, 2.98 
anesthesies generates, 1.81 hospitalisa­
tions d'une duree moyenne de 75.7 jours 
et 21 patientes sont devenues porteuses
Du *departement de gyn^cologie- obstetrique, tdepartement de dhirurgie, %d£partement des communications et §departement de radiotherapie, Hopital Notre-Dame, University de Montreal, Mon­treal, PQ
Accepte pour publication le SO juillet, 1985
Adresse pour tirds-a-part: Dr J. Corman, Departement de chirurgie, Hopital Notre- Dame, CP 1560, Station C, Montreal, PQ H2L 4K8
d'une ou plusieurs stomies definitives. La 
mortalite a et6 de 5 .45% .
Le traitement chirurgical a et6 individu­
alise pour chaque cas. Les complications 
digestives et urologiques ont ete traitees 
par une derivation lorsqu'une resection 
aurait ete trop extensive ou dangereuse. 
Des resections limitees ont ete utilisees 
pour traiter aussi bien les occlusions et 
les fistules que les perforations chaque 
fois que cela etait possible. La majorite 
des lesions du rectum ont ete traitees 
par operation de Hartmann et 
colostomie.
Of 939 patients treated by radiotherapy 
for carcinoma of the cervix at the hopital 
Notre-Dame in Montreal, between 1979 
and 1981, 275 (2 9 .3% ) had digestive, 
urologic, gynecologic, vascular, osseous 
and cutaneous complications. Surgery 
was necessary to treat 73 complications 
in 55 patients (5 .9 % ): 42 digestive (25 
occlusions, 13 fistulas and 4 perfora­
tions); 22 urologic (16 occlusions, 5 
fistulas, 1 hemorrhage); 6 gynecologic (3 
hemorrhage and 3 uterine necrosis); 1 
cutaneous, 1 vascular and 1 osseous 
necrosis.
No direct correlation was found 
between the incidence of the complica­
tions and certain predisposing factors 
such as the type of radiotherapy, 
patients' age, stage of the disease and 
gynecologic surgery before radiotherapy. 
However, there was a strong correlation 
between the incidence of complications 
and the dose of radiotherapy and the 
need for gynecologic surgery after radi­
otherapy.
High morbidity was observed in the 55 
patients treated surgically: they had to 
undergo a mean of 2.36 operations 
each, 2.98 general anesthetics, 1.81 
hospitalizations (mean duration 75.7 
days); 21 had one or more definitive 
stomas. The death rate was 5.45% .
Surgical treatment was individualized. 
Limited resections were performed for
occlusions, fistulas and perforations 
whenever it was technically feasible to 
treat digestive and urologic complica­
tions.
A bypass procedure was used when 
resection would have been too extensive 
or dangerous. The majority of rectal 
lesions were treated by colostomy and a 
Hartmann procedure.
La radiotherapie est un mode therapeu- 
tique accepte dans le traitement du can­
cer invasif du col uterin. La survie glo- 
bale a 5 ans qui etait d’environ 35% dans 
les annees 40, est actuellement de 65% .! 
Dans notre centre, une etude recente a 
montre que la survie a 5 ans a atteint 
78.6% et celle a 10 ans, 74.3% pour les 
neoplasies du col au stade lb (FIGO) trai­
tees par cette modalite.2
Cette therapeutique est cependant gre- 
vee de complications dont l’eventail est 
tres large.3-18 Dans la majorite des cas, 
un traitement medical suffit a enrayer les 
complications d’ileite, de rectite et de 
cystite mais chez un nombre non negli- 
geable de malades, la gravite des compli­
cations impose une approche chirur- 
gicale.6,17,18-32
La presente etude porte la nature et 
l’etendue du traitement des complications 
post-radiotherapie en fonction de la dose 
administree, du type de radiotherapie 
re?ue, de I’age des malades traitees, du 
stade de la neoplasie, de la duree des exa- 
mens de surveillance et de la presence ou 
de l’absence de chirurgie anterieure ou 
posterieure a l’irradiation. On s’est atta­
che plus particulierement a etudier la mor­
bidity et la mortalite ainsi que le resultat 
du traitement des complications post- 
radiotherapie ayant necessity une correc­
tion chirurgicale.
Materiel et methodes
Dejanvier 1969 a decembre 1981, 1086 
malades porteuses d’un cancer invasif du 
col uterin ont ete traitees par radiothera- 
pie a I’hopital Notre-Dame.
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Les dossiers medicaux de ces patientes 
ont ete etudies. Cent quarante-sept n ’ont 
pas ete retenus pour les raisons suivan- 
tes: abandon premature du traitement, 
absence d’examens de post-cure ou radio­
therapie a titre palliatif pour une mala- 
die a un stade trop avance. Ce qui porte 
le nombre total de dossiers utilises a 939.
La periode de surveillance varie d’un 
a 14 ans. Cinq cent cinq malades ont ete 
suivies d ’un a 5 ans, 294 de 5 a 10 ans et 
140 pendant plus de 10 ans apres leur trai­
tement.
Les techniques d ’irradiation ont varie 
suivant le stade clinique de la maladie. 
Cependant, les doses a la tumeur se situe- 
rent entre 5000 rad en 5 semaines et 7500 
rad en 7 semaines, avec des extremes de 
3600 a 13 200 rad. Ainsi, 9.9% des mala­
des ont re?u moins de 5000 rad, 39.5% 
ont re?u entre 5000 et 8000 rad, 41.3% 
entre 8000 et 10 000 rad et 9.3% 10 000 
rad et plus (tableau I).
En general, le traitement consista dans 
l’irradiation du bassin, des trous obtura- 
teurs aux cretes iliaques, par un champ 
de 225 cm2 suivie d’une surdose a la 
tumeur de 2000 rad par irradiations endo- 
cavitaires (sonde endo-uterine plus col- 
postat ou moulage vaginal radifere) (727 
cas). Cependant, 166 patientes n ’eurent 
qu’une irradiation externe et 46 malades 
eurent une irradiation endocavitaire 
isolee.
Tous les plans de traitement furent faits 
avec des courbes d’isodose calculees au 
moyen d’un ordinateur.
Repartition des stades cliniques
Trois cent quarante-trois malades 
furent traitees pour cancer au stade I 
(36.5%), 290 pour un stade II (30.9%), 
187 pour un stade III (19.9%) et 42 pour 
un stade IV (4.5%). Enfin, 77 patientes 
(8.2%) n’ont pu etre classifies, le dia­
gnostic de cancer du col ayant ete effec- 
tue chez elles sur un echantillon anatomo- 
pathologique apres hysterectomie pour 
raisons diverses.
Distribution de 1’age
La moyenne d’age des patientes traitees 
fut de 54.8 ans avec un ecart de 18 a 85 
ans. Au moment du traitement, 26.6% 
des malades avaient moins de 45 ans, 
36.9% avaient entre 45 et 60 ans et 36.5% 
avaient 60 ans et plus.
Classification des complications 
post-radiotherapie
Nous avons classifie les complications 
survenues apres la radiotherapie suivant 
une modification du systeme de classifi­
cation propose par Kagan et collabora- 
teurs33 (M = reactions aigues aux radia­
tions ou complications chroniques 
requerant un traitement medical; CH =
complications requerant un traitement 
chirurgical): la classe 0 a MI represente 
I’absence ou la presence de reactions 
aigues temporaires reversibles survenant 
pendant le traitement de radiotherapie et 
se resolvant dans les semaines qui suivent 
l’arret de celui-ci. Elies se presentent sous 
forme de douleurs abdominales, diar- 
rhees, cystites, rectites et dyspareunies.
La classe M il represente les complica­
tions tardives survenant de quelques mois 
a plusieurs annees apres la radiotherapie 
et evoluant de fagon chronique sous 
forme de subocclusion, diarrhees, cys­
tites, rectites, episodes d ’hemorragie 
digestive basses et fistules mineures 
repondant en general de fagon satis- 
faisante a un traitement medical.
La classe CH represente les memes 
complications que la classe precedente 
mais s’exacerbant ou se compliquant et 
necessitant une approche chirurgicale 
pour leur traitement.
Traitement chirurgical anterieur 
ou posterieur a la radiotherapie
Cent quatre-vingt-deux malades 
avaient subi des interventions chirur- 
gicales gynecologiques majeures soit 
anterieurement (134), posterieurement 
(44) ou encore anterieurem ent et 
posterieurement (4) a la radiotherapie.
Chez les patientes operees avant la radi­
otherapie, on denombre 26 hysterecto­
mies subtotales, 83 hysterectomies totales 
et 25 hysterectomies radicales.
Apres le traitement radiotherapeutique, 
11 malades ont subi une hysterectomie 
totale, 20 une hysterectomie radicale et 13 
patientes ont subi une exenteration pel- 
vienne soit pour completer le traitement 
radiotherapeutique, soit pour traiter les 
recidives.
Enfin, quatre malades ont subi une 
hysterectomie anterieurement a la radi­
otherapie et celle-ci fut suivie d’une exen­
teration pelvienne.
De plus, 31 patientes ont eu des inter­
ventions chirurgicales mineures long- 
temps avant le traitement de la neoplasie 
uterine telles que cure de hernie inguinale, 
appendicectomie, ovariectomie, et resec­
tion de diverticule de Meckel. Ce dernier 
groupe ne fait pas l’objet d’une etude 
statistique particuliere dans les relations 
entre le traitement chirurgicale anterieur 
ou posterieur a la radiotherapie et les 
complications.
Analyse statistique
La statistique du x2 a ete utilisee pour 
verifier l’independance de certaines vari­
ables.
Les resultats ont par ailleurs fait l’ob- 
jet d ’une analyse de regression multiple, 
l’objectif de cette methode statistique 
etant de predire l’apparition de l’une ou 
P autre complication (variable — cible) a
partir de plusieurs facteurs (variable — 
predictrice) consideres simultanement.
Resultats
Incidence, morbidity, mortality et 
traitement des complications
Classe 0-M I.—Dans cette categorie de 
complications, on denombre 664 malades 
(70.7%) (tableau II). Elles ont ete traitees 
avec succes par des moyens conservateurs: 
mesures hygieniques et dietetiques telles 
que regime pauvre en residus, analge- 
siques, antispasmodiques, emollients, 
lavements aux steroides et repos.
La morbidite a ete negligeable et la 
mortalite a ete nulle.
Classe M IL—On y compte 220 malades 
(23.4%) (tableau II). Ces complications 
evoluant de fagon chronique ont en 
general repondu de fagon satisfaisante au 
traitement medical tel que decrit dans la 
classe 0-MI mais dans un certain nombre 
de cas, elles ont evolue vers la classe 
suivante (CH).
Dans cette classe, le taux de rehospitali­
sation pour traitement ou investigation a 
ete de 14% et la mortalite a ete nulle.
Classe CH.—Chez 55 malades (5.9%), 
il a fallu recourir a un traitement chirur­
gical pour pallier a 73 complications post- 
radiotherapeutiques (tableau II).
Le delai d’apparition des complications 
a varie d ’un mois a 13 ans (moyenne: 2 
ans et 8 mois).
On releve 42 complications digestives 
dont 25 occlusions de l’intestin grele ou 
du colon, 13 fistules entero-vaginales ou 
entero-cutanees et 4 perforations intes- 
tinales.
On compte 22 complications urolo- 
giques sous forme d’occlusions ureterales,
Tableau 1-Dose d'irradiation a la tumeur
chez 939 patientes
Dose, rad x 103 No.(%) de patientes
<  5 93 (9.9)
5 - 6 64 (6.8)
6 - 7 124(13.2)
7 - 8 183(19.5)
8 - 9 244 (26.0)
9 - 1 0 144(15.3)
1 0 - 1 1 56 (6.0)
>  11 31 (3.3)
Tableau II—Incidence des complications 
Classe No. (%) de patientes
(L M I 664 (70.7)
Mil 220123.4)
CH__________________________ 55 (5.9)
0 -M I -  reaction secondaire a la radiotherapie 
aigue et reversible, Mil -  complication tardive 
et chronique necessitant un traitement medical 
soutenu, CH -  complication necessitant un 
traitement chirurgical.
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de fistules urinaires hautes ou basses et 
d’hemorragie.
Enfin, il y eut six complications 
gynecologiques dont trois hemorragies 
intarissables et trois necroses massives de 
l’uterus, une complication cutanee sous 
forme de necrose etendue de la region 
sacree, une complication vasculaire sous 
forme de fibrose retro-peritoneale ayant 
entraine un syndrome de Leriche, et une 
complication osseuse sous la forme de 
fracture pathologique des deux cols du 
femur.
Les occlusions digestives ont ete trai­
tees par 6 viscerolyses, 4 derivations ileo- 
coliques, 7 resections sementaires du 
grele, 16 resections coliques segmentaires 
ou hemicolectomies et 1 amputation du 
rectum. Elies ont conduit a six colosto­
mies definitives et six colostomies tem- 
poraires.
Les fistules digestives ont necessite trois 
operations de Hartmann, cinq resections 
coliques et deux resections segmentaires 
du grele. Neuf malades dans ce groupe 
ont eu des colostomies definitives et deux, 
des colostomies temporaires.
Les perforations digestives ont ete trai­
tees par operation de Hartmann chez 
deux malades, une resection du grele chez 
une autre et une caecostomie chez la 
quatrieme. Deux stomies ont ete defini­
tives et une temporaire.
Vingt-deux complications urologiques 
sont survenues chez 15 malades; soit 16 
stenoses ureterales, 2 fistules uretero- 
vaginales, 2 fistules vesico-vaginales, 1 
fistule uretero-cutanee et 1 cystite hemor- 
ragique. Elies ont conduit a 10 uretero- 
cysto-neostomies, 6 trans-uretero-uretero- 
stomies, 2 ureterolyses, 2 ileo-uretero- 
stomies, 1 cystectomie complete. 1
nephrectomie, 1 uretero-sigmoidostomie 
et 1 hemostase vesicate, avec 5 conduits 
ileaux definitifs.
Quant aux complications gynecolo­
giques, elles ont necessite trois ligatures 
des deux arteres hypogastriques, deux 
hysterectomies elargies et une exentera­
tion anterieure avec une stomie definitive.
La complication de necrose cutanee a 
ete traitee par un lambeau de rotation, 
debridement et nouvelle greffe cutanee. 
La complication vasculaire a ete traitee 
par un pontage axillo-femoral droit et 
femoro-femoral. Enfin, une des deux 
fractures pathologiques du col du femur 
a ete traitee par prothese de Moore.
Le traitement de ces complications a 
necessite un total de 130 interventions 
chirurgicales avec pour chaque malade 
une moyenne de 1.81 ±0.75 hospitalisa­
tions (ecart de 1 a 6) d’une duree de 
75.7 ± 48.6 jours (9 a 219) et une moyenne 
2.98 ± 1.9 anesthesies generates (1 a 10).
La morbidite postoperatoire a ete 
importante avec 15 episodes de septi- 
cemie, 5 fistules digestives, 4 eventrations,
5 necroses de colostomie, 13 infections de 
plaie, 6 ileus paralytiques, 2 pneumonies, 
3 insuffisances renales graves dont une 
seule a ete reversible, 3 thrombo-phlebites 
profondes, 1 embolie pulmonaire, 1 
infarctus du myocarde, 2 pathologies psy- 
chiatriques et 1 atteinte du nerf VIII par 
toxicite a la gentamicine. Sur les 55 
malades traitees, 21 sont devenues por- 
teuses d’une ou plusieurs stomies externes 
definitives.
Trois patientes sont decedees dans la 
periode postoperatoire immediate.
Relation entre la dose d ’irradiation 
et les complications
II existe une relation tres significative 
entre la dose de rayons administree, le 
nombre et la gravite des complications 
post-radiotherapie (x2 = 112, 6, dl = 
14, p < 0.0001). Comme en temoigne la 
figure 1, des 93 malades ayant regu moins 
de 5000 rad, aucune n’est classifiee Mil, 
et une seule (1.1%) est classifiee CH, 
tandis que des 31 patientes ayant regu 11 
000 rad ou plus, 67.7% sont classifies 
Mil et 12.9% CH.
Relation entre le type de radiotherapie 
administree et les complications
Bien que le taux de complications Mil 
et CH soit plus eleve lorsque des tech­
niques d’irradiations combinees ont ete 
utilisees, la relation n’est pas statistique- 
ment significative (p = 0.1191) (fig. 2).
Cependant, l’analyse statistique fait 
ressortir que ce sont les patientes qui ont 
ete traitees par radiotherapie externe et 
interne combinees qui ont regu le plus 
d’irradiation (x2 = 178.3, dl = 6, p < 
0.0001) (fig. 3).
-de 5 5-6 6-7 7-8 8-9 9-10 10-11 11 +
(93) (64) (124) (183) (244) (144) (56) (31)
Dose refue,milliers de rad
FIG. 1_Distribution des types de complications (classes Mil = colonnes hachurees, CH
colonnes pointillees) en fonction de la dose d’irradiation.
100,
%
-  de 5000 8000 a  
10 000
10 000 
• t  p lu s
Dose re^ue, rod
FIG. 2_Relation entre la dose recue et le type d’irradiation utilise (combinee = colonnes
intillees, externe = colonnes hachurees, interne = colonnes lignees).
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Relation entre I'age des malades traitees 
et les complications
On ne trouve pas de relation statistique- 
ment significative entre l’age auquel les 
malades ont regu de la radiotherapie et 
les complications post-radiotherapie (fig. 
4). Tout au plus, decele-t-on une tendance 
a une dimunition du taux de complica­
tions M il et CH avec la progression de 
l’age des groupes traites.
Relation entre le stade de la neoplasie 
traitee et les complications
On note que plus les stades sont 
precoces, plus leur traitement se solde par 
des complications de type Mil et CH 
(tableau III). Cependant, la relation n’est 
pas statistiquement significative (p = 
0.17).
lement en fonction d ’autres facteurs tels 
que la susceptibilite individuelle, la radio- 
sensibilite specifique des organes touches, 
le type de radiotherapie administree, l’age 
des malades traitees, le stade de leur neo- 
plasie, la presence de chirurgie au niveau 
de la sphere irradiee anterieurement ou 
posterieurement a la radiotherapie, l’obe- 
site, la diabete et les maladies inflamma- 
toires du petit bassin.35
Des doses optimales ne depassant pas 
5000 rad sont recommandees afin d ’evi- 
ter les complications.3 ' 13->9.27,28,36 ^  c e s  
niveaux, le risque de lesion des visceres 
se situe entre l°7o et 5%, mais il atteint 
progressivement des taux de 25% a 50% 
lorsque la dose de rayons utilisee depasse 
ce plafond optimal.34
Notre serie confirme cet etat de chose. 
Elle demontre que la relation entre la dose
d’irradiation et le taux de complications 
est hautement significative (p < 0.0001). 
Au total, sur les 939 malades, les 220 
(23.4%) qui ont souffert de complications 
de type M il, avaient toutes regu plus de 
5000 rad et 55 (5.9%) ont presente des 
problemes de type CH (tableau II). Aux 
extremes, sur les 93 patientes ayant ete 
traitees avec moins de 5000 rad, aucune 
n’a ete classee M il et une seule (1.1%) a 
ete classee CH, alors que dans le groupe 
des 31 malades traitees avec 11 000 rad 
et plus, 21 (67.7%) ont souffert de com­
plications Mil et 4 (12.9%) ont du avoir 
recours a une solution chirurgicale (CH) 
(fig- 1).
Le delai d’apparition des complications 
peut etre extremement long. Dans notre 
etude, il a ete limite a 14 ans par la duree 
de la surveillance post-therapeutique,
Relation entre la duree des examens 
de surveillance et le type de complications
Comme le demontre le tableau IV, les 
complications de type M il sont passees 
de 18.4% apres 1 a 2 ans de surveillance 
post-therapeutique pour se stabiliser aux 
alentours de 25% par la suite.
Les complications necessitant une solu­
tion chirurgicale sont passees de 2.2% a 
10.5% entre la 2e et la 5e annee de sur­
veillance pour se stabiliser ensuite aux 
environs de 5%.
Relation entre la presence ou I’absence 
de chirurgie anterieure ou posterieure 
a I’irradiation et Vapparition 
des complications
Le taux de complications n’est pas 
greve par la chirurgie gynecologique subie 
avant la radiotherapie, quelqu’en soit le 
type (tableau V).
Le nombre de patientes ayant subi une 
intervention en periode pre- et post- 
radiotherapie est trop limite (4) pour pou- 
voir avoir une signification statistique.
Par ailleurs, le taux de complications 
CH est significativement plus eleve 
(p < 0.001) chez les patientes operees 
apres le traitement de radiotherapie 
(tableau VI). Ce sont en particulier les 
malades qui ont subi des hysterectomies 
radicales et des exenterations pelviennes 
qui sont les plus fragiles.
Discussion
Les techniques modernes de radiothe­
rapie permettent une orientation et une 
concentration optimale de la dose cyto- 
toxique vers et sur la lesion neoplasique 
visee. Malgre tout, les visceres sains avoi- 
sinants sont la plupart du temps atteints 
a des degres divers par les rayons 
utilises34 et le degre de gravite de cette 
atteinte est dose-dependant et varie ega-
100
%
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0
FIG. 3—Distribution des complications selon le type d’irradiation regue (Mil = colonnes 
hachurees, CH = colonnes pointillees).
Combinee Externe Interne
n * 72 7  n *  166 n “ 46
moins de 4 5 a 6 0 a n s  6 0  ans et
45  ans p lus
FIG. 4—Distribution des types de complications en fonction de I’age (Mil = colonnes hachu­
rees, CH = colonnes pointillees).
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mais il peut atteindre 20 ans et 
plus.18,34' 37 De plus, l’incidence des com­
plications reste stable dans le temps (plus 
ou moins 25% pour la classe M il et plus 
ou moins 5% pour la classe CH).
Ceci attire une fois de plus l’attention 
sur l’importance des antecedents radio- 
therapeutiques pour Revaluation d’un 
malade presentant un probleme abdomi­
nal quel que soit le delai ecoule depuis 
1’irradiation.
C ontrairem ent a d ’autres e tu ­
des,1w s , 2?,35,38,39 nous n ’avons pas trouve 
de correlation directe entre l’incidence des 
complications Mil et CH et certains fac- 
teurs favorisants etudies tels que le type 
de radiotherapie administree, l’age des 
malades traitees et le stade de la neopla- 
sie. Le seul denom inates commun sta- 
tistiquement significatif reste la dose de 
rayons administree. L’analyse de regres­
sion multiple confirme cet etat de chose: 
l’etude des variables telles que la dose 
d’irradiation, l’age, le type de radiothe­
rapie administree, le stade de la neopla- 
sie et la presence ou l’absence de chirur- 
gie anterieure ou posterieure a 
l’irradiation revele que seule la dose 
d’irradiation est significative (r -  multi­
ple = 0.326, F = 99.8, p <  0.0001).
Ainsi, ce sont les malades qui ont subi un 
traitement de radiotherapie combine 
(interne et externe) qui ont regu le plus de 
rayons (figs. 2 et 3); les malades jeunes 
ont un taux plus eleve de complications 
mais ce sont elles qui ont ete traitees le 
plus agressivement; ainsi, 64.4% des 
patientes de moins de 45 ans ont regu plus 
de 8000 rad contre 58.3% pour les patien­
tes agees de 45 a 60 ans et 49.7% pour 
les malades agees de plus de 60 ans (p < 
0.0008).
Enfin, la relation entre le taux de com­
plications et les stades traites est egale- 
ment essentiellement dose-dependante. 
Les stades precoces ont en general ete trai­
tes plus vigoureusement que les stades III 
et IV ce qui explique leur taux de com­
plications legerement plus eleve (tableau 
III).
Par ailleurs, bien que 31.3% de nos 
malades ayant subi une intervention gyne- 
cologique anterieure a la radiotherapie 
aient presente des complications de type 
M il et CH, la relation avec le groupe 
n’ayant jamais subi de chirurgie n ’est pas 
significative (tableau V), contrairement 
aux resultats d ’autres publications.6-35-37 
La relation est par ailleurs hautement
cerne les complications de type CH lors- 
que l’on compare le groupe ayant neces­
sity un traitement chirurgical additionnel 
a la radiotherapie pour le traitement de 
leur cancer par rapport au groupe exempt 
de chirurgie (tableau VI). Ce sont en par- 
ticulier les malades qui ont subi des hyste­
rectomies radicales et des exenterations 
pelviennes qui paient le plus lourd tribut. 
(Notre etude comporte cependant un biais 
puisque pour des raisons techniques, nous 
n ’avons pu introduire les 31 malades 
ayant subi des interventions abdominales 
mineures avant le traitement de leur can­
cer du col.)
Les reactions secondaires aux radia­
tions de type 0-MI sont aigues. Elies sont 
le lot de la majorite des malades traitees 
par radiotherapie pour cancer du col. 
Elies sont heureusement benignes et ne 
durent que le temps du traitement radio- 
therapeutique. La morbidite est negligea- 
ble et un traitement conservateur minimal 
suffit a la juguler. Elle est le resultat d ’une 
atteinte des cellules muqueuses radiosen- 
sibles du tractus gastro-intestinal et n ’a 
pas de relation avec les complications tar- 
dives.34
Les complications de type M il sont 
plus insidieuses et ont d’emblee un carac- 
tere de chronicite. Le plus souvent, elles 
apparaissent dans un delai de 6 mois a 2 
ans apres le traitement. Dans notre etude, 
leur frequence se stabilise aux alentours 
de 25% apres ce delai. Elles correspon­
dent a une vasculite obliterative, une atro- 
phie muqueuse et une fibrose de la paroi 
intestinale.34
La morbidite de ces complications 
requiert de frequentes hospitalisations 
pour investigation ou traitement. Un trai­
tement conservateur ne reussit pas tou- 
jours a stabiliser le processus. La resis­
tance au traitem ent m edical avec 
rectorragies severes, tenesme et douleurs 
rebelles, occlusions digestives et fistules, 
et deterioration de l’etat general conduit 
une certaine porportion de ces malades 
vers la classe CH. Cette evolution peut 
survenir n’importe quand et elle est 
imprevisible meme lorsque le delai ecoule 
depuis le traitement radiotherapeutique 
est de plusieurs annees. La symptoma- 
tologie peut faire penser a une recidive de 
la neoplasie. Elle impose des examens pel- 
viens sous anesthesie generate, de multi­
ples biopsies, des rectosigmoidoscopies, 
des pyelographies endoveineuses et des 
cystoscopies.
Comme on peut s’y attendre, en raison 
de leur relation etroite avec la sphere geni- 
tale et de leur radiosensibilite, ce sont 
l’ileon, le colon sigmoidien et le rectum 
qui sont les localisations des complica­
tions post-radiotherapeutiques les plus 
frequentes et ce sont ces lesions qui neces- 
sitent le plus souvent une correction chi- 
rurgicale. Les complications urologiques 
prennent la seconde place, suivies des 
complications gynecologiques. Les attein-
significative (p < 0.001) en ce qui con-
Tableau Ill-Distribution (%) des types de complications Mil et CH en 
fonction des stades traites
Stade 1 Stade II Stade III Stade IV
Classe (n -  343) (n = 290) (n = 187) (n = 42)
Mil 25.7 23.1 21.9 21.4
CH 5.8 7.6 3.7 2.4
77 classifications sont manquantes.
Tableau IV—Distribution (%) des types de complications Mil et CH en
fonction de la duree de la surveillance post-therapeutique
Duree, ans
Classe 1 - 2 2 - 5 5 - 1 0 >  10
Mil 18.4 26.1 25.9 23.6
CH 2.2 10.5 6.1 4.3
Tableau V—Distribution (%) des types de complications Mil et CH 
fonction de la chirurgie pre- et post-radiotherapie
en
Absence de Chirurgie Chirurgie
chirurgie pre-radiotherapie post-radiotherapie
Classe (n = 757) (n -  134) (n = 44)
Mil 23.5 26.1 15.9
CH 5.3 5.2 15.9*
*p <  0 .001 .
Tableau VI—Distribution (%) des types de complications Mil et CH en fonction de 
la chirurgie post-radiotherapie
Chirurgie post-radiotherapie
Absence de Hysterectomie Hysterectomie Exenteration
chirurgie totale radicale pelvienne
Classe (n = 757) (n -  11) In = 20) (n -  13)
Mil 23.5 18.2 0.0 38.4
CH 5.3 0.0 20.0* 23.2*
*P < 0.001.
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tes des gros vaisseaux et des structures 
osseuses et cutanees sont plus rares.
La majorite des lesions digestives et 
urologiques se manifestent par des suboc­
clusions ou des occlusions des visceres. 
Un nombre non negligeable de celles-ci 
evoluent cependant vers la fistulisation. 
Les complications gynecologiques sont 
essentiellement d’ordre hemorragique et 
necrotique.
Les modalites du traitement chirurgi- 
cal des complications digestives sont 
l’objet d ’une controverse dans la littera- 
ture. Les interventions de derivation ont 
pour avantage de limiter les dissections 
extensives ce qui evite de compromettre 
la vascularisation deja deficiente des anses 
intestinales touchees par la radiothe­
rapie.7’25’26'37 Se basant sur le fait que les 
derivations n ’empechent pas la progres­
sion de la radio-enterite et que, par con­
sequent, elles ne mettent pas la malade a 
l ’abri de complications futures, d’autres 
auteurs preconisent des interventions de 
resection.12’20 Enfin, certains croient que 
chaque cas devrait etre indivi­
dualise.17,24’29’32
Dans notre serie, les derivations ont ete 
utilisees essentiellement chez les malades 
pour qui une resection aurait ete exten­
sive et dangereuse. Chaque fois que cela 
a ete possible, une resection limitee a ete 
pratiquee pour traiter aussi bien les occlu­
sions et les fistules que les perforations.
Les lesions du rectum ont ete traitees 
majoritairement par colostomie de deri­
vation avec operation de Hartmann. Les 
fistules entero-vaginales ont ete traitees 
soit par resection soit par diversion tem- 
poraire avec interposition d’epiploon sur 
le foyer de la fistule.
Sur le plan urologique, on a tente d’uti- 
liser, chaque fois que cela etait possible, 
l’arbre urinaire inferieur; ainsi, 10 des 16 
stenoses ureterales ont pu etre corrigees 
par uretero-neo-cystostomie. Dans la 
majorite des autres cas, il a fallu recou- 
rir a des derivations conduisant chez un 
tiers des patientes a des conduits ileaux.
Bien que la mortalite postoperatoire 
(5.45%) soit relativement acceptable dans 
les circonstances, la morbidite a ete ele- 
vee et ce en raison non seulement de la 
precarite des tissus operes mais egalement 
de la malnutrition et des deficiences 
immunitaires dont sont atteintes la majo­
rite de ces patientes. Plusieurs d’entre- 
elles ont du subir des interventions itera- 
tives et la duree moyenne des hospitali­
sations a ete tres elevee (75.7 jours).
Enfin, 38% des 55 malades traitees sont 
porteuses d ’une ou plusieurs stomies 
externes definitives.
Conclusions
Le traitement du cancer du col par 
radiotherapie a cause par ordre de fre­
quence des complications enteriques, uro­
logiques, gynecologiques, vasculaires,
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cutanees et osseuses chez 29.3% des 939 
malades qui ont ete traitees dans notre 
institution sur une periode de 13 ans. La 
frequence des complications a ete direc- 
tement proportionnelle a la dose de 
rayons administree et la relation avec 
d’autres facteurs favorisants n’a ete 
qu’indirecte.
Dans 5.9% des cas, les complications 
ont necessity un traitement chirurgical. La 
resection du segment malade a ete [’inter­
vention de choix dans les complications 
digestives et urologiques et les derivations 
ont ete reservees aux cas ou la resection 
n’etait pas realisable.
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Parathyroid Exploration for Primary Hyperparathyroidism
Parathyroidectomy was studied 
retrospectively in 107 patients with 
primary hyperparathyroidism. This condi­
tion was diagnosed by measuring both 
the total serum calcium and ultrafiltera- 
ble calcium (non-protein-bound) levels. 
The identification of ultrafilterable cal­
cium is an important adjunct to 
parathyroid surgery as it allows the diag­
nosis of hyperparathyroidism when the 
total serum calcium level is normal. The 
surgical technique for selective 
parathyroidectomy and multiple biopsies 
was uniform. Parathyroid adenoma was 
discovered in 73 patients, diffuse hyper­
plasia in 26 and combined disease in 8. 
Postoperatively, two patients suffered 
from permanent hypocalcemia and three 
had hypercalcemia.
Les resultats de la parathyroidectomie 
ont ete etudies retrospectivement chez 
107 patients souffrant d’hyperparathyroV- 
die primaire. La maladie a ete diagnosti- 
quee par determination de la calcemie 
totale de meme que des taux de calcium 
ultrafiltrable (non lie). L'identification du 
calcium ultrafiltrable est une aide impor-
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tante a la chirurgie parathyroidienne car 
elle permet le diagnostic d'hyperthyroidie 
meme en presence d'une calcemie totale 
normale. La technique chirurgicale de 
parathyroidectomie selective ainsi que 
cede des biopsies multiples ont ete uni- 
formes. Un adenome parathyroTdien a ete 
decouvert dans 73 cas, une hyperplasie 
diffuse dans 26 cas et une maladie com- 
binee, 8 fois. En postoperatoire, deux 
patients ont ete atteints d'hypocalcemie 
permanente et trois ont presente une 
hypercalcemie.
Surgery of the parathyroid glands for 
primary hyperparathyroidism is con­
troversial. The preferred surgical tech­
nique varies1-3 and the histologic find­
ings are often difficult to interpret by even 
the most skilled pathologist.4 We review 
retrospectively 107 patients who had 
parathyroid exploration for primary 
hyperparathyroidism to study the diag­
nostic methods used, the reliability of 
accurate measurements of total and 
ultrafilterable serum calcium levels, the 
results following a uniform surgical 
approach and the histologic findings.
Patients and Methods
During a 20-year period, the senior 
author (J.R.M.) performed parathyroi­
dectomy on 107 patients with a diagno­
sis of primary hyperparathyroidism. As 
in most series, women were affected more 
often than men. There were 79 women 
(average age 56 years) and 28 men (aver­
age age 45 years).
The principal clinical features of this 
disorder were renal stones (44 patients), 
bone disease comprising osteoporosis and 
osteitis fibrosa (44 patients), constitu­
tional symptoms that included fatigue, 
lassitude, anorexia, depression and gener­
alized pain (51 patients), and gastrointes­
tinal complaints—peptic ulcer, indiges­
tion, constipation (26 patients). In 13 
cases, unsuspected hypercalcemia was dis­
covered during routine biochemical 
screening.
The surgical technique was similar in 
all cases. Through a collar incision, care­
ful exploration identified the parathyroid 
tissue in a bloodless field. A small seg­
ment was excised from each parathyroid 
gland encountered and sent for immedi­
ate histologic study. Parathyroid ade­
nomas were completely removed and nor­
mal glands left in situ unless they were 
abnormally large. When all the glands 
were hyperplastic, they were excised, leav­
ing a glandular remnant with an estimated 
mass of 40 to 60 mg. Glands, or portions 
thereof left in situ, were marked with 
black silk sutures in case re-exploration 
was necessary later.
We disagree with the practice of discon­
tinuing exploration if an adenoma along 
with one normal gland is found, because 
there is ample evidence that multiple ade­
nomas can exist.5,6 Further, we do not 
concur that if two glands are hyperplas­
tic, then all glands must be so.7 Subtotal 
parathyroidectomy as advocated by 
Paloyan and associates3 was not per­
formed routinely. Our surgical technique 
was similar to that of Clark and 
colleagues8 in which all glands are iden­
tified and selective excision is performed.
We did not localize glands by arteriog­
raphy, selective venous sampling or tolui- 
dine blue staining. In recent years tomog­
raphy and ultrasonography have localized 
enlarged glands in some patients but use 
of these techniques does not preclude 
thorough surgical exploration.
Diagnosis
The presence of a calcium research 
laboratory at the Kingston General 
Hospital permitted accurate measure­
ments of total serum calcium and 
ultrafilterable calcium (non-protein- 
bound) levels. The diagnosis of hyper­
parathyroidism was based on the demon­
stration of elevated total serum and or 
ultrafilterable serum calcium levels with 
the exclusion of other causes of hyper­
calcemia. The upper limits of normal in 
this laboratory (for both sexes) for total 
serum calcium and ultrafilterable serum 
calcium are 2.54 mmol/L and 1.46
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mmol/L respectively. Measurement of 
urinary cyclic adenosine monophosphate 
excretion (immunoassay kit supplied by 
New England Nuclear, Boston, Mass.) 
and serum immunoreactive parathyroid 
hormone (immunoassay kit supplied by 
Nichols Institute Diagnostics, San Juan 
Capistrano, Calif.) were of limited diag­
nostic value.
Operative Findings
Adenoma was discovered in 73 patients 
(including one adenocarcinoma), diffuse 
hyperplasia in 26 and combined adenoma 
and hyperplasia of the parathyroid glands 
in 8. In the eight patients with hyperpla­
sia, glands were diagnosed as normal on 
microscopic examination of frozen sec­
tions, but focal nodules of hyperplasia 
were evident on examination of the per­
manent sections.
Surgical exploration identified 84% of 
the glands in 102 patients (assuming an 
average of four parathyroid glands per 
patient); more than four glands were 
found in the other 5—five glands in 4 of 
them and eight glands in the fifth. The 
anatomic locations of the glands, espe­
cially the inferior pair, were highly vari­
able, as reported by others.9 Ectopic 
glands were found in the thyroid glands, 
the thymus gland, the carotid sheath, on 
the lower trachea, posterior to the esopha­
gus, in the posterior superior mediasti­
num and retrosternally. In one case there 
were bilateral adenomas and, in another, 
five discrete adenomas were located 
within one parathyroid gland, confirm­
ing that multiple parathyroid adenomas 
do exist,5 although they are not com­
mon. The 1.9% incidence of multiple ade­
nomas in this series is similar to the 1.9% 
incidence described by Verdonk and 
Edis.6 The adenomas ranged in weight 
from 35 mg to 35 g.
Results
Follow-up of the 107 patients, ranging 
from 4 months to 20 years, revealed that 
two who had adenomas removed have 
permanent hypocalcemia. In one only two 
glands were found, the adenoma was 
completely excised and in the other, nor­
mal gland, a biopsy only was done. In the 
second case an adenoma was completely 
excised and biopsies were done on the 
three normal glands. These are the only 
cases in the series in which biopsy of nor­
mal glands could be incriminated as the 
cause of hypocalcemia.
Three patients remain hypercalcemic 
despite a second neck exploration. In one, 
four glands were identified. One gland 
that appeared grossly enlarged, but sub­
sequently proved to be histologically nor­
mal was excised, and biopsies were done 
on three normal glands at the first proce­
dure. Upon re-exploration two and one-
third of the three remaining, normal­
appearing glands were removed. This 
patient subsequently proved to have 
benign familial hypercalcemia. In the 
second patient, three glands were found: 
one adenoma weighing 255 mg was ex­
cised, one gland, thought to be hyperplas­
tic on frozen section but subsequently 
proved normal was excised and a 40-mg 
remnant of a third gland, histologically 
normal, was left in situ. During re­
exploration, a fourth gland was not found 
and hemithyroidectomy failed to reveal 
parathyroid tissue within the specimen or 
to alter the elevated calcium levels. In the 
third patient only three parathyroid 
glands were found; two were normal 
histologically and the third contained an 
adenoma weighing 170 mg. It seems likely 
that this patient has a second adenoma 
in a fourth gland that was not found.
There were no deaths or serious com­
plications. Specifically, there was no case 
of permanent hoarseness postoperatively 
or major wound problems. A temporary 
Horner’s syndrome was noted in one and 
a small pneumothorax in two patients.
Other biochemical diagnostic methods 
were not as accurate as the ultrafiltera- 
ble serum calcium level. Measurement of 
urinary cyclic AMP excretion resulted in 
13 of 22 patients having surgically proven 
parathyroid adenomas. This was espe­
cially true in patients with mild hyper­
calcemia (total serum calcium equal to or 
less than 2.7 mmol/L) and in whom uri­
nary cyclic AMP excretion was normal 
(12 of 16). However, cyclic AMP excre­
tion was elevated in five of six patients 
in whom total serum calcium levels 
exceeded 2.7 mmol/L. Measurement of 
serum immunoreactive parathyroid hor­
mone was likewise proven of limited value 
because normal values were found in 59% 
of the patients with surgically proven ade­
nomas.
Discussion
The controversy over subtotal versus 
selective parathyroidectomy for hyper­
parathyroidism has been reported by 
many authors.2’3'10>u The policy fol­
lowed in this series was that of so-called 
“selective” excision of parathyroid tissue, 
based upon the gross and microscopic 
appearance of the parathyroid glands at 
exploration.
The reported frequency of hypocalce­
mia after routine subtotal parathyroidec­
tomy varies widely (Table i2.3.8,12-14). 
Paloyan and colleagues3 reported a rate 
of 2%, Beahrs15 13% and Bruining11 
37%. It is difficult to understand why 
routine subtotal parathyroidectomy 
should not, eventually, lead to a higher 
rather than a lower rate of subsequent 
hypocalcemia than selective excision with 
preservation of more of the normal 
parathyroid tissue.
Persistent hypercalcemia postopera­
tively results from failure to identify and 
excise enough hyperfunctioning para­
thyroid tissue, usually the consequence of 
variation in number and location of 
parathyroid glands.
The importance of accurate measure­
ments of ultrafilterable serum calcium 
levels in diagnosing hyperparathyroidism 
deserves special attention. In this series 
10 of the 107 patients had clinical 
manifestations of underlying hyperpara­
thyroidism but normal total serum cal­
cium levels. In each of them, the 
ultrafilterable serum calcium level was 
elevated above the normal limit of 1.46 
mmol/L. Postoperatively, they had nor­
mal total and ultrafilterable serum cal­
cium levels.
The criteria for histologic differentia­
tion between parathyroid adenoma and 
hyperplasia have been questioned,4 and 
frozen-section diagnosis from a tiny 
biopsy specimen of tissue cannot always 
be made with accuracy. For this reason 
the gross appearance o f exposed 
parathyroid glands must be combined 
with the pathologist’s interpretation of 
frozen sections, in order to make an 
accurate diagnosis in the operating room.
Thorough exploration of the neck is 
required, even if an adenoma is found
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early in the operation, because of the fre­
quent association of adenoma with hyper­
plasia (7.8% in this series), the occasional 
occurrence o f multiple parathyroid 
adenomas5,6 and the possibility of more 
than four glands. Some authors believe 
that too thorough a search may endanger 
the blood supply and functional survival 
of normal parathyroid glands, but the 
occurrence of permanent hypocalcemia in 
this series would indicate that it is not 
likely to be a major problem if the oper­
ative field is kept reasonably dry and care­
ful biopsy of these “ normal glands” is 
performed away from the blood supply.
Complete mediastinal exploration 
through a sternal splitting incision was 
carried out only once in this series.
Our policy is to consider it necessary 
only after a second neck exploration, 
including thyroidectomy, has failed to 
reveal the presence of abnormal para­
thyroid tissue.
However, when four parathyroid 
glands or an adenoma cannot be found 
during exploration of the neck, the
retrosternal tissue, including the thymus 
gland, is removed through the neck inci­
sion before part of the thyroid gland is 
excised. Parathyroid glands are occasion­
ally found in this location and can be 
removed without splitting the sternum.
Our sincere thanks to the pathologists at the 
Kingston General Hospital and to the staff of 
the calcium research laboratory.
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pated in heart transplantation; of these 
14 had also performed combined heart- 
lung transplantation. Between December
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1967 and December 1984, 1599 
recipients had undergone 1644 trans­
plant procedures. By September 1985, 
112 heart-lung transplant procedures 
had been performed in 110 patients. 
Overall survival at 1 and 3 years respec­
tively, excluding perioperative mortality, 
averaged 8 0 %  and 6 5 % ; for heart trans­
plantation alone survival rates were 8 5 %  
and 7 5 % , respectively.
In Canada, of 81 heart and 5 heart- 
lung transplant procedures that were per­
formed in nine centres between April 
1981 and September 1985, 38 heart 
and 2 heart-lung transplants were car­
ried out in the first 9 months of 1985. 
Sixty-four of the heart and 2 of the 
heart-lung transplant recipient were 
alive from 20 days to 4.42 years 
postoperatively.
Au 1er septembre 1985, 62 gtablisse- 
ments de par le monde avaient ete iden­
tifies comme ayant participe a des gref- 
fes cardiaques; parmi ceux-ci, 14 avaient 
aussi realise des greffes coeur-poumons. 
De decembre 1967 £ decembre 1984, 
1599 receveurs avaient subi un total de 
1644 greffes. En septembre 1985, 112 
greffes coeur-poumons avaient ete prati- 
quees chez 110 patients. A I'exclusion 
des deces peroperatoires, la survie glo- 
bale a 1 et 3 ans a ete en moyenne de 
8 0 %  et 6 5 %  respectivement; pour les 
greffes cardiaques seules, ces taux 
etaient respectivement de 8 5 %  et 7 5 % .
Au Canada, sur 81 greffes cardiaques 
et 5 greffes coeur-poumons pratiquees 
dans neuf etablissements entre avril 
1981 et septembre 1985, 38 greffes 
cardiaques et 2 transplantations coeur- 
poumons ont ete realises au cours des 
9 premiers mois de 1985. Soixante- 
quatre greffds cardiaques et 2 receveurs 
de greffes coeur-poumons ont surv^cu 
de 20 jours a 4.42 annees apres leur 
operation.
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The pioneering efforts of Shumway and 
Lower in the late 1950s and the 1960s 
resulted in the development of surgical 
techniques for both heart and heart-lung 
transplantation that routinely allowed 
animal survival intra- and postopera- 
tively.1 Extended survival was then 
achieved following heart transplantation 
by immunosuppressing the animals with 
azathioprine and prednisone.2 A reliable 
method of determining organ rejection 
based on a 20% decrease in cumulative 
electrocardiographic voltage was recog­
nized and, finally, a means of reversing 
rejection episodes with pulsed doses of 
steroids was developed.3 4 These efforts 
provided the experimental basis for 
human-to-human heart transplantation.5
Stimulated by the first few cardiac 
transplant procedures, nearly 50 other 
centres around the world undertook 
cardiac transplantation, with little prepa­
ration beyond the surgical technique 
itself. Over 100 transplants were per­
formed in 1968 alone and 250 by the end 
of 1970. With the death of most recipients 
because of infection or rejection, initial 
enthusiasm waned and most centres aban­
doned heart transplantation.
Over the ensuing decade, only five 
centres continued heart transplantation. 
By the end of the 1970s, new diagnostic 
and management strategies had been 
developed, leading to improved survival, 
particularly at Stanford University Med­
ical Center, and with the introduction of 
cyclosporine immunosuppression in De­
cember 1980, a renaissance in cardiac 
transplantation occurred around the 
world. Despite three initial failures of 
combined heart-lung transplantation in 
the late 1960s and early 1970s, heart-lung 
transplantation was successfully restarted 
clinically by Reitz and colleagues.6.
Since the introduction of cyclosporine 
for clinical cardiac transplantation, 62 
centres worldwide have participated in 
heart or heart-lung transplantation in 
1599 recipients.
The information for this report derives 
from the International Heart Transplan­
tation Registry,7 the Canadian Heart 
Transplantation Registry, personal com­
munication with the 9 Canadian centres 
that have active heart transplant pro­
grams, the 14 centres pursuing combined 
heart and lung transplantation, and the 
recent literature.
The report reviews experience in heart 
transplantation from December 1967 to 
December 1984 (world experience) and 
until September 1985 (Canadian ex­
perience), and in heart-lung transplanta­
tion from March 1981 to September 1985.
Overview
The number of centres performing 
heart transplantation alone or heart and
heart-lung transplantation numbers 55 
according to the International Heart 
Transplantation Registry7 (62 by per­
sonal communication). Of the 62 centres, 
39 are in the United States, 9 in Canada 
and 14 elsewhere.
Fifty-five centres in nine countries per­
formed 1644 transplants in 1599 recipients 
between December 1967 and December 
1984. One thousand patients received new 
organs in the United States, 53 in Canada 
and 546 elsewhere. The near-exponential 
rise in transplantation is illustrated by the 
fact that 44.6% (713 patients) of all 
transplant procedures were performed in 
1984.
The predominant age group for
recipients ranged from 35 to 55 years. Ten 
recipients were younger than 10 years and 
9 older than 60 years (Fig. 1).
Cyclosporine was used for immunosup­
pression in 1014 of the recipients. Figure 
2 compares actuarial survival for 120 
patients who underwent cardiac trans­
plantation with (46 patients) and without 
(74 patients) cyclosporine immunosup­
pression, excluding those who died within 
30 days of operation. At 3 years, 74% of 
recipients who had cyclosporine immuno­
suppression versus 47% of those who did 
not, remained alive. In order to achieve 
more homogeneous groups of patients, 
the above data were re-analysed for only 
those patients transplanted after 1978. If
HG. 2 Actuarial survival of 120 patients who underwent heart transplantation with and 
without cyclosporine immunosuppression (p < 0.0001). (Reproduced by permission from Kaye 
MP, Elcombe SA, O’Fallow WM: J Heart Transpl 1985; 4: 290-292.)
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FIG. 3—Actuarial survival of patients who underwent heart transplantation with and without 
cyclosporine immunosuppression during and after 1978. Deaths within 30 days of operation 
are excluded. (Reproduced by permission from Kaye MP, Elcombe SA, O’F'allow WM: J  Heart 
Transpl 1985; 4: 290-292.)
YEAR
FIG. 4—Actuarial survival of patients who underwent heart or heart-lung transplantation. 
Survival 1 and 2 years after heart-lung transplantation is comparable to that of heart trans­
plantation alone. (Reproduced by permission from Kaye M P, Elcombe SA, O’Fallow WM: 
J  Heart Transpl 1985; 4: 290-292.)
FIG. 5—Probability of surviving 1, 2, 3, 4 or 5 years after transplantation for recipients rang­
ing in age from 5 to 60 years.
mortality in the first 30 days is again 
excluded, 3-year survival still remains sig­
nificantly (p < 0.0001, Mayo compu­
ter main-frame) improved with cyclospo­
rine therapy (Fig. 3). Figure 4 illustrates 
that 1- and 2-year survival rates following 
combined heart and lung transplantation 
are comparable to those of heart trans­
plantation alone.
From a study of the effect of age on 
survival following cardiac transplanta­
tion at centres where more than 20 
transplant procedures have been per­
formed, the International Registry for 
Heart Transplantation developed a 
proportional-hazards model involving age 
and cyclosporine use to determine the 
probability of survival for recipients using 
cyclosporine for immunosuppression by 
their age at the time of transplantation 
(Fig. 5). Because of the small number of 
patients at 4 and 5 years, caution must be 
used in interpreting the apparent dip in 
all survival curves that may relate simply 
to extrapolation of the mathematical 
model. While these curves represent the 
means of data generated by a number of 
centres, the goal of any transplant pro­
gram must be to perform better than the 
best, which at this time is Stanford 
University Medical Center (Fig. 6).
Heart Transplantation in Canada
In 1968 and 1969, 20 cardiac transplant 
procedures were performed in Ontario 
and Quebec. Most patients died of infec­
tion or rejection within 1 year, but one 
patient from Quebec survived over 4 years 
before dying of rejection and a cerebro­
vascular accident and one patient from 
Ontario survived over 5 years. From 1970 
until 1980, no further cardiac transplant 
procedures were performed in Canada, 
but in April 1981, Dr. Neil McKenzie at 
the University Hospital in London, Ont., 
reintroduced cardiac transplantation, and 
in May 1983 he performed Canada’s first
FIG. 6—Actuarial survival for patients who 
underwent heart transplantation at Stanford 
University Medical Center (including periope­
rative mortality). O = not transplanted,
------------- = January 1968 to December 1973,
-------- = January 1974 to December 1980,
----------= December 1980 to May 1985.
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combined heart and lung transplantation. the 20 transplants performed before 1970, been performed. The age of the recipients
Table I summarizes the subsequent 81 heart transplants in 80 recipients and has ranged from 12 to 60 years,
developments in this country. Excluding 5 combined heart-lung transplants have The indications for heart transplanta-
Table 1-Heart Transplantation in Canada: April 1981 to September 1985
Start of 
program
Patients transplanted Age range,
yrCentre M F Total
University Hospital, London, Ont. 4/81 33 6 39 t 12-58
Hopital Notre-Dame, Montreal 7/82 9 3 12 21-48
Institut de Cardiologie de Montreal 4/83 8 4 12 17-52
Hopital Sainte-Justine, Montreal 1/84 1 0 1 15
University of Ottawa Heart Institute 5/84 5 1 6 30-51
Toronto General Hospital 6/84 2* 0 2 32, 60
Royal Victoria Hospital, Montreal 1/85 5 1 6 42-56
Toronto Western Hospital 3/85 2 0 2 26,37
University of Alberta Hospitals, 
Edmonton 7/85 2 0 2 41,53
Totals 65 15 80
'Heart—lung procedures.
t1 patient underwent a second procedure giving a total of 81 transplants in 80 patients.
Table V—Indications for Heart-Lung Transplantation
Indication No. of procedures
Primary pulmonary hypertension 49
Eisenmenger's syndrome 44
Valvular heart disease and pulmonary hypertension 1
Multiple pulmonary emboli 1
Emphysema* 3
Alpha-1 antitrypsin deficiency* 3
Cystic fibrosist 2
Eosinophilic granuloma 1
Fibrosing alveolitist 1
Primary pulmonary fibrosis 1
Pulmonary asbestosist 1
Pulmonary lymphangioleiomyomatosist 1
Pulmonary staphylococcal infection 1
Pulmonary sarcoidosis 1
Chronic rejection*§ 2
Total 112
*1 patient still alive. 
tDied.
4 Died at 23 months from progressive fibrosis and bronchial obstruction.
§2 patients underwent second procedure, giving 112 transplant procedures in 110 patients.
Table II—Indications for Transplantation
Indication
No. of 
procedures
Cardiomyopathy 38
Ischemic heart disease 37
Valvular heart disease 4
Idiopathic hypertrophic 
subaortic stenosis 1
Rejection 1
Total 81
Table Ill-Surviva l* and Rehabilitation
Feature No. (%)
Transplantations 80
Currently alive 64 (80.0)
Fully rehabilitated 54 (84.4)
Partially rehabilitated 9(14.1)
Not rehabilitated 1 (1.6)
'Duration of survival ranged from 20 d to 4.42 
V■
Table IV—Heart-Lung Transplantation: World Experience March 1981 to September 1985
Start of 
program
Patients transplanted Age range,
yrCentre M F Total
Stanford University Medical Center 3/81 17 10 27* 19-45
Hopital de la Pitie, Paris 3/82 5 2 7 18-42
University of Pittsburgh 5/82 11 15 2 6 t 12-45
Texas Heart Institute, Houston 7/82 2 2 4 38-55
University of Munich 2/83 2 0 2 21-27
University Hospital, London, Ont. 5/83 1 2 3 35-47
Johns Hopkins Hospital, Baltimore 7/83 3 1 4 20-35
University of Brussels 8/83 1 2 3 24-
Harefield Hospital, Harefield, 
Middlesex, England 12/83 9 12 21 3.5-52
Papworth Hospital, Cambridge, 
England 4/84 1 4 5 30-40
Toronto General Hospital 6/84 2 0 2 32-60
Arizona Heart Institute, Phoenix 12/84 1 1 2 39-42
University of Capetown 2/85 1 2 3 20-28
Hanover Medical School, Hanover, 
W, Germany 4/85 0 1 1 40
Totals 56 54 110 3.5-60
*1 patient underwent a second transplantation, giving 28 transplant procedures in 27 patients, 
t l  patient underwent a second transplantation, giving 27 transplant procedures in 26 patients.
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tion in Canada are outlined in Table II 
and, like most other centres, include 
predominantly cardiomyopathy and 
ischemic heart disease.
Table III summarizes the survival and 
rehabilitation data in the 80 heart-trans­
plant recipients. Meaningful actuarial sur­
vival curves cannot be generated owing 
to the relatively small number of patients 
and because 38 (41.5%) of the 80 received 
heart transplants in the first 9 months of 
1985. Nevertheless, 64 (80%) patients are 
alive from 20 days to 4 years and 4 
months after transplantation. Of these, 
54 (84.4%) are fully rehabilitated (i.e. 
follow-up longer than 3 months back at 
work or carrying out preoperative activi­
ties, or capable of returning to work or 
carrying out preoperative activities). For 
9 (14.1%) of the 64 patients the follow­
up is less than 3 months and 1 patient has 
no rehabilitation potential.
Sixteen recipients died — of rejection 
(3), infection (2), right ventricular failure 
(3), respiratory failure (3), “ stone heart” 
(2), pancreatitis (1), thrombotic throm­
bocytopenia (1) and myocardial infarc­
tion (1).
Heart-Lung Transplantation:
World Experience
Combined heart and lung transplanta­
tion was first performed in 1969; by the 
end of 1971 three such procedures had 
been performed, with the longest survival 
being only 23 days.8-10 All patients died 
of infection or bronchial disruption, or 
both. No further heart-lung transplants
Table VI—Heart—Lung Transplantation: 
Survival and Rehabilitation*
Feature No. (%)
Transplantation 110
Currently alive 59 (53.6)
Fully rehabilitated 48 (81.4)
Partially rehabilitated 10(16.9)
Not rehabilitated 1 (1.7)
‘ Duration of survival ranged from 17 d to 4.42
V-
were performed until March 1981, when 
Reitz and Shumway, stimulated by suc­
cess in the laboratory with primates and 
immunosuppression with cyclosporine in 
clinical cardiac transplantation, per­
formed the first clinically successful com­
bined heart-lung transplant in a 45-year- 
old woman, who is still alive and well 4.5 
years later.6
One year elapsed before another centre, 
La Pitie in Paris, followed the Stanford 
lead. Table IV summarizes results from 
the 14 transplantation centres that have 
carried out heart-lung transplantation. 
Between March 1981 and September 
1985, 56 males and 54 females, ranging 
in age from 3.5 years to 60 years, have 
undergone a total of 112 procedures.
The indications for these 112 proce­
dures are outlined in Table V. The 
predominant indicators were primary pul­
monary hypertension and Eisenmenger’s 
syndrome.
A most interesting group of patients, 
those with primary lung parenchymal dis­
ease (i.e., cystic fibrosis, emphysema) 
accounts for only a small proportion of 
the recipients to date but represents a 
huge reservoir of potential candidates. 
The ultimate utility of combined heart- 
lung transplantation for the management 
of patients with primary nonvascular lung 
disease in unknown, and only 6 of 17 such 
patients remain alive.
Table VI reviews the survival and 
degree of rehabilitation achieved in the 
110 transplant patients. Of these, 59 
(53.2%) patients are alive from 17 days 
to 4 years and 5 months after the proce­
dure. Actuarial survival data are not 
available for the entire group, but 70% 
at 3 years is the survival rate for patients 
transplanted at Stanford University Med­
ical Center (personal communication).
Overall, of the patients currently alive 
48 (81.4%) are fully rehabilitated, 10 
(16.9%) are partially rehabilitated and 1 
(1.6%) has no opportunity for rehabili­
tation.
That heart-lung transplantation rep­
resents a more complex and technically 
difficult procedure than heart transplan­
tation is reflected in the large number of
Table VII—Heart—Lung Transplantation: Cause of Death in 51 
Recipients
Cause of death No. of patients
Infection
Multisystem organ failure + postop bleeding 15
Acute respiratory failure 5
Tracheal dehiscence 2
Cerebral edema + infection 2
Renal failure 2
Myocardial infarction 1
Tracheo-aortic fistula 1
Respiratory failure: donor-recipient mismatch 1
Respiratory failure due to chronic rejection 1
Liver failure 1
Lymphoma 1
patients who have died of multisystem 
organ failure, often related to hemor­
rhage perioperatively. The cause of death 
in 52 patients is summarized in Table VII.
Overall survival and quality of life fol­
lowing cardiac transplantation have been 
greatly improved since the introduction 
of cyclosporine immunosuppression. The 
most up-to-date information from the 
Registry of the International Heart Trans­
plantation Society (December 1985) indi­
cates 1- and 4-year survival rates of 90% 
and 80% respectively, although the results 
for heart-lung transplantation are not 
quite as good. Some centres have reported 
a 90% 4-year survival, including patients 
older than 50 years.
With over 114 centres around the world 
(December 1985) actively performing 
heart or heart-lung transplantation, it is 
likely that throughout the next decade 
cardiac-transplant patients will enjoy a 
quality of life comparable to that of the 
normal population, and the results of 
heart-lung transplantation will improve 
accordingly.
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novantrone
Mitoxantrone Hydrochloride Injection 
For Intravenous Infusion Only
ANTINEOPLASTIC
CAUTION
NOVANTRONE* IS A POTENT DRUG AND SHOULD BE USED ONLY BY PHYSI­
CIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE 
WARNINGS AND PRECAUTIONS). BLOOD COUNTS SHOULD BE TAKEN AT FRE­
QUENT INTERVALS PRIOR, DURING AND POST THERAPY. CARDIAC MONITOR­
ING IS ADVISED IN THOSE PATIENTS WHO HAVE RECEIVED PRIOR ANTHRACY- 
CLINES, PRIOR MEDIASTINAL RADIOTHERAPY OR WITH PRE-EXISTING 
CARDIAC DISEASE.
PHARMACOLOGICAL ACTION
Although its mechanism of action has not been determined, mitoxantrone is a DNA- 
reactive agent. It induces nuclear aberrations with chromosome scattering in cell 
cultures (human colon carcinoma line) and is a potent inhibitor of RNA and DNA 
synthesis. Compared on an equimolar basis, mitoxantrone is seven times more 
potent than doxorubicin in inhibiting the uptake of 3H-uridine and four times more 
potent in inhibiting the uptake of 3H-thymidine by mouse lymphoma L5178Y cells in 
vitro.
INDICATIONS
NOVANTRONE* is indicated for chemotherapy in patients with carcinoma of the 
breast, including locally advanced and metastic disease. Also for relapsed adult 
leukemia and lymphoma patients with hepatoma.
CONTRAINDICATIONS
NOVANTRONE* is contraindicated in patients who have demonstrated prior hyper­
sensitivity to anthracyclines.
WARNINGS
Since NOVANTRONE* produces myelosuppression (see ADVERSE EFFECTS], it 
should be used with caution in patients in poor general condition or with pre-existing 
myelosuppression.
Cases of functional cardiac changes, including congestive heart failure and 
decreases in left ventricular ejection fraction have been reported. These cardiac 
events have occurred almost exclusively in patients who have had prior treatment 
with anthracyclines, prior mediastinal radiotherapy or with pre-existing heart disease. 
Cardiac monitoring is advisable in such patients. It is suggested that cardiac monitor­
ing also be performed in other patients during therapy exceeding 160 mg/m2 
(approximately 12 courses) of NOVANTRONE*, as experience during prolonged 
treatment is limited.
NOVANTRONE* may impart a blue-green colouration to the urine for 24 hours 
after administration, and patients should be advised to expect this during active 
therapy. A reversible blue coloration in the sclerae has been reported in two cases. 
Safe use of NOVANTRONE* in pregnancy has not been established. No information 
is available concerning the presence of NOVANTRONE* in the milk of nursing 
mothers. Safety for intrathecal use of NOVANTRONE* has not yet been established. 
PRECAUTIONS
Full blood counts should be undertaken serially during a course of treatment. Dosage 
adjustments may be necessary based on these counts [see DOSAGE section].
It is recommended that NOVANTRONE* not be mixed in the same infusion with 
other drugs. [See DRUG COMPATIBILITY section],
ADVERSE EFFECTS
NOVANTRONE* is clinically well tolerated, demonstrating a low overall incidence of 
adverse events, particularly those of a severe, irreversible or life-threatening nature.
Some degree of leucopenia is to be expected following recommended doses of 
NOVANTRONE*. With dosing every 21 days, suppression of WBC counts below 
1000/mm3 is infrequent; leucopenia is usually transient, reaching its nadir at about 10 
days after dosing, with recovery usually occurring by the 21st day. Thrombocytope­
nia can occur, and anaemia occurs less frequently. Myelosuppression may be more 
severe and prolonged in patients having had extensive prior chemotherapy or radio­
therapy or in debilitated patients.
The most commonly encountered side effects are nausea and vomiting, although 
in the majority of cases these are mild (WHO Grade 1) and transient. Alopecia may 
occur, but is most frequently of minimal severity and reversible on cessation of 
therapy.
Other side effects which have occasionally been reported include allergic reactions 
(one with anaphylaxis), abdominal pain, amenorrhoea, anorexia, constipation, 
diarrhoea, dyspnoea, fatigue, weakness, fever, gastrointestinal bleeding, stomatitis/ 
mucositis, and non-specific neurological side effects. Tissue necrosis following 
extravasation has been reported rarely.
Changes in laboratory test values have been observed infrequently, e.g., 
increased liver enzyme levels, elevated serum creatinine and blood urea nitrogen 
levels (with occasional reports of severe impairment of hepatic function in patients 
with leukemia).
Cardiovascular effects, which have only occasionally been of clinical significance, 
include decreased left ventricular ejection fraction (determined by ECHO or MUGA 
scan), EKG changes and acute arrhythmia. Congestive heart failure has been 
reported. Such cases generally responded well to treatment with digitalis and/or 
diuretics. In patients with leukemia there is an increase in the frequency of cardiac 
events, the direct role of NOVANTRONE* in these cases is difficult to assess, since 
most patients had received prior therapy with anthracyclines and since their course is 
frequently complicated by anemia, fever, sepsis, and intravenous fluid therapy.
In leukemia patients treated with a single course of 12 mg/m2 1.V. daily x 5 days, the 
following drug-related toxicities occured: moderate or severe jaundice or hepatitis in 
8%, moderate nausea or vomitting in 8%, moderate or severe stomatitis/mucositis in 
9-29%, diarrhea in 9-13%, and moderate or severe alopecia in 11%.
CLINICAL RESULTS 
Introduction
Clinical trials experience has established the dosage range, efficacy and safety pro­
file of NOVANTRONE.
A single dose can be given intermittently every three or four weeks. The recom­
mended initial treatment dose in good risk patients is 14 mg/m2.
Efficacy
Breast
Efficacy data are available on 349 patients with locally advanced or metastatic breast 
carcinoma. Results are dependent on many predisposing factors including prior 
chemotherapy and/or radiotherapy, the health of the patients, sites of metastases,
and dose of the agent employed. In a European multi-centre first-line single-agent trial 
using an initial dose of 14 mg/m2, the overall response rate was 39%, which com­
pared favourably to doxorubicin therapy at a dose of 60-75 mg/m2 when given to 
patients with similar stage disease. In an ongoing study of a direct comparison with 
doxorubicin, given as second-line therapy to breast cancer patients who failed a 
standard first-line combination, response rates are 27% for NOVANTRONE and 23% 
for doxorubicin. The mean duration of response observed after NOVANTRONE was 
greater than those reported after doxorubicin. Responses have been seen in all major 
sites of metastases including lymph nodes, lung, bone, skin and viscera, in patients 
both with and without prior hormonal therapy. Available data suggest that 
NOVANTRONE is comparable in efficacy with doxorubicin in the treatment of 
advanced breast cancer. Myelosuppression with 21-day treatment intervals is com­
parable with that observed with doxorubicin. Multiple courses of single-agent 
NOVANTRONE therapy, in some cases for longer than twelve cycles, have been 
administered with excellent tolerance and a good response. NOVANTRONE showed 
incomplete cross-resistance with doxorubicin since responses have been observed 
in patients in whom doxorubicin had failed or who relapsed after response to that 
drug. A continuing large-scale clinical trials program with combination therapy also 
demonstrated early positive results for efficacy and safety. In seven studies, over 100 
cycles of combination therapy have been given to 77 patients.
Additional Indications
A total of 966 patients have been treated with NOVANTRONE* for three other indica­
tions of which 259 patients had non-Hodgkin's lymphona (NHL). 546 had leukemia, 
and 161 had hepatocellular carninoma (HOC). The following summarizes the accrual 
of these 966 patients:
Indication
NHL
Leukemia
(including pediatric cases)
Lederle-Sponsored 
Studies 
(No. Treated)
186
282
Independent Studies 
Reported in the 
Literature 
(No. Treated)
73
264
HCC _75 J36
543 423
NON-HODGKIN’S LYMPHOMA. Three key studies evaluated single agent 
NOVANTRONE* in 148 patients with relapsed or refractory advanced NHL at a dose 
of 14 mg/m2, IV, every 3 weeks. Of 127 patients evaluable for response in two trials, 
there were 10 complete responses (CR) and 42 partial responses (PR) producing an 
overall therapeutic response rate of 41%. The median duration of responses in the 
multicenter study (122 evaluable patients) was 195 days. Many patients’ responses 
lasted in excess of one year. Responses were seen in all histological subtypes of 
NHL. Response to NOVANTRONE* was independent of prior chemotherapy and 
independent of whether the patient received prior doxorubicin. This demonstrated a 
lack of complete cross-resistance between NOVANTRONE* and other drugs includ­
ing anthracyclines.
NOVANTRONE* was evaluated in combination with other agents for the treatment 
of NHL. A total of 28 patients were treated with different regimens. A first-line compar­
ative trial of the combination of intermediate dose METHOTREXATE with LEUCOV- 
ORIN rescue + bleomycin + doxorubicin + cyclophosphamide + vincristine + 
dexamethasone (m-BACOD) versus the same combination with 10 mg/m2 
NOVANTRONE* replacing doxorubicin (m-BNCOD) has shown activity: 4 PRs in 6 
evaluable patients with m-BNCOD and 3 PRs in 6 with m-BACOD. The combination 
of NOVANTRONE* at 10 mg/m2, daily for 3 days, + vincristine + dexamethasone 
(NOD) produced 3 PRs in 5 evaluable patients. A first-line comparative trial of the 
combination of cyclophosphamide + vincristine + prednisone + doxorubicin 
(CHOP) versus the same combinations with 10 mg/m2 NOVANTRONE* replacing 
doxorubicin (CNOP) has only recently begun.
NOVANTRONE * at 5 mg/m2, daily for 3 days every 3 weeks produced one CR and 
2 PRs in 8 evaluable patients with NHL; ten patients were enrolled. Several other 
studies reported in the literature and not sponsored by Lederle support the activity of 
NOVANTRONE* in the treatment of NHL.
LEUKEMIA. Four key studies sponsored by Lederle evaluated single agent 
NOVANTRONE* in 181 adult patients with refractory or relapsed acute non- 
lymphocytic leukemia (ANLL) or chronic myelogenous leukemia in blast crisis (B- 
CML) at doses ranging from 8 to 12 mg/m2, IV, daily for 5 days, every 3 weeks. A dose 
response effect was evident. Optimal activity was seen at a dose of 12 mg/m2, daily for 
5 days. At this dose level, there were 19 CRs in 49 evaluable adult patients with ANLL 
in relapse producing an overall response rate of 39%. The median duration of com­
plete response in the largest (121 patients) single agent study was 98 days. Several 
patients had remissions lasting in excess of one year. There were four studies com­
prising 63 patients in which NOVANTRONE* was evaluated in combination with 
other agents in the treatment of leukemia. The highest complete remission rate of 
49%  (11 CRs in 23 eva luable pa tients w ith ANLL) was obta ined when 
NOVANTRONE* at 10 to 12 mg/m2, daily for 3 days, was combined with cytosine 
arabmoside at 100 mg/m2 daily for 7 days. When NOVANTRONE* at 10 mg/m2, daily 
for 5 days was combined with the same dose of cytosine arabinoside, it produced 2 
CRs in 8 evaluable patients. Treatment of patients with acute lymphoblastic leukemia 
using 10 mg/m2 NOVANTRONE*, daily for 3 days, + vincristine + prednisone 
produced 10 responses in 16 evaluable patients, for a response rate of 62.5%.
Activity was also seen in B-CML. Since no standard therapy exists for this disease 
and bone marrow is never truly normal in this disorder, both CRs and PRs were 
considered evidence of efficacity. The optimal dose of NOVANTRONE* was 12 
mg/m2, daily for 5 days, producing 6 responses in 17 evaluable patients.
Experience in pediatric leukemia patients is limited. Twenty-four patients were 
treated with 6 to 8 mg/m2 NOVANTRONE *, daily for 5 days. There were 3 responses 
in 24 evaluable children.
Fourteen adult leukemia patients received 20 to 37 mg/m2 NOVANTRONE* once 
every two weeks. No therapeutic responses were observed using this schedule.
Several other studies reported in the literature and not sponsored by Lederle 
support the activity of NOVANTRONE* in the treatment of ANLL and B-CML.
HEPATOCELLULAR CARCINOMA. Three clinical trials sponsored by Lederle have 
been conducted using NOVANTRONE* in the therapy of HCC. NOVANTRONE* 
was administered to 65 patients intravenously at 12 mg/m2 every 3 weeks in two 
studies, and in one study with 10 patients at 6 to 10 mg/m2/day by continuous hepatic 
artery infusion for three consecutive days, every 3 weeks. Considering the short life 
span of patients presenting with HCC, a response of stable disease was included 
along with PRs and CRs in assessing efficacy. In these three studies, the overall 
therapeutic response rate was 46.7% (11 CRs and PRs + 10 stable disease in 45 
evaluable patients). Activity was confirmed in other studies not sponsored by Lederle. 
Durations of response were variable among these studies and ranged between 3 and 
52 weeks.
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Safety
Data on the overall safety profile of NOVANTRONE (based on 989 patients) demon­
strated advantages of NOVANTRONE compared to the anthracyclines with respect 
to both the quality of life and the long-term safety of patients. The majority of side 
effects with NOVANTRONE are m ild in nature. Removal of patients from 
NOVANTRONE treatment for reasons of toxicity has been rare in clinical studies. A 
number of patients have reported no side effects at all. In addition, the relatively low 
risk of serious side effects has permitted treatment of patients on an out-patient basis. 
The most common acute effects were nausea and/or vomiting (only 3.5% severe or 
very severe with NOVANTRONE, compared to 10-15% reported with doxorubicin), 
stomatitis/mucositis (only- 0.3% severe or very severe with NOVANTRONE) and 
alopecia (only 0.9% severe or very severe, and 15% overall with NOVANTRONE 
compared with 85% severe or very severe and 100% overall reported with doxoru­
bicin). Serious local reactions have been reported rarely following extravasation of 
NOVANTRONE at the infusion site.
With respect to myelosuppression, initial NOVANTRONE doses of 14 mg/m2 every 
three weeks are well tolerated in good-risk patients. Severe degrees of myelosup­
pression have been rare. The median white cell nadir in a European second-line 
study was 2.5x103; in a European first-line study only 4.8% (2/42) of patients experi­
enced a nadir of less than 1,000. The nadir usually occurs around day 10 or 11 and 
returns to normal baseline value by day 21, in time for the next course of treatment. 
After multiple courses of NOVANTRONE, white blood cell and platelet nadirs show no 
further decrease beyond those observed in the first few cycles, indicating no cumula­
tive or permanent effects of NOVANTRONE on marrow reserves.
NOVANTRONE* had an exceptional safety profile and was well-tolerated by 
patients treated for NHL, leukemia and hepatoma, as well as for breast cancer. 
However, due to the pathophysiology of leukemia and the higher doses of 
NOVANTRONE* employed, the safety profile differed from that seen in NHL and in 
hepatoma (see ADVERSE EFFECTS). The most severe and life-threatening events,
i.e. bleeding and infection, are well described morbid complications of acute 
leukemia. Many of the episodes of hepatic dysfunction were probably related to the 
increased bilirubin load and increased exposure to hepatitis viruses as a result of the 
multiple transfusions of blood products necessary in the proper treatment of this 
disorder.
Cardiotoxicity
Adverse cardiac experiences have been infrequent. In contrast, doxorubicin has 
been reported to produce chronic cardiomyopathy and irreversible congestive heart 
failure in up to 11% of patients given nine or more courses of that drug at the usual 
dose schedule (60 mg/m2 every three weeks). W hether or not related to 
NOVANTRONE, only 119 cardiac-related episodes have been reported from a total 
data-base of more than 3,200 treated patients, including only 29 (0.9%) reports of 
clinical congestive heart failure, of which only one had no other known predisposing 
factors. The risk of cardiotoxicity is increased with prior anti-neoplastic drug or radia­
tion therapy. In patients without predisposing factors, development of congestive 
heart failure with NOVANTRONE therapy is rare.
Clinical experience suggests there is no need to lower the dose for patients with 
existing renal or hepatic disease.
In summary, NOVANTRONE* is well tolerated and provides a better quality of life 
for patients compared with doxorubicin and yet shows comparable efficacy.
NOVANTRONE has been used alone or in combination in patients with or without 
prior chemotherapy, as well as in those who have received prior adjuvant therapy. It is 
less cardiotoxic than anthracyclines such as doxorubicin and thus represents a clear 
therapeutic advance over currently available compounds.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no known specific antidote for NOVANTRONE. As would be expected from 
the pharmacological actions of the drug, haematopoietic, gastrointestinal, hepatic 
and renal toxicity may be seen, depending on the dosage given and the physical 
condition of the patient. The management of overdosage is symptomatic and sup­
portive and patients should be monitored closely. (See also the sections “ WARN­
INGS", "PRECAUTIONS" and "ADVERSE REACTIONS” ).
DOSAGE
Breast Cancer, Lymphoma, Hepatoma
The recommended initial dosage for use as a single agent is 14 mg/m2 of body 
surface area, given as a single intravenous dose, which may be repeated at 21-day 
intervals. A lower initial dose (12 mg/m2 or less) is recommended in patients with 
inadequate marrow reserves due to prior therapy or poor general condition.
Dosage modification and timing of subsequent dosing should be determined by 
clinical judgement depending on the degree and duration of myelosuppression. If 
21-day white blood cell and platelet counts have returned to adequate levels, prior 
doses can usually be repeated. The following Table indicates a guide to dosing based 
on myelosuppression.
WBC AND TIME TO
PLATELET NADIR RECOVERY
IF WBC NADIR>1 500 RECOVERY
AND <21 DAYS
PLATELET NADIR>50 000
SUBSEQUENT DOSING
REPEAT PRIOR DOSE OR 
INCREASE BY 2 mg/m2 IF 
MYELOSUPPRESSION NOT 
CONSIDERED ADEQUATE
IF WBC NADIR >1 500 RECOVERY
AND >21 DAYS
PLATELET NADIR > 5 0  000 
IF WBC NADIR <1 500 ANY DURATION
OR
PLATELET NADIR < 5 0  000
IF WBC NADIR <1 000 ANY DURATION
OB
PLATELET NADIR < 2 5  000_______________
WITHHOLD UNTIL RECOVERY 
THEN REPEAT PRIOR DOSE
DECREASE BY 2 mg/m2 FROM 
PRIOR DOSE AFTER RECOVERY
DECREASE BY 4 mg/m2 FROM 
PRIOR DOSE AFTER RECOVERY
Combination Therapy for Breast Cancer, Lymphoma
NOVANTRONE* has been given in various combination regimens with the following 
cytotoxic agents for the treatment of breast cancer and lymphomas: cyclophos­
phamide, fluorouracil, vincristine, vinblastine, bleomycin, METHOTREXATE (stan­
dard dose or 200 mg/m2 with LEUCOVORIN rescue) and glucocorticoids.
As a guide, when used in combination chemotherapy with another myelosuppres- 
sive agent, the initial dose of NOVANTRONE* should be reduced by 2-4 mg/m2 
below the doses recommended above for single agent usage; subsequent dosing, 
as outlined above, depends on the degree and duration of myelosuppression. 
Dosage for Patients with Acute Leukemia in Relapse
The recommended dosage for induction is 12 mg/m2 of body surface area, given as a 
single intraveneous dose daily for five consecutive days (total of 60 mg/m2).
In clinical studies, with a dosage of 12 mg/m2 daily for 5 days, patients who 
achieved a complete remission did so as a result of the first induction course.
Re-induction upon relapse may be attempted with NOVANTRONE* and again the 
recommended dosage is 12 mg/m2 daily x 5.
Combination Therapy for Leukemia
NOVANTRONE *, together with cytosine arabinoside, has been used successfully for 
the treatment of both first line and second line patients with acute non-lymphocytic 
leukemia.
For induction, the recommended dosage is 10-12 mg/m2 of NOVANTRONE* for 3 
days and 100 mg/m2 of cytosine arabinoside for 7 days (the latter given as a continu­
ous 24 hour infusion).
If a second course is indicated, then the second course is recommended with the 
same combination at the same daily dosage levels but with NOVANTRONE * give for 
only 2 days and cytosine arabinoside for only 5 days.
If severe or life-threatening non-hematological toxicity is observed during the first 
induction course, the second induction course should be withheld until the toxicity 
clears.
Note regarding pediatric usage: Experience in pediatric patients is limited; how­
ever, complete remissions have been observed with NOVANTRONE * as single agent 
therapy at a dosage of 8 mg/m2 daily for 5 days.
ADMINISTRATION OF SOLUTION
NOVANTRONE* solution should be diluted to at least 50 mL with either Sodium 
Chloride for Injection (USP) or 5% Dextrose for Injection (USP). This solution should 
be introduced slowly into the tubing of a freely-running intravenous infusion of 
Sodium Chloride for Injection (USP) or 5% Dextrose for Injection (USP) administered 
over not less than three to five minutes intravenously. If extravasation occurs, the 
administration should be stopped immediately and restarted in another vein. The 
nonvesicant properties of NOVANTRONE minimize the possibility of severe reactions 
following extravasation, however, tissue necrosis has been reported rarely.
NOVANTRONE should be administered by individuals experienced in the use of 
antineoplastic therapy.
Caution in the handling and preparation of NOVANTRONE solutions must be 
exercised and the use of protective eyeglasses, gloves and other protective clothing 
is recommended. (See "GUIDELINES FOR SAFE USE BY HOSPITAL PERSON­
NEL" section.)
STORAGE DIRECTIONS
NOVANTRONE should be stored at room temperature-DO NOT FREEZE. With 
recommended storage, NOVANTRONE remains stable for two (2) years.
Following preparation of the infusion, the diluted solution should be stored at room 
temperature and used within 24 hours. Any original solution which remains in the vial 
should be discarded. NOTE: LIKE THE ORIGINAL SOLUTIONS, THE DILUTIONS 
SHOULD ALSO NOT BE FROZEN.
DRUG COMPATIBILITY
NOVANTRONE* should not be administered concommitantly with heparin since a 
precipitate may form. Until specific compatibility data are available, it is recom­
mended that NOVANTRONE* not be mixed in the same infusion with other drugs. 
GUIDELINES FOR SAFE USE BY HOSPITAL PERSONNEL-CONSULT THE 
PACKAGE INSERT.
CHEMISTRY
Composition
NOVANTRONE* mitoxantrone hydrochloride, a synthetic anthracenedione, is a 
potent antineoplastic agent. Its molecular formula is C222H28N „062HCI and its molec­
ular weight is 517.4. It is a hygroscopic dark blue solid supplied as a sterile, aqueous 
solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone 
free base, with sodium chloride, sodium acetate, and acetic acid as inactive ingredi­
ents. The product does not contain antibacterial preservatives. Its structural formula 
appears below.
H H
HO O NCH2CH2NCH2CH2OH
Molecular Formula: C22H28N40 6.2 HCI 
Molecular Weight: 517.4
Chemical Name: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)aminol-ethyl]amino]-
9,10-anthracenedione dihydrochloride
AVAILABILITY
NOVANTRONE mitoxantrone hydrochloride injection is supplied as a sterile aqueous 
solution at a concentration equivalent to 2 mg mitoxantrone free base per mL, and is
available in the following vial sizes:
10 mL/vial (20 mg) Product C o d e .....................................................................9393-34
12.5 mL/vial (25 mg) Product Code...................................................................9393-72
Identification
Glass vials containing 10 and 12.5 mL of a clear, dark blue solution.
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Inguinal Intranodal Blue Nevus: a Case Report
Inguinal intranodal blue nevus is a rare 
lesion, but awareness of the condition 
will avoid a mistaken diagnosis of 
metastatic melanoma. The authors 
describe the case of a 40-year-old 
woman in whom an inguinal node blue 
nevus was discovered incidentally during 
radical vulvectomy for squamous cell 
carcinoma. They describe the character­
istic light and electron microscopic fea­
tures. With increased awareness of this 
lesion the authors believe it will be found 
in lymph-node chains other than the 
inguinal and axillary ones previously 
reported.
II est rare qu'on decouvre un naevus 
bleu dans un ganglion inguinal. II faut en 
garder la possibilite a I'esprit afin d'eviter 
un diagnostic errone de melanome 
metastatique. Les auteurs decrivent le 
cas d'une patiente de 40 ans chez qui 
on a decouvert accidentellement un nae­
vus bleu dans un ganglion inguinal au 
cours d'une vulvectomie radicale pour 
epithelioma malpighien. Ils decrivent les 
caracteristiques observees aux microsco­
pes optique et electronique. Si Ton recher­
che davantage cette lesion, les auteurs 
croient qu'elle sera identifiee dans des 
chaines ganglionnaires autres que les 
chatnes inguinale et axillaire ou elles ont 
deja ete signalees.
Blue nevi are uncommon pigmented 
lesions composed of bipolar or dendritic 
melanocytes and are usually found in the 
skin. Intranodal blue nevus was first 
described as a distinct pathologic entity 
in 1977 by Azzopardi and associates.1 
Since their report of two cases, 10 other 
patients with this lesion have been 
described.2' 8 Of these 12 patients, 10 
were female and 2 male, and the axillary
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lymph nodes were involved in 8. We 
report a further case in which an ingui­
nal lymph node was involved.
Case Report
A 40-year-old multiparous Caucasian woman 
complained of a lesion on the vulva, present
for 1 month. A 1-cm raised ulcerated lesion was 
seen on the inner aspect of the left labium 
minus and there were several smaller (up to 5 
mm), slightly pigmented, macular lesions on 
the perineum and right labium. No enlarged 
lymph nodes could be palpated in either groin 
and no other genital tract lesions were noted. 
The uterus and cervix had been removed 4
HG. 1—Photomicrograph of inguinal lymph node containing intracapsular pigmented bipo­
lar nevo-melanocytes (hematoxylin and eosin, original magnification x 200).
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FIG. 2—Electron micrograph of nevo-melanocyte characterized by basement membrane 
and melanosomes at different stages of maturation (original magnification x  22 000).
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years before because of dysfunctional uterine 
bleeding.
Excisional biopsy of the left labial lesion was 
performed. Histologic examination of the 
specimen revealed a small area of squamous 
cell carcinoma with early stromal invasion aris­
ing in a background of extensive carcinoma in 
situ.
A radical vulvectomy was performed with 
en-bloc resection of the superficial inguinal 
lymph nodes bilaterally. During the right ingui­
nal dissection, a single darkly pigmented lymph 
node, measuring 1.8 cm, was noted superficial 
to the cribriform fascia.
The pigmented lymph node contained elon­
gated bipolar and dendritic cells with numer­
ous intracytoplasmic melanin granules and 
some pigment-laden melanophages (Fig. 1). 
The pigment stained positively with Masson- 
Fontana stain but negatively with Ziehl- 
Neelsen (lipofuscin) and Prussian blue (iron) 
stains. The lesion involved the capsule of the 
lymph node, extending along the fibrous 
trabeculae, but it did not involve the subcap- 
sular sinus or the nodal parenchyma. There was 
no necrosis or mitoses in this lesion and 
metastatic squamous carcinoma was not evi­
dent. Electron microscopic examination rev­
ealed a dual cell population. Some cells were 
elongated with a prominent basement mem­
brane, occasional cytoplasmic processes and 
cytoplasmic organelles, including melanosomes 
at different stages of maturation (Fig. 2). In 
addition, prominent melanophages were seen.
No residual invasive carcinoma was present 
in the vulva, but there was extensive in-situ car­
cinoma at the margins of the previous biopsy. 
The smaller pigmented lesions were multifo­
cal in-situ squamous carcinomas with features 
suggesting an associated condyloma virus infec­
tion. None of the other submitted lymph nodes 
contained melanocytes or metastatic car­
cinoma.
Discussion
Blue nevi are usually found in the skin, 
but they have also been described in the 
cervix,9-13 prostate,14 palate15 and, more 
recently, in the capsule o f lymph 
nodes.2-8 The histogenesis is uncertain 
but has been discussed by Azzopardi and 
colleagues' and Epstein and associates.6 
Briefly, the intranodal blue nevus may 
develop from a “benign metastasis” or 
passive transfer of melanocytic cells from 
a melanocytic lesion in the region drained 
by the involved lymph node. Alterna­
tively, aberrant migration of neural crest 
cells may explain the intranodal location. 
Such aberrant neurocristic cells may 
exhibit melanocytic or nerve-sheath 
differentiation,6 the latter occurring in 
this case.
Although malignant transformation of 
a dermal blue nevus is uncommon, such 
an event involving an intranodal blue 
nevus has been postulated in patients with 
metastatic melanoma in whom no pri­
mary tumour could be found.2'5,6 In a 
recent autopsy study a primary location 
could not be found in 4% of patients who 
died of melanoma.16
Eight of the 12 previously reported
cases of intranodal blue nevi involved 
axillary lymph nodes in mastectomy 
specimens of women with breast carci­
noma. Only two previous cases involved 
inguinal lymph nodes and one each a sub- 
mental and popliteal lymph node.
The two inguinal intranodal blue nevi 
previously reported were found in a 
56-year-old man who underwent surgery 
for varicose veins7 and a 20-year-old 
woman reported to have melanoma of the 
foot.8 Two of the resected inguinal 
lymph nodes in this woman were believed 
to contain metastatic melanoma. On 
review 10 years later both the lesion in the 
foot and inguinal lymph nodes were blue 
nevi.
Only two of the previously reported 
cases have involved men. The pre­
dominance of women and axillary lymph- 
node involvement is probably related to 
the frequency with which axillary lymph 
nodes are removed from women with 
breast carcinoma. We decided to report 
this case of a blue nevus in an inguinal 
lymph node because we suspect that with 
an awareness of this entity, further exam­
ples will be found in other lymph-node 
chains. Further, an enhanced awareness 
o f this relatively rare condition by both 
pathologists and surgeons will avoid a 
mistaken diagnosis of metastatic mela­
noma and a futile investigation for an 
occult primary melanoma or even unwar­
ranted further surgery.
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BOOK REVIEWS 
continued from page 246
Pathologic features that might be encoun­
tered are well illustrated by the use of colour 
pictures taken through the sigmoidoscope, giv­
ing the visual cues of size, colour and shape. 
This is the best means of conveying the image 
of possible abnormalities of the colorectum. 
These pictures will be of greatest value to the 
primary care physician who is an occasional 
sigmoidoscopist. In general, surgeons will 
recognize the pathologic conditions based upon 
experience with rigid sigmoidoscopy and 
familiarity with surgical specimens.
This book will serve the physician- 
endoscopist as a reference resource for sig­
moidoscopy. The index is reasonably complete, 
which is a primary requirement for a good 
reference source.
L ee E . Sm it h , md
Department of Surgery,
George Washington University,
2550 Pennsylvania Ave. NW,
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MANUAL ON CONTROL OF INFECTION 
IN SURGICAL PATIENTS. 2nd ed. 
American College of Surgeons Committee 
on Control of Surgical Infections of the 
Committee on Pre- and Postoperative 
Care. Edited by William A. Altemeier 
(Chmn.), John F. Burke, Basil A. Pruitt, 
Jr. and William R. Sandusky. 388 pp. 
Illust. J.B. Lippincott Company, Philadel­
phia, 1984. S35. (US). ISBN 0-397-50575-2.
The first edition of this book, published in 
1976, was a review and summary of four work­
shops on the control of surgical infection, 
organized by Dr. Altemeier between 1970 and 
1972 and attended by most active investigators 
in this field. This edition revises and updates 
the first with much of the new material com­
ing from the scientific meetings of the Surgi­
cal Infection Society, formed in 1980. The 
stated aim is to “ provide an up-to-date, read­
ily available source of information and guide 
that will be useful for the prevention and con­
trol of surgical infection in hospital practice” .
This manual provides a broad, authoritative 
database, of value to health professionals 
interested in solutions to the problems of infec­
tion. The material is well organized into dis­
tinct chapters. The commentary and references 
are often repetitive, but this has the advantage 
of allowing different groups to access areas of 
particular interest without having to read the 
entire book.
Chapters dealing with definitions and clas­
sification of surgical infections, incidence and 
cost, epidemiology and surveillance, preoper­
ative preparation of the patient, preparation 
of the operating team (attire and surgical 
scrub), preparation and maintenance of a safe 
operating-room environment, hospital design 
requirements for safe surgery, housekeeping 
techniques, laboratory support, sterilization 
and isolation, provide practical, state-of-the- 
art, authoritative information. These chapters 
are probably of greatest interest to operating- 
room nurses and supervisors, infectious-disease 
specialists, infection-control committees,
continued on page 292
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Immune Response After Gastric Bypass 
and Weight Loss
The immune response of 22 morbidly 
obese patients was measured before and 
6 months after gastric bypass. In-vivo 
skin testing was carried out using five 
recall antigens. In-vitro response 
assessed the ability of isolated lympho­
cytes to take up radioactive thymidine 
after culture with the same antigens.
The mean ( ± SD) preoperative weight of 
the patients of 122 ± 14 kg declined by 
33.5 ± 8 kg after 6 months. The num­
ber of positive skin tests increased from 
a mean (±  SEMI of 1.8 ± 0.17 to 2.1 
± 0.17 (p = 0.2). Mean (±  SEM) indu­
ration of the skin-test response assessed 
at 24 hours after antigen injection 
increased from 4.7 ± 0.6 mm to 5.5 ± 
0.6 mm (p = 0.35) and at 48 hours 
from 5.4 ± 0.7 mm to 6.9 ± 0.9 mm 
(p = 0.05). One patient who was aner­
gic before gastroplasty responded nor­
mally 6 months later after substantial 
weight loss. In-vitro response, expressed 
as a stimulation index (±  SEM), 
increased from 4.71 ± 0.65 to 7.95 ± 
1.56 (p = 0.06) for the average of all 
antigens and from 12.85 ± 2.05 to 
15.79 ± 2.84 (p = 0.2) for the largest 
response. The authors conclude that the 
response to test antigens in vitro and in 
vivo is not reduced significantly 6 
months after gastric bypass and pro­
found weight loss. Patients with severe 
vomiting, rapid weight loss or sepsis 
may respond differently and require 
individual assessment.
La reponse immunitaire de 22 patients 
souffrant d'obesite pathologique a ete 
mesuree avant et 6 mois apres derivation 
gastrique. Une intradermoreaction a ete 
pratiquee a I'aide de cinq antigenes de 
rappel. La reponse in vitro a evalue la 
capacite de lymphocytes isol6s a capter 
la thymidine marquee apres culture en 
presence de ces memes antigenes. Le
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poids moyen (±  ecart type) preopera- 
toire des patients Stait de 122 ± 14 kg 
a ete r6duit de 33.5 ± 8 kg apres 6 
mois. Le nombre d'intradermoreactions 
positives a augmente d'une moyenne (±  
erreur type) de 1.8 ± 0.17 a 2.1 ±
0.17 (p = 0.2). En ce qui concerne le 
diametre d'induration de la reaction cuta- 
n£e, la moyenne (±  erreur type) apres 
24 heures a augmente de 4.7 ± 0.6 mm 
a 5.5 ± 0.6 mm (p = 0.35) alors 
qu'apres 48 heures elle passait de 5.4 ± 
0.7 mm d 6.9 ± 0.9 mm (p = 0.05).
Un patient anergique avant gastroplastie 
a presente une reponse normale 6 mois 
plus tard apres une perte de poids impor- 
tante. La reaction in vitro exprimg sous 
forme d'indice de stimulation ( ± erreur 
type) a augmente de 4.71 ± 0.65 a 
7.95 ± 1.56 (p = 0.06) pour la 
moyenne de tous les antigenes, et de 
12.85 ± 2.05 a 15.79 ± 2.84 
<p = 0.2) pour les reactions les plus 
importantes. Les auteurs concluent que 
la reponse in vitro et in vivo aux antige­
nes de rappel n'est pas reduite significa- 
tivement 6 mois apr6s derivation gastri­
que et perte de poids importante. II est 
possible que les patients qui ont des 
vomissements importants, une perte de 
poids rapide ou une sepsie repondent dif- 
feremment et necessitent une evaluation 
individuelle.
Gastroplasty and gastric bypass are fre­
quently performed for the management 
o f morbid obesity. MacLean and 
associates1 found that a substantial 
proportion of these patients have become 
m alnourished postoperatively. In 
developing countries malnourishment is 
known to be associated with an impaired 
host immune response.2,3 Meakins and 
colleagues4,5 have used skin testing to 
predict postoperative complications. 
Since patients who undergo gastroplasty 
may require further operations urgently 
for problems such as stomal obstruction 
or electively for management of hernias, 
gallstones or dependent skin, it seemed 
appropriate to assess the skin-test 
response in a group of obese patients after 
gastroplasty. We chose 6 months as a 
suitable time for postoperative follow-up,
since most weight loss occurs within this 
period. We evaluated the skin-test 
response by the techniques of Meakins 
and an in-vitro test of cellular immunity 
that has been useful in monitoring 
patients who have undergone transplan­
tation.6
Patients and Methods
Twenty-two morbidly obese patients (2 
men, 20 women) ranging in age from 20 
to 60 years (mean [±SD ] 41 ± 9  years) 
were admitted to University Hospital in 
London for gastric bypass. All weighed 
more than twice the ideal weight. A Roux- 
en-Y gastric bypass was done in all. At 
least 2 days before operation skin testing 
was carried out using five recall antigens 
(Candida, mumps, purified protein 
derivative [PPD], Trichophyton and Var- 
idase); 0.1 ml of antigen was injected 
intradermally as described by others.4 
The area of induration was measured at 
24 and 48 hours and a test considered 
positive if the diameter of induration was 
greater than 5 mm. The test was repeated 
6 months after operation. A mean skin- 
test response was also calculated by meas­
uring the diameter of induration for each 
antigen, adding the values and dividing 
by five. This score was calculated 24 and 
48 hours after antigen injection, before 
and 6 months after operation.
For in-vitro testing the procedure was 
carried out as described previously for 
cell-mediated lym phocytotoxicity.6 
Before testing, 40 ml of blood was drawn 
from each patient. Lymphocyte separa­
tion was carried out by a Ficoll-Hypaque 
technique. Cells were made up to a con­
centration of 2 X 106 ml and suspended 
in tissue culture medium (RPMI) with 
20% heat-inactivated autologous serum 
or A serum. Tests were carried out in 
triplicate on microtitre plates using 0.1 ml o f cells and 0.1 ml of medium con­
taining antigen, giving a final cell num­
ber of 1 x  105 cells and a serum concen­
tration of 10%. Controls included 1 x  
105 cells in 0.1 ml of 20% A serum in 
RPMI, 1 x  105 cells in 0.1 ml o f 20% 
autologous serum in RPMI and 1 x  105 
cells in 0.1 ml of RPMI medium only.
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Antigen dilutions were Candida (Bencard 
Allergy Service, Division of Beecham 
Laboratories, Weston, Ont.) 1/100 and 
1/200, mumps (Eli Lilly, Co., Scar­
borough, Ont.) 1/200 and 1/400, PPD 
(Connaught Laboratories, Toronto, Ont.) 
0.2 mg and 0.02 mg, Trichophyton 1/100 
and 1/200 and Varidase (Bencard Allergy 
Service) 0.1 ml (5 units streptokinase and 
1.2 units of streptodornase or 0.5 units 
streptokinase and 0.12 units streptodor­
nase). Cells were incubated for 4 days at 
37°C with 5% carbon dioxide and then 
pulsed with 1 /rCi of 3H-thymidine for 16 
hours. After harvesting, each plate was 
counted for 5 minutes in a B counter. 
Blastogenic response was recorded as a 
stimulation index: the mean count per 
minute of stimulated cells divided by the 
mean count per minute for control cells. 
The test was repeated 6 months later. 
Twenty values were obtained for each 
patient at each testing since there were 
two dilutions of each of the five antigens 
and all tests were carried out in autolo­
gous and A sera. The mean of all values 
was obtained for each patient preopera- 
tively and postoperatively. The changes 
in the largest stimulation index were also 
calculated for each patient, since this was 
assumed to be the antigen to which the 
patient was most sensitized preoperatively 
and which might show the greatest change
after weight loss. The paired f-test was 
used to compare results before and after 
operation.
Patients were seen preoperatively and 
postoperatively in hospital by a dietician 
and given diet sheets to take home. They 
were followed up by their family doctor 
and seen monthly at our obesity clinic. 
High protein intake was encouraged but 
exact caloric intake was not assessed. 
Multiple vitamins containing iron were 
taken by all patients.
Results
The average weight of the patients 
immediately preoperatively was 122 ± 14 
(SD) kg. Six months later the average 
weight had decreased to 86 ± 11 kg. 
Results of skin testing and in-vitro 
response are summarized in Table I. 
Response tended to increase rather than 
decrease postoperatively, but the change 
was not significant. Skin testing was con­
sidered normal or reactive if there was a 
positive response (induration greater than 
5 mm) to two or more antigens. Response 
to only one antigen indicated relative 
anergy and no response indicated anergy. 
Table II compares the mean skin-test 
score (diameter of induration in mil­
limetres per antigen) before and 6 months 
after operation. Again the response 
tended to improve although only the
Table 1- Immune Response After Gastroplasty in 22 Patients*
Measurement of
immune response Preoperative Postoperative p value
No. positive skin tests 1.8 ± 0.17 2.1 ± 0.17 0.2
Average stimulation index 4.71 ± 0.65 7.95 ± 1.56 0.06
Largest stimulation index 12.85 ± 2.05 15.79 ± 2.84 0.2
'Figures are mean ± standard error.
Table 11-Mean Skin-Test Response per Antigen Before and After 
Gastroplasty*
Time of measurement 
after antigen injection, h
Induration diameter, mm
Preoperative Postoperative p value
24 4.7 ± 0.6 5.5 ± 0.6 0.35
48 5.4 ± 0.7 6.9 ± 0.9 0.05
’ Figures are mean ± standard error.
Table Ill-Skin-Test Response After Gastroplasty in 22 Patients
Response Preoperative Postoperative
Normal 17 17
Relative anergy 4 5
Anergy 1 0
Table IV—Change in Immune Response Related to Weight Loss
No. of Weight loss,
Change Preoperative Postoperative patients %
Improved Anergy Normal 1 25
response Relative anergy Normal 3 28
Same response Relative anergy Relative anergy 1 26
Normal Normal 14 29
Worse response Normal Relative anergy 3 24
result read after 48 hours was significant 
(p = 0.05). Table III indicates the 
proportion of patients in each category 
before and after operation and Table IV 
shows the change in immune response 
relative to weight loss.
Review of clinical data revealed no 
unusual features except in the patient who 
was anergic preoperatively. He underwent 
a transverse gastroplasty reinforced with 
Marlex around a greater curve channel. 
An umbilical hernia was also repaired. 
His weight at the time of operation was 
180 kg and his height 188 cm. Initial 
recovery was uncomplicated and he was 
discharged 8 days after operation. Over 
the next 2 months excessive vomiting was 
a major problem and upper gastrointes­
tinal series with barium confirmed that 
the stoma was narrow and gastric emp­
tying delayed. Within 2 months of oper­
ation he had lost 40 kg (22% of body 
weight). Because of continued vomiting, 
the gastric bypass was revised within 3 
months of operation. Skin testing before 
reoperation showed that he was anergic. 
Postoperative recovery and his subse­
quent course were smooth. One year later 
his weight was 104.6 kg.
Discussion
Our patients, who recovered from gas­
tric bypass without complications and lost 
27% of body weight in 6 months, showed 
no significant reduction in immune 
response. In fact there was a tendency for 
the test results to improve although the 
changes approached statistical sig­
nificance only for the mean skin-test score 
48 hours after antigen injection. Studies 
in a larger number of patients might show 
a significant increase in skin-test and in- 
vitro immune response for all tests. 
Preoperatively, many obese patients ate 
a poorly balanced diet high in fat and car­
bohydrate. Postoperatively, the diet is 
low in calories but should be high in pro­
tein and vitamins. The improved diet 
could explain the tendency for immuno­
logic test results to improve.
The fact that four of our patients were 
relatively anergic before gastroplasty is 
surprising and unexplainable. In a group 
of 727 patients with a variety of health 
problems preoperatively, including cancer 
and sepsis, 18% were relatively anergic 
and 12% anergic.5 In the same study, 25 
morbidly obese patients all had normal 
preoperative skin-test results. It is not 
clear whether our results are due to faulty 
technique, since skin testing is difficult to 
interpret,7 or whether our patients were 
abnormal before gastroplasty. Measure­
ment of the skin-test response using seven 
rather than five antigens in a multitest 
may give a more standardized assessment 
of cell-mediated immunity,8 but the 
small size of the reaction is difficult to 
read.
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The one anergic patient should have 
been excluded from the study because of 
a prior gastroplasty, but he demonstrates 
that anergy can occur. We were fortunate 
that he did well following a revision gas­
troplasty. In retrospect he should have 
been placed on parenteral nutrition to 
counteract the excessive preoperative 
weight loss. The lack of skin-test response 
was an even stronger indication for delay­
ing operation. Placement of a feeding 
tube was not possible because of a 
stenotic stoma, but a smaller operation 
such as jejunostomy would have allowed 
correction of his nutritional deficit before 
the major revision. Such procedures have 
proven useful after gastroplasty.9
Whether patients are malnourished 
after gastric stapling operations is a con­
troversial matter. One study,1 using 
sophisticated methods to determine the 
sodium to potassium ratio, showed that 
patients suffered serious malnutrition 
after gastroplasty. Another study10 that 
determined body-cell mass by whole-body 
counting after gastric bypass showed that 
lean mass was preserved although tem­
porarily reduced early after operation. 
Protein malnutrition does not always 
affect the immune response.11 Anergy 
may be more important than nutritional 
status in predicting susceptibility to infec­
tion .12 However, other clinical studies13 
suggested that nutritional data can predict 
postoperative complications.
In our study immunosuppression was 
not detected 6 months after gastric 
bypass. Testing early postoperatively 
might have demonstrated a change in 
skin-test responsiveness.8 Although most 
of the weight loss occurs in the first 6 
months, the most rapid loss occurs dur­
ing the first 3 months, when immunologic 
testing might have shown a reduced 
response. For patients requiring emer­
gency reoperation after gastroplasty or 
gastric bypass, there is no time for nutri­
tional or immunologic assessment. When 
elective operations such as cholecystec­
tomy, hernia repair or abdominal lipec- 
tomy are performed, nutritional assess­
ment is important. For most patients 
clinical judgement may be as useful as 
immunologic testing in predicting 
postoperative complications.14 For the 
exceptional case in which the patient has 
severe vomiting or excessive weight loss, 
skin testing may help to determine the 
need for parenteral nutrition and delayed 
operation. In some patients sepsis must 
be treated and abscesses drained before 
anergy can be corrected.15
In conclusion, most patients will have 
no detectable change in skin-test response 
or in-vitro tests of cellular immunity 6 
months after gastric bypass and substan­
tial weight loss. Careful dietary advice 
and regular follow-up are essential to 
maintain nutritional status and allow 
early detection of complications.
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SESAP V Critique
ITEM 44
Carcinoma of the pancreas is not amenable to surgical excision of the tumor for most patients. Relief of biliary and 
duodenal obstruction and reduction of pain are the goals of palliative operation. Percutaneous intubation of the bile duct 
under radiographic control relieves biliary obstruction in many patients, but does not relieve duodenal obstruction and 
may be associated with major morbidity related primarily to sepsis and hemorrhage.
Biliary enteric bypass via the gallbladder is possible only if gallstones are absent, the gallbladder is healthy, and the 
cystic duct is not obstructed. Distention of the gallbladder, which may be associated with tumor encroachment on the 
cystic duct, is not a reliable indication of cystic duct patency. If the gallbladder cannot be used, biliary bypass should 
be by choledochojejunostomy.
Obstruction of the duodenum occurs in up 30% of patients with pancreatic carcinoma. Obstruction may occur in 
the duodenal sweep and also in the fourth portion of the duodenum. If gastrojejunostomy is performed only for patients 
with established duodenal obstruction, 13% of patients not undergoing bypass subsequently develop duodenal obstruc­
tion. Whether the duodenum should be bypassed with gastrojejunostomy will require surgical judgement depending on 
the operative findings.
Drainage of the obstructed pancreatic duct has been described, but its value has not been demonstrated. U tubes 
are contraindicated for patients with pancreatic cancer and obstructive jaundice.
cT
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Needle-Guided Breast Biopsy for Mammographic Abnormalities
in 561 Patients
Between 1977 and 1983, 561 consecu­
tive patients underwent 595 surgical 
biopsies for suspicious mammographic 
lesions with negative clinical correlation. 
The procedure consisted of preoperative 
needle localization, with or without 
immediate radiologic examination of the 
biopsy specimen, depending on the 
presence or absence of microcalcifica­
tions in the mammographic lesion. 
Eighty-four carcinomas were found. Of 
these, 60 (7 1 % ) were infiltrating carci­
noma and 24 (29% ) were noninvasive 
carcinoma. The carcinoma yield was 
24.2%  in the patients with lesions 
involving foci of microcalcifications and 
9 %  in those lesions without calcifica­
tions. Surgical treatment of infiltrating 
carcinoma consisted of 39 modified radi­
cal mastectomies, 10 (2 5 .6% ) of which 
were associated with positive nodes, 16 
partial mastectomies with axillary dissec­
tion, 3 (18 .7% ) of which were 
associated with positive nodes, and 5 
wedge resections. Treatment of noninva­
sive carcinoma consisted of 19 partial 
mastectomies with axillary dissection 
and 5 modified radical mastectomies. 
None of these were associated with 
positive nodes. Modified radical mastec­
tomy was used with decreasing fre­
quency. Of the 10 patients with infiltrat­
ing carcinoma and positive axillary nodes 
treated by modified radical mastectomy, 
7 had one to three involved nodes and 3 
had four or more; of those with positive 
nodes treated by partial mastectomy, 1 
had one to three involved nodes and 2 
had four or more. These results confirm 
the correlation between suspicious mam­
mographic non-clinical lesions and breast 
carcinoma.
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De 1977 d 1983, 561 patientes cons6- 
cutives ont subi 595 biopsies chirurgica- 
les pour des lesions suspectes a la mam- 
mographie, en I'absence de correlation 
clinique. L'intervention a consiste en une 
localisation de I'aiguille en preop£ratoire, 
avec ou sans examen radiologique imme- 
diat du materiel de biopsie, selon que 
Ton avait deceie ou non des microcalcifi­
cations a la mammographie. Quatre- 
vingt-quatre lesions cancereuses ont 6te 
trouvees. Parmi celles-ci, 60 (71%) 
etaient des cancers infiltrants et 24 
(2 9 % ) des tumeurs non envahissantes.
Le rendement de lesions cancereuses 
etait 24 .2 %  chez les patients avec les 
calcifications. Dans les cas de tumeurs 
infiltrantes, on a procede e 39 mastecto­
mies radicales modifiees dont 10 
(2 5 .6 % ) ont mis en evidence des gan­
glions positifs, 16 mastectomies partiel- 
les avec dissection axillaire dont 3 
(1 8 .7 % ) ont ete associees e des gan­
glions positifs et 5 resections cuneifor- 
mes. Le traitement des cancers non 
envahissants s'est fait, chez 19 patien­
tes, par resection partielle avec dissec­
tion axillaire et, chez 5, par mastectomie 
radicale modifiee. Dans aucun cas, on 
n'a mis en evidence des ganglions posi­
tifs. La frequence des mastectomies radi­
cales modifiees est aliee en decroissant. 
Des 10 patientes porteuses de cancers 
infiltrants avec ganglions axillaires posi­
tifs et qui ont subi une mastectomie radi­
cale modifiee, 7 avaient une atteinte de 
un a trois ganglions, alors que 3 avaient 
une atteinte de quatre ganglions ou plus; 
parmi cedes qui avaient des ganglions 
positifs et qui ont ete traitees par mas­
tectomie partielle, 1 avait un envahisse- 
ment de un e trois ganglions et 2 avaient 
quatre ganglions positifs ou plus. Ces 
resultats confirment la correlation obser- 
vee entre les lesions suspectes a la 
mammographie, sans manifestation clini­
que, et le cancer du sein.
Over the last 40 years there has been a 
trend toward conservatism in the surgi­
cal treatment of breast carcinoma, from
Halsted’s radical mastectomy, then modi­
fied radical mastectomy to the present- 
day controversial wedge resection or par­
tial mastectomy with an axillary dissec­
tion. Also, the use of mammography by 
both the primary physician and in breast 
screening programs has increased. This, 
combined with the development o f fine- 
grain film and dedicated equipment, has 
greatly increased the accuracy and iden­
tification o f clinically nonpalpable 
lesions, thus posing the challenge o f how 
to manage the patient found to have sus­
picious changes on mammography. In 
1971, Gallagher and Martin1 introduced 
the term “ minimal breast carcinoma” , 
defining it as a carcinoma less than 0.5 
cm in size. However, the term has come 
to represent most clinically occult lesions, 
up to and including those 1.0 cm in size, 
which for years were considered to have 
a more favourable prognosis because of 
their small size and earlier detection.
Patients and Methods
Mammograms from 561 women were 
evaluated by one radiologist who recom­
mended biopsy on the basis o f the follow­
ing criteria.
• M icrocalcifications present: (a) 
Clusters of fine, irregular calcifications of 
different shapes, sizes and density. The 
finer the granules and the greater the 
number, the more likelihood there is of 
a malignant lesion, (b) Lace-like branch­
ing linear groups of microcalcifications 
that may or may not be associated with 
nodular densities.
• No microcalcifications: (a) Irregular 
nodular densities, (b) Asymmetric densi­
ties. (c) Focal structural parenchymal 
alterations with a fluffy or stellate 
appearance.
During the period January 1977 to 
December 1983, 595 procedures were car­
ried out by one surgeon using a technique 
of needle localization as follows. In the 
mammography unit, just before surgery,
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the lesion is noted on the preoperative 
films in the craniocaudal and mediolateral 
projections, and the distance of the lesion 
from the middle of the nipple is measured 
in both the horizontal and vertical planes 
on both projections. The depth of the 
lesion is measured on the projection in 
which the lesion is closer to the skin. The 
appropriate needle size is selected. Nee­
dles used were 25 gauge x  5/8 inch and 
22 gauge x 1'A inches for more superfi­
cial lesions and 22 gauge x 3!4 inches for 
deeper lesions. The needle is securely 
anchored to the skin with Steristrips and 
a two-view mammogram is obtained. If 
not sufficiently close, the needle is reposi­
tioned without complete removal and 
mammography is repeated. Once a satis­
factory needle position has been obtained, 
the patient is transferred to the operat­
ing room and under general anesthesia 1.0 
ml of toluidine blue is injected as the 
needle is withdrawn. Incisions are made in 
the areola where possible or along natural 
skin lines and the suspect, stained tissue 
is excised. The amount of tissue removed 
is minimal and the cosmetic results are 
excellent. Meticulous hemostasis is 
obtained, no reconstruction is done and 
drainage is not used.
If a clinically obvious carcinoma is 
demonstrated, quick-section examination 
is performed and a specimen sent for 
determination of estrogen and progester­
one receptors. All other specimens 
undergo routine pathological examina­
tion. In biopsies taken because of the 
presence of microcalcifications the calcifi­
cations are confirmed by tissue radiogra­
phy and an additional separate biopsy is 
done at the same time if required (as in 
approximately 3% of our procedures). 
Areas of microcalcification are tagged for 
the pathologist, who also has the benefit 
of the tissue x-ray films. Mammography 
of the biopsied breast is done 3 months 
postoperatively to verify that the suspi­
cious lesion has been excised. This is 
preferably performed in the same insti­
tution as the initial procedure. Fewer than 
six patients required re-excision for 
missed lesions or inadequate excision. 
One patient in this group was found to 
have noninvasive carcinoma.
Results
The 595 biopsies yielded 84 carcinomas 
(14.1% of procedures or 15.0% of 
patients). Of these carcinomas, 60 
(71.4%) were of the infiltrating type and 
24 (28.6%) were noninvasive. Carcinoma 
was found in 49 (24.2%) of the 202 biop­
sies done for microcalcifications. Biopsies 
undertaken for lesions without microcal­
cifications yielded a positive result in only 
9%.
Further surgical treatment consisted of
the following. Of the 60 women with 
invasive carcinoma, 39 underwent modi­
fied radical mastectomy; 10 (25.6%) had 
involved axillary nodes. Sixteen had par­
tial mastectomy with axillary dissection 
and 3 (18.7%) had axillary node involve­
ment. Because they refused further treat­
ment or because of referral back to the 
original surgeon, five women had wedge 
resection only. Thus, 13 of the 55 patients 
with infiltrating carcinoma at the time of 
detection already had axillary involve­
ment with the clinically occult lesion.
Of the 24 patients with noninvasive car­
cinoma, 19 underwent partial mastectomy 
with axillary dissection and 5 had a modi­
fied radical mastectomy. None had axil­
lary node involvement.
The frequency of modified radical 
mastectomies decreased during the series, 
because of a change in philosophy in the 
management of breast carcinoma. Now, 
patients with focal areas of noninvasive 
cancer are treated by wedge resection only 
and closely followed up.
Discussion
We emphasize the use of dedicated 
equipment, proper compression technique 
and dedicated technologists and radiolo­
gists. To acquire expertise in this proce­
dure, the radiologist should have follow­
up data on all patients who have had 
breast biopsy recommended as a result of 
mammographic findings. This will 
increase diagnostic confidence and 
decrease mammographic overcall. In our 
view, it is necessary to have preoperative 
localization of the lesion verified by mam­
mography. We see no virtue in inserting 
a needle preoperatively and not accurately 
localizing the lesion.2 Even when per­
formed by radiologists experienced in the 
procedure, needle localization on the first 
attempt may be inaccurate, requiring a 
reinsertion and further mammographic 
verification. Without this visual guidance 
the surgeon is operating “ blind” .
In their series, Schwartz and 
colleagues3 reported a 31.4% incidence 
of carcinoma. The largest group had 
lesions 1 to 2 cm in diameter, which 
would not be considered minimal breast 
cancer. Fewer than six patients with 
infiltrating cancer in our series did not 
fulfil the criteria of minimal breast cancer 
in its broader definition. Schwartz and 
associates also reported a 37.8% inci­
dence of axillary node involvement in 
patients with infiltrating cancer. Some of 
their patients had disseminated disease at 
the time of surgery but we could not 
document a single such case by conven­
tional testing. The differences may be 
explained by different criteria of opera­
bility. Powell and colleagues4 looked 
only at those patients with microcalcifi­
cations and noted a 17% incidence of car­
cinoma and a 9% incidence of axillary 
involvement.
All these reports confirm the simplic­
ity of the procedure and the lack of seri­
ous morbidity, indicating that it is an 
effective tool in the armamentarium of 
the surgeon treating breast disease.
Conclusions
With the increased use of screening, 
suggestive changes found on mammogra­
phy should be dealt with early and 
aggresssively owing to the substantial 
correlation with carcinoma. The term 
“aggressive” is not used to denote radi­
cal in the surgical sense, but early inter­
vention as opposed to a “ wait-and-see” 
attitude. Occult lesions can frequently be 
managed with conservative surgery.
It is time we discarded the notion that 
minimal breast carcinoma is not serious. 
In our series, almost 25% of clinically 
occult invasive breast cancers were 
associated with axillary involvement at 
the time of surgery. However, this 
represents a 50% decrease in axillary node 
involvement over carcinomas that present 
clinically and thus should result in 
improved survival.
Addendum
We have recently become concerned by the 
low cancer yield from mammographic lesions 
without calcification that have been described 
as either irregular nodular densities or asym­
metric densities. Repeat mammography on the 
day of surgery has often failed to confirm a 
lesion and the proposed surgery has been can­
celled. The discrepancy may be due to techni­
cal factors or regression of an area of benign 
breast disease. We now repeat the mammog­
raphy before scheduling an operation. This 
policy, we believe, will reduce the number of 
unnecessary biopsies.
We thank Miss Morag M. Simpson for typ­
ing the manuscript.
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Effect of Total Parenteral Nutrition 
on Biliary Lipids in Neonates
To study the effect of total parenteral 
nutrition (TPN) on biliary lipids in criti­
cally ill neonates, biliary lipid concentra­
tions were determined in 13 neonates 
before starting TPN, in 8 receiving TPN 
for up to 2 weeks and in 9 receiving 
TPN for up to 8 weeks. Bile was very 
dilute in the 13 neonates not receiving 
TPN owing to a low concentration of bile 
acids. In many the bile-acid concentra­
tion was below the critical micellar con­
centration, thus cholesterol in bile was 
not dissolved. The neonates receiving 
TPN for up to 2 weeks showed a marked 
increase in bile-acid content and had 
levels above the critical micellar concen­
tration. This apparently beneficial effect 
of TPN disappeared after 2 weeks and 
neonates who received TPN for 3 to 8 
weeks again had bile-acid levels below 
the critical micellar concentration. Three 
conclusions may be drawn from this 
study: (a) in the fasting state before TPN 
is begun, the cholesterol content of bile 
relative to phospholipid and bile acids 
increased in linear fashion during the 
fasting period; (b) short-term TPN of up 
to 2 weeks' duration was associated 
with an increased bile-acid content to 
levels at which cholesterol could be dis­
solved; (c) neonates on long-term TPN
From the *Department o f Surgery and the tDivision o f  Medical Biochemistry, the University o f Alberta and University o f  Alberta Hospital, Edmonton, Alta.
Presented at the annual meeting o f  the Canadian Association o f Pediatric Surgeons held in conjunction with the 54th annual meeting o f the Royal College o f  Physicians and Surgeons o f Canada, Vancouver, BC, Sept. 9, 1985
Supported by the Special Services and Research Fund, University o f  Alberta Hospital
Accepted for publication Dec. 16, 1985
Reprint requests to: Dr. Olin G. Thurston, 11-104D Clinical Sciences Bldg., The University o f Alberta, Edmonton, Alta.T6G 2G3
and no oral intake secrete extremely 
dilute bile with an insufficient concentra­
tion of bile-acid molecules to form 
micelles to dissolve cholesterol. This 
finding may explain some of the adverse 
hepatobiliary changes associated with 
long-term administration of TPN.
Dans le but d'etudier les effets de I'ali­
mentation parentgrale complete (APC) 
sur les taux de lipides biliaires du 
nouveau-ne gravement malade, les con­
centrations de lipides biliaires ont ete 
mesures chez 13 nouveau-nes sur le 
point de recevoir I'APC, chez 8 qui rece- 
vaient de I'APC depuis 2 semaines au 
maximum et chez 9 qui avaient ete sous 
APC pour une periode allant jusqu'd 8 
semaines. La bile des 13 nouveau-nes 
qui n'avaient pas requ d'APC etait tr6s 
diluee a cause de la faible concentration 
en acides biliaires. Chez plusieurs, la 
concentration d'acide biliaire etait en 
deca de la concentration micellaire criti­
que de sorte que le cholesterol n'etait 
pas dissous dans la bile. Les nouveau- 
nes qui avaient recu de I'APC pour une 
periode allant jusqu'a 2 semaines presen- 
taient une augmentation marquee de la 
teneur en acide biliaire, au dessus de la 
concentration micellaire critique. Cet 
effet benefique apparent de I'APC avait 
disparu apres 2 semaines et les nouveau- 
nes qui avaient et6 sous APC pour de 3 
a 8 semaines avaient de nouveau des 
taux d'acides biliaires sous la concentra­
tion micellaire critique. De cette etude, 
trois conclusions peuvent etre tirees: 
a) avant la mise en route de I'APC, la 
teneur en cholesterol de I'acide biliaire 
relative aux phospholipides et aux acides 
biliaires augmente de fagon lineaire pen­
dant la pgriode de jeune; b) a court 
terme (jusqu'a 2 semaines) I'APC est 
reliee a une augmentation des acides 
biliaires jusqu'd des concentrations per- 
mettant la dissolution du cholesterol; c) 
les nouveau-nes sous APC £ long terme 
qui ne sont pas alimentes par la bouche 
secretent une bile extremement diluee 
dont la teneur en molecules d'acides 
biliaires est insuffisante pour former les 
micelles necessaires pour dissoudre le
cholesterol. Ces resultats sont capables 
d'expliquer quelques uns des change- 
ments hepatobiliaires indesirables qui 
sont relies e I'APC a long terme.
Disturbances o f hepatobiliary function 
are common in patients of all ages receiv­
ing total parenteral nutrition (TPN) in 
place of normal oral alimentation.1 3 
Although TPN has been implicated by 
association as the cause o f these condi­
tions, it is difficult to separate the effects 
of TPN from those of prolonged fasting, 
underlying disease and, in neonates, liver 
immaturity. In neonates in an intensive 
care unit we studied biliary lipid 
(cholesterol, phospholipid and total bile 
acid) concentrations during the fasting 
state of up to 6 days before the start of  
TPN and for up to 8 weeks after.
Patients and Methods
Thirty neonates were divided into three 
groups. Group 1 (control) consisted of 13 
babies who were fasting for up to 6 days 
before the initiation of TPN and were 
maintained on dextrose-electrolyte solu­
tion administered by peripheral vein. 
Group 2 comprised eight neonates on 
TPN for up to 2 weeks with no oral 
intake. In group 3 were nine patients who 
were on TPN for 3 to 8 weeks with no 
oral intake. Table I shows the incidence 
of neonatal jaundice and gastrointestinal 
disorders (predominantly necrotizing 
enterocolitis) affecting the enterohepatic 
circulation in the three groups. The inci­
dence of neonatal jaundice in group 3 was 
less than in group 1 (p < 0.05), reflect­
ing the older age o f the neonates in the 
former group. The proportion of infants 
with gastrointestinal disorders did not 
differ significantly in the three groups. 
The groups were also similar in regard to 
gestational age, birth weight and weight 
at the time of study (Table I). Infants in 
group 3 tended to be heavier at the time 
of bile sampling, but the differences were 
not significant. None of the mothers had received phenobarbital before delivery.4
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The infants in groups 2 and 3 received 
TPN through a centrally-placed catheter. 
The amount of TPN was increased gradu­
ally and stabilized at a daily rate of 2.0 
to 2.5 g/kg protein (Travasol; Travenol 
Canada Inc., Mississauga, Ont.), 2.0 to 
3.0 g/kg fat (Intralipid; Cutter Labora­
tories, Mississauga, Ont.) and 12 to 15 
g/kg glucose. Electrolytes, vitamins and 
trace elements were added to the TPN 
solution.
Collection and Analysis o f  Bile Specimens
Duodenal bile was obtained by duo­
denal intubation using a no. 5 to 8 
French, soft rubber catheter passed with 
the patient positioned on the right side. 
The duodenal position of the tube was 
determined by pH monitoring (more than 
6.5) and colour o f the aspirate (yellow). 
Whenever possible tube position was veri­
fied by an x-ray film taken for other pur­
poses (e .g ., pneum othorax, pneu­
moperitoneum) or by palpation at the 
time of laparotomy. Gallbladder contrac­
tion was induced 20 minutes before we 
collected the bile specimen, by instilling 
an amino-acid solution (0.5 to 1.0 ml/kg 
o f 10% Travasol) into the duodenum. 
Bile-rich duodenal juice was then aspi­
rated over 1 to 2 hours to give a 1- to 
3-ml specimen. Bile specimens were 
taken to the laboratory immediately after 
collection where they were extracted and 
refrigerated until they were analysed for 
lipid content.
The molar concentrations o f choles­
terol, phospholipid and total bile acids 
were determined for each specimen; from 
these data the total biliary lipid concen­
tration was calculated. Cholesterol con­
centration was determined by an enzy­
matic colorimetric method using the 
Abbott bichromatic analyser — ABA-100 
(Abbott Laboratories, South Pasadena, 
Calif.).5 Phospholipid concentration was 
measured by the method o f Sunderman 
and Sunderman6 using the Unicam spec­
trophotometer (Pye Unicam Ltd., Cam­
bridge, UK) at 675 nm. The enzymatic 
determination o f total bile acids was car­
ried out using the method of Engert and 
Turner7 and the Beckman DU-8 spec­
trophotometer (Beckman Instruments, 
Fullerton, Calif.) at 340 nm.
We attempted to portray the biliary 
lipid data on triangular coordinates and 
to use Carey’s tables8 for cholesterol 
solubility in bile; however, the extremely 
dilute nature o f bile in the premature 
neonate puts most specimens out of the 
range of these devices. The data are 
presented as a percentage o f total lipid 
millimoles and total lipid concentration 
with reference to cholesterol solubility in 
bile in only group 1. Tests o f statistical 
significance (Student’s /-test for unpaired 
data, X2 test and linear regression analy­
sis) were done using a Hewlett-Packard 
97 programmable calculator (Hewlett- 
Packard [Canada] Ltd., Mississauga, 
Ont.).
The study was approved by a Univer­
sity of Alberta, Faculty of Medicine, Ethi­
cal Review Committee. Parental consent 
was obtained after a full explanation of 
the study as was the consent of a neona- 
talogist who was not involved in the 
study.
Results
The concentration of lipids in the bile 
of neonates studied was extremely dilute 
compared with the generally stated range 
for normal adults (Fig. 1, Table II). 
Dilute bile was noted in all three groups
Table 1—Infant Data
Group 1 Group 2 Group 3
Feature (n -  13) (n = 8) (n = 9)
Male/female 8/5 4/4 4/5
Duration of total parenteral
nutrition, wk 0 2 3-8
Neonatal jaundice, no.* 10 5 3
Gastrointestinal disorder, no. 8 7 8
Gestational age, wk (x ± SEM) 33.3 ± 1.2 33.8 ± 1.6 32.8 ± 1.8
Birth weight, g (x ± SEM) 1892 ± 201 1784 ± 213 1858 + 297
Weight at time of testing, g
(x ± SEM) 1938 ± 192 2070 ± 223 2651 ± 357
'Group 1 vs group 3 p < 0.05.
Table II—Lipid Concentrations for the Three Groups of Neonates*
Lipid values Group 1 Group 2 Group 3
Total bile, g/L 1.17 ± 0.19 2.49 ± 0.49 0.77 ± 0.10
Cholesterol, mmol/L 0.30 ± 0.05 0.40 ± 0.05 0.23 + 0.04
Phospholipid, mmol/L 0.70 ± 0.16 0.67 ± 0.10 0.56 ± 0.08
Total bile acids, mmol/L 1.04 ± 0.18 3.67 ± 0.88 0.50 ± 0.12
'Normal adult range of total biliary lipid concentration is 3 to 300 g/L.
but particularly in groups 1 and 3. The 
total biliary lipid concentrations of only 
three specimens, all from group 2, fell 
within the lower limits of the normal adult 
range.8
When total biliary lipid concentration 
is broken down into the three components 
(cholesterol, phospholipid and total bile 
acids), it is apparent that cholesterol and 
phospholipid concentrations in bile 
changed little in the three groups (Table 
II). Total bile-acid concentration showed 
a large increase in group 2 compared with 
groups 1 and 3 and accounts for the in­
crease in total biliary lipid concentrations 
seen in that group (Fig. 2, Table II).
The critical micellar concentration 
(CMC) or minimum concentration at 
which micelles start to form for bile acids 
in bile is 0.9 to 2.2 mmol (mean 1.45 
mmol).9'10 Five o f the 13 neonates in 
group 1 showed bile-acid concentrations 
below the CMC. In group 2 in which bile- 
acid concentration was much higher, all 
bile specimens were at or above the CMC. 
In group 3 the concentrations of only two 
specimens were at the lower range of the 
CMC for bile acids and in the remaining 
seven, specimens were clearly below the 
CMC (Fig. 3).
In group 1 patients (control group), the 
relation between cholesterol in bile 
expressed as a percent of total lipid mil-
FIG. 1—Total biliary lipid concentration 
(g/L) in groups 1, 2 and 3 (mean ± SEM). 
Shaded area indicates normal range for total 
biliary lipid concentration.
B ile  A c id  
C o n c e n tra t io n  
in  B ile
P h o sp h o lip id  
C o n c e n tra t io n  
in  B ile
C h o le s te ro l 
C o n c e n tra t io n  
in  B ile
2.0 - 
1.0 - 
o*— E%2PG ro up  1 G ro up  2 G ro up  3
FIG. 2—Concentrations of cholesterol, 
phospholipid and bile acids (mmol/L) in bile 
(mean ± SEM).
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limoles and duration of the fasting period 
in days was linear (y = -  18.72 + 7.37x) 
with a correlation coefficient of 0.90 (Fig. 
4). This temporal relation did not apply 
in groups 2 and 3 and or to phospholipid 
or bile acids in any group. This relation 
between biliary cholesterol and fasting is 
also seen in normal adults in whom bile 
tends to become supersaturated with 
cholesterol during fasting. In Fig. 4 we 
have indicated the cholesterol solubility 
line of Admirand and Small11 (at 
approximately 10% cholesterol-percent of 
total millimoles) as a reference point.
Discussion
A notable finding in this study was that 
the infants in groups 1 and 3 had ex­
tremely dilute bile compared with that 
of adults8 and full-term infants.4 This 
was owing mainly to the small amount of 
bile acid present in the bile obtained from 
the duodenum. This observation is con­
sistent with the finding that the functional
C ritica l M icellar 
C oncen tra tion  
o f B ile  Acids 
in Bile
FIG. 3—Total bile-acid concentrations 
(mmol/L). Shaded area indicates critical micel­
lar concentration of bile acids in bile.
maturity of the liver is reduced in prema­
ture infants, whose livers cannot carry out 
the complex functions of synthesizing bile 
acid from cholesterol, conjugating the 
bile acid with glycine or taurine and 
secreting the conjugates into bile. The 
most important finding was that bile 
became more concentrated in the 
neonates in group 2 who received TPN 
for up to 2 weeks due to a large increase 
in bile-acid content. Short-term TPN 
appeared to provide substrate for bile- 
acid synthesis or in some way “ turned on 
a switch” for bile-acid conjugation and 
secretion. Unfortunately this beneficial 
effect was short lived as infants receiving 
TPN for longer than 3 weeks again had 
very dilute bile. It is noteworthy that 
Postuma and Trevenen12 and Cohen and 
Olsen13 noted a deterioration in liver 
function and histologic changes in the 
livers of neonates receiving TPN for lon­
ger than 14 days.
A consequence of the dilute bile and 
low bile-acid content seen in groups 1 and 
3 infants is that their bile-acid level was 
below the critical micellar concentration 
for bile acids; this is the level below which 
there are insufficient bile-acid molecules 
present to form micelles to dissolve 
cholesterol. Although the bile sludge and 
stones formed in the gallbladders of 
patients on TPN has largely been at­
tributed to gallbladder stasis,14'15 the bile 
of many infants in this study was also 
incapable of solubilizing cholesterol.
The neonates in group 1 (fasting 
without TPN) showed the same type of 
relation between cholesterol content of 
bile (as a percent of total millimoles) and 
fasting as is seen in normal adults; 
namely, that bile becomes supersaturated 
with cholesterol in the fasting state.16-18 
The bile content of cholesterol relative to 
bile acids and phospholipids increased 
during the fasting period of up to 6 days. 
In Fig. 4 we have indicated the cholesterol 
solubility line of Admirand and Small as 
a reference point only because some bile 
samples in this group were below the crit­
ical micellar concentration for bile acids 
and were incapable of solubilizing even 
relatively small amounts of cholesterol.
In summary, it appears that bile be­
comes increasingly saturated with 
cholesterol in fasting neonates. However, 
short-term TPN (up to 2 weeks) is asso­
ciated with an increase in bile-acid con­
tent and hence decreased cholesterol satu­
ration of bile. These effects disappear on 
continued TPN without oral intake. The 
reasons for the apparent beneficial effect 
of short-term TPN need further investi­
gation.
FIG. 4—Percent cholesterol in bile plotted 
against duration of fasting period for group 
1 (control group receiving no TPN). Broken 
horizontal line indicates approximate limit of 
cholesterol solubility in bile.
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Index Reminder
The 1983 index to the Canadian Jour­
nal o f  Surgery, volume 26, is still avai­
lable. If you would like to receive a 
copy, please return the request card 
that was included in the November 
1985 issue or notify the Library, Cana­
dian Journal o f  Surgery, PO Box 
8650, Ottawa, ON K1G 0G8; (613) 
731-9331.
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continued from  page 283
microbiologists, hospital administrators and 
chiefs of service, and should probably be 
required reading. The busy clinical surgeon and 
surgical resident are more concerned with the 
30% to 40% of surgical patients who are 
admitted with home-based spontaneous infec­
tion from acute inflammation or viscus perfo­
ration, the proper choice and use of antibiotics 
(both prophylactic and therapeutic) and sur­
gical techniques. They will be more attracted 
to the chapters concerning influence of oper­
ating technique on rate of wound infection; 
inhospital (nosocomial) infections other than 
surgical wound infection; use of antimicrobial 
agents and infection in the immunocom­
promised host.
The chapter on operating technique is dis­
appointingly elementary and dated. The princ­
iples enunciated—careful technique to 
minimize tissue injury, protection of wound 
edges, debridement of dead tissue, hemosta­
sis and avoidance of seroma and dead space— 
are basic. Of the 20 references, 13 are earlier 
than 1971 and only 2 are from reports of the 
1980s. Equally disappointing is the chapter on 
pathophysiology of infection that reviews the 
inflammatory and immunologic responses of 
the invaded body and the energy metabolism 
and synthesis of proteins essential to maintain 
immunocompetence, to heal wounds, and to 
preserve the structure of vital organs. Although 
it introduces the average practitioner to a daz­
zling array of new terms (e.g., leukocidin, bac­
terial L-forms, erythrogenic toxin, lipid A, 
kallikrein, opsonic proteins, peptidases, throm­
boxane, prostacyclin, interleukin and fibronec- 
tin), this kaleidoscopic review is overwhelm­
ing. In attempting to touch all bases, it fails 
to develop a comprehensive picture. This is 
probably more a reflection of the state of the 
art than a failure of the editors. The defects
in these two chapters are compensated for by 
the outstanding in-depth tabulated review of 
the classes of antimicrobial agents, their mode 
of action and side effects, and a guide to the 
selection of the most appropriate agent or an 
alternative. This is complemented by an excel­
lent review of the causes and prevention of 
nosocomial infection, especially of the catheter- 
ized urinary tract, and the diagnostic and spe­
cial preventive and therapeutic considerations 
in infections in immunodepressed patients (the 
aged, malnourished and critically ill) that are 
being encountered with increasing frequency. 
These two chapters alone make this a worth­
while reference text.
It is noteworthy that there has been a shift 
of the bacteria in secondary infections occur­
ring during hospitalization (hospital acquired 
or nosocomial) from gram-positive Staphy­
lococcus, the major offender, to predominantly 
aerobic gram-negative bacilli. There has also 
been a sharp increase in the number of infec­
tions caused by invasive gram-negative bacteria 
previously considered to have little or no viru­
lence, and infections by fungi and viruses. 
Approximately 80% of serious infections by 
these organisms developed while patients were 
on antibiotic prophylaxis or therapy for other 
infections. It.is incumbent upon the operating 
surgeon to be familiar with their control.
The organization, headings, layout and print 
make this manual easy to read and subjects 
easy to locate. There is liberal use of drawings 
and photographs, most of which add little to 
the text and are redundant but serve well to 
break the monotony of the written page. The 
multiple tables and lists are exhaustive but 
useful.
M arvin J. W exler, m d , frcsc
Associate professor of surgery,
Royal Victoria Hospital,
McGill University,
Montreal, PQ,
H3A 1A1
TUMORS OF THE KIDNEY AND URI­
NARY TRACT. Color Atlas and Text­
book. Steen Olsen. 291 pp. Illust. Munks- 
gaard International Publishers Ltd., 
Copenhagen, 1984. Price not stated. ISBN 
87-16-09040-3.
When many urology texts seem to be word- 
processor-generated variations of each other, 
it is refreshing to read this book.
Urologists and pathologists will find 
the book both enjoyable and beneficial. 
Its emphasis is on histologic features and 
ultrastructure. The full colour micrographs are 
of the highest quality and clearly illustrate the 
text. They are particularly good in the con­
troversial sections such as those on urothelial 
atypia, renal cell adenoma and carcinoma.
The book begins with a clear and logical dis­
cussion of the problems of definition and ter­
minology of renal cell adenoma and carci­
noma. The author does not draw a definite line 
between adenoma and carcinoma, but he nar­
rows the grey area and highlights the dilemma 
facing the histopathologist trying to distinguish 
between the two.
Lesions mistaken for tumours, such as cys­
titis cystica and malakoplakia, are discussed, 
and the diagnostic features are well illustrated; 
prostatic hyperplasia is discussed briefly and 
only to allow a comparison with carcinoma.
The different staging and grading systems 
of urologic malignant disease are discussed 
and compared, and as an appendix the book 
contains the complete UICC (TNM system) 
classification. The references are numerous and 
up to date.
This book can be recommended to urologists 
and pathologists. It should be available as a 
reference in all teaching units.
N orman G. Futter, mb, frcsc
Head of urology,
Ottawa General Hospital,
Ottawa, Ont.,
K1H 8L6
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ment hospital in community of 1 2 000 and ser­
vicing the regional needs of 30 000 people. 
Camrose is a beautiful place to live; close, but not 
too close to Edmonton, with a Junior College and 
active recreational, sports and cultural programs. 
Relocation expenses will be provided. Contact: 
Mr. T.C. Ofrim, Administrator, Smith Clinic, 
4825-51 St., Camrose, AB, Canada T4V 1R9. 
Tel: (403) 672-2424. -S 8 6 -2 0
CLINICAL BURN FELLOWSHIP: -  Six months or 
twelve months, regional adult burn centre, Welles­
ley Hospital, beginning January 1, 1987. New 
10-bed, ultra modern burn centre, 100 burns per 
year. Position totally funded. For more informa­
tion please contact: Dr. Walter Peters, Suite 224, 
Turner Wing, Wellesley Hospital, 160 Wellesley 
St. E., Toronto, ON M4Y 1J3. -S 8 6 -1 9
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ANUSOL-HC AND TUCKS 
TEAM UP FOR RELIEF
TUCKS*Anusol-HC and Tucks team up to effec­
tively relieve the discomfort associated 
with hemorrhoids and other anorectal 
disorders.
ANUSOL*-HC
• Relieves pain and itch caused by 
inflammation.
• Lubricating petrolatum base mini­
mizes friction.
• Colorless ointment and suppositories 
protects against personal embarrass­
ment.
• Soothes inflamed hemorrhoidal tissue.
• Eliminates mechanical irritation from 
toilet tissue.
• Helps maintain proper hygiene.
TEAM UP FOR RELIEF
PARKE-DAVIS
Parke-Davis Canada Inc., Scarborough, Ontario
*Reg. T.M. Parke, Davis & Company, ^  ipaabI
Parke-Davis Canada Inc., Auth. user EED Irani
For prescribing information see page 227
Meet some members 
of our family
The third generation of 
in >nahs< >rhahle nu >n< >filainent 
sutures has just begun...
The New Standard of Excellence
Davis + Geek IntroducesTHE SMOOTH ONE
S 'FKiLT
S om eth ing 
you ’re used to  
w ith ou t 
the  problem s 
you ’re used to
You told us that you liked using catgut but you didn’t like its 
problems. So we took catgut and made It
• soft and supple
• easy to tie
• less likely to curl, "pigtail" and tangle 
■ easy to handle and control
DEXON* PLUS
Excellent knot security plus superior handling 
and smoother tissue passage.
R
DISPOSABLE SKIN STAPLER
w y No hang ups!/ Staples are now
1]I / immediately, autom atica lly
and com p le te ly  released
X L | regardless o f d irection of
stapler movement.
..from the  b + G  w ound c losure  system
quality professional products from
DAVIS+GECK A TRADITION OF INNOVATION
Cyanamid Canada Inc. Atria North, 2255 Sheppard Avenue East, Willewdale, (Ontario) M2J 4Y5
